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SUMMARY
This thesis examines the role of microRNAs in renal fibrosis. MicroRNAs constitute 
a large family of approximately 22-nucleotide-long non-coding RNAs, that in animal 
cells regulate gene expression posttranscriptionally. At the start of the project, 
microRNAs were emerging as potentially important factors in various physiological 
and pathological processes; however, there was very little known about their 
expression and function in the kidney, in particular in tubulointerstitial fibrosis. In this 
thesis, global microRNA expression has been analysed in vitro in proximal tubular 
epithelial cells, and in vivo in formalin-fixed, paraffin-embedded kidney biopsy 
samples from patients with diabetic nephropathy. Among microRNAs altered 
by profibrotic stimuli, the greatest difference has been found in expression 
ofmiR-192, which is downregulated in severe diabetic nephropathy. Further 
examination of miR-192 in kidney biopsy samples has revealed that its expression 
correlates well with renal function and inversely correlates with fibrosis. A possible 
function of miR-192 has been then studied in vitro in proximal tubular epithelial cells. 
It has been found that treatment of the cells with the profibrotic cytokine TGF-betal 
downregulates miR-192. Moreover, manipulation of miR-192 expression has shown 
that miR-192 is involved in E-cadherin regulation. The mechanism of that regulation 
has been investigated, pointing to two transcriptional repressors of E-cadherin, ZEB1 
and ZEB2, as direct targets ofmiR-192. The presented data suggest that, in the 
kidney, miR-192 may prevent epithelial-to-mesenchymal transition, known to 
contribute to renal fibrosis. In parallel, global microRNA downregulation in proximal 
tubular epithelial cells has been attempted. However, knockdown of Dicer or TRBP, 
proteins involved in microRNA processing, has not been sufficient to induce changes 
in microRNA expression. The possible explanations have been discussed. Finally, 
microRNA role in direct regulation of TGF-betal synthesis has been investigated. 
In particular, human microRNAs similar to viral hsv-miR-LAT, reported to directly 
target TGF-betal mRNA, have been tested.
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CHAPTER ONE:
In t r o d u c t io n
1.1 The kidney
The human kidneys are two relatively small but vital organs, located at the end 
of the rib cage, one on each side of the spine, behind the peritoneal cavity 
(Figure 1.1 A). Their main roles are removal of waste products from the blood, 
maintenance of homeostatic balance in the body, and secretion of important 
hormones. In order to perform their tasks, the kidneys have evolved over thousands 
of years into organs of an unusually sophisticated anatomy and physiology.
1.1.1 Kidney structure
The kidneys are bean-shaped, in a normal adult about 10 cm long, 6 cm wide 
and 3 cm thick, and together constitute approximately 0.5% of total body weight. 
The outer part of the kidney is known as the renal cortex, whereas the inner bit is 
the renal medulla (Figure 1.1B). Each kidney is attached to the renal artery, the renal 
vein, nerves, and the ureter. Above the kidney is situated the adrenal gland [1].
The nephron
The basic structural and functional unit of the kidney is the nephron (Figure 1.1C). 
Each nephron starts with the renal corpuscle, composed of a cluster of blood vessels 
supported by the mesangium, together called the glomerulus, located within
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a chamber-like structure known as the Bowman’s capsule. The renal corpuscle is 
attached to the renal tubule, encircled by the peritubular capillaries. The tubule walls 
are made of epithelial cells that specialise in transport of small molecules, with 
varying properties in distinct sections of the tubule, which are consecutively: proximal 
convoluted tubule, loop of Henle, distal convoluted tubule, and collecting duct (shared 
by several nephrons) [1].
A healthy kidney contains typically more than one million nephrons. The vast 
majority of them are located almost entirely in the renal cortex, apart from loops 
of Henle and collecting ducts which descend into the medulla [1].
1.1.2 Kidney function
The most basic function of the kidneys is the removal of waste products and toxins 
from blood. Accordingly, despite their relatively small mass, the kidneys are supplied 
with 20-25% of total arterial blood pumped by the heart. Every day the kidneys filter 
approximately 200 litres of blood. This makes them particularly valuable sensors 
of plasma concentrations of important minerals, glucose, oxygen, and hydrogen ions. 
Certain mechanisms have evolved, enabling the kidneys not only to sense, but also 
react to unusual composition of the blood, so that the optimal concentrations are 
restored. Their role in maintaining the bodily fluid homeostasis is so significant that 
the kidney is considered one of the main homeostatic devices of the human body [1].
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Urine formation and maintenance of homeostasis
There are three fundamental processes, occurring in nephrons, that result in both urine 
formation and maintenance of electrolyte and water balance. These are filtration, 
reabsorption, and tubular secretion.
Filtration
Filtration takes place in the renal corpuscle. Blood enters the glomerulus under 
pressure, so that the water and small molecules from the blood are forced into 
Bowman’s capsule through a layer of glomerular endothelial cells, basement 
membrane, and podocytes. The gaps in the filtration barrier are too small to let bigger 
molecules (> 50-70 kDa) and the blood cells through. Consequently, the filtrate, 
which now flows from the Bowman’s capsule to the renal tubule, has a very similar 
composition to the blood plasma, but lacks the majority of plasma proteins [1].
Reabsorption
In the tubule, useful substances are returned from the filtrate back to the blood 
in a process known as reabsorption. This occurs in two steps. The substances are first 
transported from the tubule to the interstitium (connective tissue surrounding 
the nephron), and then to the peritubular capillaries. That is driven by active transport, 
osmosis and diffusion, and differs in various parts of the tubule. For instance, 
the proximal tubule specialises in reabsorption of glucose, amino acids, and vitamins, 
and also claims back the majority of inorganic salts and water. The process continues 
in the next tubule sections, with more focus on sodium and water reabsorption. 
In particular the loop of Henle with the following distal tubule are perfectly suited to
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reclaim as much water as possible and form very concentrated urine due to the very 
smart counter-current multiplier system [1].
Tubular secretion
The tubular secretion is the auxiliary process, in which some particular substances, 
toxic or present in excess in blood, are secreted directly from the peritubular 
capillaries to the tubular fluid. It has the greatest role in maintaining constant pH 
of the blood (by secretion of more hydrogen ions, combined with ammonia, when 
the blood becomes acidic), but is also used to excrete some poisons (like antibiotics) 
and excess potassium [1].
Having passed through the entire nephron, the urine is formed, ready to exit 
the kidney and eventually the organism. It contains only substances that cannot be 
used by the body, either because of their nature or because they are present in a great 
excess. On top of the already clever system, which in most circumstances would be 
sufficient to keep the right fluid balance in the body, there are additional mechanisms 
to adjust the contents of the urine to the physiological needs at the particular moment 
(for review see [2]).
Secretion of hormones
In addition to regulatory roles exerted through urine formation, the kidneys also 
influence the body functions by release of hormones. The most important of them are 
erythropoietin, or EPO, stimulating production of erythrocytes in the bone marrow; 
calcitriol, the active form of vitamin D, regulating calcium metabolism; and renin,
11
a key component of the renin-angiotensin-aldosterone system, which controls blood 
pressure [1].
1.1.3 Renal diseases
Considering their importance and complexity, it is not surprising that the impairment 
of the kidney functions has serious consequences for the organism. The most 
fundamental is dysfunction of other tissues and organs caused by the waste products 
accumulating in the blood. Without appropriate treatment, that will very likely lead to 
a prompt death.
Sadly, in Western countries renal diseases are becoming increasingly widespread. 
It has been estimated that 1 in 10 people has some kind of kidney disease, and 1% 
of them will in due course develop end stage renal disease and will need renal 
replacement therapy (either dialysis or transplantation) to stay alive [3].
Although the final tragic outcome, the end stage renal disease, characterised by 
the loss of nephrons and deposition of extracellular matrix, is common for all sorts 
of non-malignant kidney diseases if they are not stopped at an earlier stage, the initial 
causes vary greatly. Renal disease may start with hypertension, glomerulonephritis 
(inflammation in the glomerulus, usually resulting from an infection or autoimmune 
reaction), formation of large cysts gradually replacing the normal tissue (like 
in the most frequent inherited kidney disease known as polycystic kidney disease), 
or overuse of medicines or “street” drugs [4]. The most common cause, however, 
is poorly controlled diabetes [4].
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1.2 Diabetic nephropathy
Diabetes mellitus is a condition characterised by the presence of elevated glucose 
levels in blood. This may be caused by lack of insulin production (type I diabetes, 
~5-10% patients with diabetes mellitus), or, most often, inability to respond to insulin 
(type II diabetes). Over time hyperglycaemia causes significant anomalies 
in the vasculature [5], which lead to micro- and macrovascular complications 
of diabetes: nephropathy, retinopathy, neuropathy, and atherosclerosis.
In Europe approximately 3.5% of the population have been diagnosed with diabetes, 
and the frequency of diabetes is growing rapidly [6]. Approximately one third 
of the diabetic patients (both type I and II diabetes) suffer from kidney disease [7]. 
Diabetic nephropathy is therefore the most common single cause of end stage renal 
disease and accounts for 20% of all patients requiring renal replacement therapy in the 
UK [8]. Furthermore, the mortality is higher in diabetic patients in comparison 
with non-diabetic patients [8]. This creates an urgent need to design more effective 
therapies for diabetic nephropathy, most likely based on better understanding 
of mechanisms driving the disease.
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1.2.1 Factors contributing to development 
and progression of diabetic nephropathy
Only about 30% of patients with diabetes develop nephropathy [7]. There are a few 
factors known to increase the risk of kidney disease in both type I and II diabetic 
patients. The most widely acknowledged are poor glycaemic control and 
hypertension.
Glycaemic control
Substantial epidemiological data suggest that the development of diabetic 
nephropathy is related to poor glycaemic control. It has been also demonstrated that 
strict glycaemic control is effective in prevention of development and progression 
of diabetic nephropathy at early stages [9]. Whether or not it can also slow down 
progression or cause reversal of the advanced disease is more controversial. It has 
been reported, however, that ten years after pancreas transplantation in patients with 
type I diabetes and nephropathy, some morphological alterations of diabetic 
nephropathy, such as increased thickness of the basement membranes and mesangial 
expansion, decreased [10]. This suggests that at least in some cases and after a long 
time (more than five years) control of blood glucose may cause regression of diabetic 
nephropathy.
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Blood pressure
In the later stages, it is the degree of hypertension that correlates best with the rate 
of progression of diabetic nephropathy [11]. Additionally, it has been demonstrated 
that aggressive treatment of hypertension with angiotensin-converting enzyme (ACE) 
inhibitors significantly delays the progression [12]. Although lowering of blood 
pressure by the ACE inhibitors has a great impact on renal function itself, it is clear 
now that blockade of the renin-angiotensin system is also beneficial for diabetic 
nephropathy patients in other ways, independent of its antihypertensive effects [13]. 
The possible mechanisms will be discussed later in this chapter.
Other factors
A few other factors have been linked to development or quick progression of diabetic 
nephropathy. These include hypercholesterolaemia, dietary protein intake, obesity, 
and cigarette smoking [14]. There is also strong evidence suggesting that genetic 
factors play an important role. The likelihood of developing nephropathy in those 
patients who have a sibling or parent with diabetic nephropathy is substantially 
increased, and this cannot be completely explained by environmental factors [15]. 
Furthermore, the incidence of diabetic nephropathy varies according to ethnicity [15]. 
So far, however, success in identifying genes responsible for development 
and progression of diabetic nephropathy has been limited, mostly by the modest data 
collections and small number of candidate genes examined. A recent genome-wide 
association study, using DNA samples from approximately 2000 patients for each 
of seven major diseases (including type I and II diabetes mellitus, but not diabetic
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nephropathy), is a perfect demonstration of how to approach the problem [16]. 
Hopefully, a similar work will be done to identify genetic loci for diabetic 
nephropathy susceptibility.
1.2.2 The clinical course of diabetic nephropathy
Clinically incipient nephropathy manifests initially as persistent microalbuminuria 
(i.e. albumin excretion: 20-200 mg per day). Then, persistent proteinuria occurs 
(i.e. total protein excretion > 200 mg per day) and is an indication of overt diabetic 
nephropathy. Following the onset of proteinuria, there is a progressive decline 
in kidney function, leading to end stage renal disease. The rate of progression is 
heavily influenced by glycaemic and blood pressure control, as well as the other 
factors mentioned above [14]. In approximately 50% of patients with overt 
nephropathy the progression is quick and the kidney function is nearly lost in less than 
five years [17].
A routinely used measure of kidney function is estimated glomerular filtration rate 
(eGFR), which is calculated using the following equation [18]:
eGFR = 186*(Scr)"1154 * (Age)-0 203 * (0.742 if female) * (1.210 if African-American) 
(ml/min per 1.73 m2)
where Scris serum creatinine concentration in mg per 100 ml, and age is in years.
Creatinine is a waste product of the muscle, and in patients with impaired kidney 
function removal of creatinine from blood is not effective, so elevated creatinine
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levels are commonly detected. After adjustment for patient age, sex, and race, 
creatinine concentration is an indication of the stage of kidney disease (Table 1.1). 
Normal eGFR is about 120 ml/min in young adults and declines with age [18].
1.2.3 Pathological changes in diabetic 
nephropathy
The changes seen in diabetic kidneys are comparable in patients with type I and II 
diabetes, and are also similar to, but in some aspects distinguishable from, those found 
in non-diabetic chronic renal diseases [19].
The earliest histopathological change in diabetic nephropathy is renal 
hypertrophy [20]. This may be explained by both mesangial and interstitial expansion. 
Whereas the expansion within the renal corpuscle is caused mainly by matrix 
deposition, the interstitial expansion is a result of hypertrophy of interstitial cells [21]. 
In the course of the disease, further damage in both the renal corpuscle 
and tubulointerstitium is observed. In addition to the mesangial expansion, 
the corpuscular changes include glomerular basement membrane thickening, 
glomerular sclerosis, and, at later stages of the disease, also loss of podocytes [20].
In the tubulointerstitium fibrosis develops. The tubular basement membrane 
thickens [21]. Tubules and peritubular capillaries are gradually replaced 
by extracellular matrix and interstitial cells. The latter include, apart from usual 
fibroblasts and resident macrophages, myofibroblasts and infiltrating immune 
cells [22].
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1.2.4 Molecular basis of tubulointerstitial 
fibrosis in diabetic nephropathy 
and other chronic kidney diseases
The tubulointerstitium comprises the tubular epithelium, vascular structures, 
and interstitium, and accounts for 85 to 90% of the kidney volume [23]. After 
realisation that the degree of tubulointerstitial fibrosis correlates best with the rate 
of progression of chronic kidney disease, the mechanisms underlying this process 
have become a subject of intensive studies.
To facilitate discussion, the pathophysiology of tubulointerstitial fibrosis is sometimes 
divided into three sequential phases [19]: cellular activation and injury, profibrotic 
signalling, and the fibrogenic phase.
Cellular activation and injury
During the initial phase of fibrogenic cascade, tubular cells are exposed to bioactive 
molecules not present in the normal ultrafiltrate. These consist mainly of proteins 
and, in diabetic nephropathy, also glucose in unusually high concentrations, coming 
from the plasma or injured glomeruli [24]. Some of those molecules are directly toxic 
to the tubular cells and contribute to further renal injury. An example of such a protein 
is the iron-binding protein transferrin, which facilitates generation of reactive oxygen 
species in the Haber-Weiss Fenton reaction. Accordingly, transferrin-bound iron is 
toxic for tubular cells in vitro [25], and iron-deficient mice were more resistant 
to kidney damage caused by anti-glomerular basement membrane antibodies [26]. 
Another example is the complement system. Once in the tubule, the complement
proteins may destroy the tubular cells via formation of the membrane attack 
complex [27]. A toxic effect may also be exerted by proteins from the glomerular 
filtrate indirectly. For instance, albumin, immunoglobulin G, and transferrin have 
been shown to induce secretion of vasoactive peptides, such as endothelin-1, which 
cause vasoconstriction and consequently tubular damage due to ischemia [28]. 
Constituents of the tubular fluid may also trigger inflammation in the interstitium. 
Albumin and transferrin have been reported to stimulate secretion of monocyte 
chemoattractant protein-1 [29]; while a mixture of serum proteins, especially 
30-100 kDa fraction, has been shown to induce expression of the complement 
C3 gene by cultured tubular epithelial cells [30]. These, together with endothelial cells 
of peritubular capillaries, additionally facilitate leucocyte migration into 
the interstitium by exposure of adhesion molecules on the cell surface (e.g. ICAM-1, 
VCAM-1) [31]. Profound changes in gene expression in the activated cells 
of the tubulointerstitium result in display of unusual antigens in MHC I, which may 
elicit T-cell-mediated immune response that adds to the tubulointerstitial 
inflammation [32].
In addition to injury and inflammation, the abnormal contents of the glomerular 
filtrate may also directly cause fibrosis of the tubulointerstitium. Profibrotic cytokines 
such as transforming growth factor-beta (TGF-beta, discussed in detail in the next 
section) or insulin-like growth factor 1 (IGF-1) may enter the tubule, bind to their 
receptors on the tubular cells, and cause production of extracellular matrix [24]. Also 
elevated glucose concentration in diabetic patients may have similar effect [33]. 
Additionally, it has been shown that TGF-beta induces epithelial-to-mesenchymal 
transition (EMT) of tubular cells, which lose contact with other epithelial cells 
and migrate into the interstitium to become myofibroblasts [34]. These cells specialise
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in production of large amounts of matrix components as well as profibrotic cytokines, 
and their presence in renal interstitium is a feature of progressive kidney disease [35].
The profibrotic signalling phase
As a result of the events described above, a number of regulatory molecules are 
released by the cells of the tubulointerstitium. It is widely accepted that amongst 
these, a key potentiator of renal fibrosis is TGF-beta.
TGF-beta
TGF-beta is a prototype of a multifunctional cytokine. Its activities include regulation 
of extracellular matrix synthesis and degradation, control of EMT, context-specific 
inhibition or activation of cell proliferation, induction of apoptosis, and modulation 
of immune responses [34, 36].
Increased expression of TGF-beta has been reported in practically all human 
and experimental models of renal fibrosis, including patients suffering from diabetic 
nephropathy [37, 38], and diabetic rodents [39]. In addition, transgenic mice 
with enforced TGF-beta expression in the liver, resulting in elevated plasma 
concentration of TGF-beta, develop glomerular and interstitial fibrosis [40]. 
Conversely, inhibition of TGF-beta by antibodies, antisense oligonucleotides, soluble 
TGF-beta type II or III receptor, the TGF-beta inhibitor decorin, or TGF-beta latency- 
associated peptide prevents fibrosis in animal models [41].
Both resident renal cells and infiltrating immune cells can produce TGF-beta 
in response to several stimuli, which include glucose, angiotensin II, endothelin 1, 
ischemia, insulin, IGF-1, platelet-activating factor, thromboxane, and medications
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such as cyclosporine [19]. Additionally, TGF-beta may also induce its own 
expression [42].
Three human TGF-beta genes have been identified: TGF-beta 1, TGF-beta2, 
and TGF-beta3. The sequences of the mature TGF-beta molecules are similar, with 70 
to 75% of conserved amino acids [38]. Although their effects on cells are comparable 
[43], they differ greatly in their spatial and temporal expression patterns. This can be 
explained by differences in regulatory sequences of the three genes [38]. The most 
commonly studied in the context of renal fibrosis is the first one, which later in this 
thesis will be referred to as TGF-beta.
TGF-beta is secreted as a latent precursor molecule (LTGF-beta) [38]. It requires 
activation into a mature form for receptor binding and activation of signal 
transduction pathways. In vitro, activation may be achieved for example by treatment 
with plasmin, furin, glycosidase, transglutaminase, metalloproteinase 9, acidic pH, 
or thrombospondin [19]. How this activation occurs in the kidney is unclear, but it 
seems to be an important step in the regulation of TGF-beta bioactivity.
Active TGF-beta binds to specific receptors found on most cell types [19]. Typically, 
the active TGF-beta binds to the TGF-beta type II receptor, a serine/threonine kinase 
that recruits and phosphorylates the TGF-beta type I receptor. Together they 
phosphorylate proteins of the SMAD family: SMAD2 and SMAD3, which then 
in concert with SMAD4 migrate into the nucleus, where they act directly as 
transcription factors, or modulate activity of other transcription factors [44].
Genes regulated by TGF-beta include matrix genes, inhibitors of matrix-degrading 
enzymes, matrix-binding integrins, and chemoattractants for monocytes [19]. 
TGF-beta also controls genes responsible for EMT in tubular cells, and in fibroblasts 
-  transformation into myofibroblasts [19].
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Other profibrotic factors
In addition to TGF-beta, activated tubular and interstitial cells produce a few other 
important factors that have a profibrotic effect. One of them, connective tissue growth 
factor (CTGF), is thought to act downstream of TGF-beta, and induce fibroblast 
proliferation, matrix protein synthesis, and integrin expression [45]. It has been 
detected in human biopsy samples in areas of chronic damage [46], and in a mouse 
model of diabetic nephropathy [47].
Angiotensin II, on the other hand, is known to be a potent stimulator of TGF-beta 
production by renal cells [48]. Additionally, its TGF-beta-independent effects may 
include induction of collagen gene expression in tubular cells and interstitial 
fibroblasts, and vasoconstriction, contributing to tubulointerstitial ischemia [19, 49]. 
As mentioned in 1.2.1, ACE inhibitors have been proven beneficial for patients with 
renal fibrosis, an effect independent of hypertension control. This has been confirmed 
in several animal models of kidney disease [19]. Furthermore, it has been shown that 
mice genetically deficient in angiotensinogen develop less renal fibrosis after 
unilateral ureteral obstruction [50].
Very similar properties to angiotensin II has endothelin 1, which also stimulates 
production of TGF-beta by renal cells, causes vasoconstriction, and directly regulates 
matrix accumulation [19, 51]. In agreement, endothelin 1 receptor blockers have been 
reported to decrease the severity of tubulointerstitial damage in rat models of renal 
disease [52], whereas transgenic mice overexpressing endothelin 1 have been shown 
to develop glomerulosclerosis, tubulointerstitial fibrosis, and renal cysts, but not 
hypertension [53].
Another molecule upregulated in fibrotic renal diseases is platelet-derived growth 
factor (PDGF). It has been shown to induce the appearance of myofibroblasts
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in the interstitium [54], and has also been implicated in regulation of TGF-beta 
synthesis [55].
The role of proinflammatory cytokines, such as tumour necrosis factor (TNF) 
or interleukin 1 (IL-1), in the fibrogenic response is not completely clear. Their role 
in acute renal injury is well established [56, 57], but it has been suggested they may 
have some profibrotic effects as well. For instance, IL-1 receptor antagonist has been 
shown to reduce tubulointerstitial fibrosis in rats with crescentic nephritis [58]. 
Whether this was a direct effect of IL-1 on the fibrogenic response is questionable.
Antifibrotic factors
It is conceivable that, together with extensive production of fibrosis-promoting 
molecules, activated cells of the tubulointerstitium may synthesise also antifibrotic 
factors. In keeping with this hypothesis, increased expression of hepatocyte growth 
factor (HGF) has been noted in areas of tubular damage in human kidney 
biopsies [59]. Subsequent experiments revealed that HGF has antifibrotic properties. 
In a mouse model of chronic kidney disease, for example, recombinant HGF 
decreases renal production of PDGF and TGF-beta, reduces number 
of myofibroblasts, and generally inhibits tubulointerstitial fibrosis [60]. 
Disappointingly, it has been also shown that HGF-overexpressing mice develop cystic 
renal disease and glomerulosclerosis [61], so its potential use in a therapy would 
certainly require a great caution.
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The fibrogenic phase
As a result of signalling from the profibrotic molecules mentioned above, a new set 
of genes is expressed by cells of the tubulointerstitium. In general, these are genes that 
lead to extracellular matrix accumulation along tubular basement membranes 
and in the interstitial space. Matrix accumulation is thought to occur due to its 
increased synthesis and decreased degradation.
Increased matrix synthesis
There are two lines of evidence suggesting that the increase in extracellular matrix 
during progressive renal fibrosis is a result of increased matrix production. Firstly, 
more mRNA of matrix genes can be detected. Secondly, matrix components not found 
in the normal kidney appear [19].
The matrix typically found in the fibrotic kidney comprises of matrix proteins 
(various collagens, a few splice variants of fibronectin, laminin), proteoglycans, 
and polysaccharides (mainly hyaluronan) [19]. In situ hybridisation studies suggest 
that their main source are interstitial myofibroblasts [62]. In addition to providing 
structural support, the unusual matrix may also significantly influence behaviour 
of the neighbouring cells (e.g. control further production of profibrotic genes directly 
or by sequestration of growth factors, including TGF-beta), or attract immune cells to 
the scar [19].
Decreased matrix degradation
Normal kidney cells produce several matrix degrading proteases, which are believed 
to help maintain normal kidney architecture. Amongst the most important are
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the large group of matrix metalloproteinases (MMPs). A common feature of renal 
fibrosis is a strong induction of one of the natural MMP inhibitors, the tissue inhibitor 
of metalloproteinases 1 (TIMP-l) [63]. TIMP-l is synthesised in response to 
TGF-beta and some other growth factors, cytokines, endotoxin, and thrombin 
by various tubulointerstitial cell types, including fibroblasts, macrophages, 
and tubular epithelial cells [19]. Surprisingly, genetic deficiency of TIMP-l does not 
rescue a mouse from renal fibrosis [63]. It has been suggested that in this model 
the three other TIMPs may compensate for the lack of TIMP-l, so more studies are 
needed before any conclusion can be drawn.
A member of another group of proteases, the serine protease plasmin, has also been 
studied in the context of renal fibrosis. The first role assigned to plasmin was 
degradation of fibrin, but it can also directly degrade some components 
of the basement membrane and extracellular matrix, as well as activate MMPs, which 
are normally secreted as inactive zymogens [19]. Plasmin itself is synthesised 
as inactive plasminogen, and in the kidney it is typically activated by another serine 
protease, the urokinase-type plasminogen activator (uPA). Its natural inhibitor, 
the plasminogen activator inhibitor 1 (PAI-1), is inducible by TGF-beta in proximal 
tubular epithelial cells, fibroblasts and myofibroblasts [64, 65] and is profoundly 
upregulated in several models of renal fibrosis [66]. Moreover, PAI-1-deficient mice 
develop less fibrosis than wild-type mice in response to protein overload or ureteral 
obstruction [67].
Ultimately, if the fibrogenic cascade is not stopped, extracellular matrix replaces 
nephrons and the kidney cannot function any longer.
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Despite great progress in medical technologies, the number of patients with end stage 
renal disease is steadily growing. Advances in fundamental biology, in particular 
those in the field of gene expression regulation, may offer new approaches to chronic 
kidney disease treatment and/or diagnosis.
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1.3 Control of gene expression
In a multicellular organism all cells, as a general rule, have the same DNA, 
yet the different cell types produce distinct sets of proteins, and therefore differ 
greatly in terms of structure and function. The mechanisms by which a specific subset 
of genes are expressed in each cell operate at many levels. Figure 1.2 shows the steps 
of the eukaryotic DNA-to-protein pathway which may potentially be regulated. These 
include transcription, mRNA maturation and export from the nucleus, degradation 
of the mRNA in the cytoplasm, translation, and posttranslational modifications 
influencing the protein activity [68].
Since many human diseases, including diabetic nephropathy, result from altered gene 
expression, understanding how the gene expression is regulated seems essential 
and holds great medical promise.
1.3.1 Transcriptional control
Regulation at the level of transcription is vital for expression of any gene. 
In eukaryotic organisms this is a complex issue, like the process of transcription itself. 
There are a few stages required for initiation of transcription, all of which are subject 
to regulation by numerous activators and repressors.
The order of events leading to the start of transcription differs from gene to gene, 
but in most cases eventually RNA polymerase II and general transcription factors 
assemble at the promoter region of the gene. A protein complex known as Mediator
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links all of them with gene-specific regulatory proteins (often acting over very large 
distances), as well as with chromatin-modifying proteins, which can allow better 
access to the DNA present in chromatin [69]. The total number of proteins necessary 
for the initiation of transcription in a eukaryotic cell exceeds one hundred [68].
Among proteins that interact with DNA, it is the gene regulatory proteins that are 
responsible for turning genes on or off in an individual manner. Unlike the few 
general transcription factors, abundant in every nucleated cell and needed for all 
genes transcribed by RNA Polymerase II, there are thousands of different gene 
regulatory proteins, with diverse expression patterns and regulatory capabilities [70]. 
Their mechanisms of action vary greatly. Predominantly they control the assembly 
of the general transcription factors, Mediator, and the polymerase at the promoter, 
or they alter local chromatin structure. They may achieve all that by their ability to 
recognise and bind to short specific sequences of DNA, and then by making use 
of DNA looping (as the regulatory sequences sometimes are located even several 
thousands nucleotide pairs apart from the promoter) and unique properties of protein- 
protein interactions [71, 72].
The regulatory proteins are usually divided into two groups: activators and repressors 
of transcription, although there are known examples of proteins that may enhance 
or inhibit transcription depending on the availability of other factors within 
the cell [73]. The cooperation of the gene regulatory proteins seems to be very 
important for the final outcome. Quite often gene activator proteins act 
synergistically. In some cases they can bind DNA only after they have formed 
a complex with other regulators. Then again, one of the mechanisms used 
by the repressors is blocking the action of the activators. Thus, the occurrence and rate 
of transcription are determined by a whole spectrum of proteins, facilitating adequate
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eukaryotic cell response to numerous and complicated signals that come 
from the environment.
Apart from the gene regulatory proteins, which have been extensively studied 
for many years, it becomes apparent now that also other molecules, like non-coding 
RNAs, may be involved in regulation of transcription [74]. Some, such as XIST RNA 
which drives the inactivation of one of the X chromosomes in female cells, cause 
global repression of transcription through heterochromatin formation [75]. The others, 
for example small non-coding RNA molecules (siRNAs, microRNAs), may regulate 
transcription of specific genes in a sequence-dependent manner [76]. The mechanism 
is not completely understood yet, but some lines of evidence suggest that small RNAs 
are able to interact with non-coding transcripts that overlap gene promoters. By that 
they guide chromatin reorganisation in the vicinity of the promoters, which results 
either in transcriptional activation or silencing of specific genes [76].
Furthermore, DNA itself can be modified (mainly by methylation of cytosine 
in the sequence CG), usually causing gene silencing. Interestingly, modifications 
of either DNA or histones can be preserved during cell division, so that the new cells 
do not express certain genes, similarly to the parent cell [77], adding to 
the complexity of the transcriptional control.
1.3.2 Posttranscriptional control
Although critical for gene expression, occurrence of transcription of a particular gene 
does not guarantee that the protein encoded by that gene will be produced or active in 
the cell. In the case of many genes, especially those responsible for quick and accurate
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responses to changes in the environment, posttranscriptional and posttranslational 
control is of great importance [78]. There are several opportunities for 
posttranscriptional regulation of gene expression, i.e. between the start 
of transcription and the end of translation, in eukaryotic cells.
RNA processing in the nucleus
In eukaryotes, transcription elongation is tightly coupled to RNA processing. 
Transcription is only the first of a few steps needed to generate mRNA. Other 
essential steps are modifications of the both transcript ends, and removal of intron 
sequences in a process known as splicing [79].
Among the modifications of the transcript ends, 3' end processing in particular leaves 
some opportunities for regulation. The 3' end of a eukaryotic mRNA is not formed 
by the termination of transcription by the RNA polymerase. Instead, during 
transcription additional factors are recruited to cleave the transcript and finish it with 
a poly A tail [80]. A cell may control the site of this cleavage [81], and thus possibly 
change the end of the eventual protein or at least the 3'-untranslated region (3'UTR) 
of the mRNA, which, as I shall discuss later in this chapter, may be of great 
consequence for the transcript translation or stability.
An additional chance to alter the final mRNA (and the resulting protein) is splicing. 
In the case of many mRNA precursors, various permutations of exon inclusion 
and skipping can lead to several variations of final mRNA being generated from 
a single gene. This is described as alternative splicing [82]. In humans it has been 
estimated that nearly 95% of multi-exon genes produce multiple transcripts in this 
way [82]. In some cases alternative splicing occurs constitutively, with different final
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forms chosen by chance, because of an intron sequence ambiguity. Very often, 
however, this is a regulated event. The regulation may be either negative, when 
a regulatory factor prevents the splicing machinery from accessing a particular 
splicing site, or positive, if a regulatory molecule attracts the splicing machinery to 
a weak splicing site [82].
Another way used by cells to alter the mature mRNA is called RNA editing. Most 
surprisingly, it changes the nucleotide sequences of the primary transcripts [83]. 
In mammals the most common types of editing include deamination of adenine 
to create inosine, and deamination of cytosine giving uracil [83]. Both types of editing 
change the base-pairing properties of the bases, and therefore may have a great impact 
on the amino acid sequence of the protein (if the change is located within the coding 
sequence) and other posttranscriptional regulatory mechanisms. The process is carried 
out by a different set of enzymes for each type of editing, recognising precisely 
the sites which need to be modified [83]. Their expression varies between different 
tissues, being responsible, as has been shown for a few genes, for expression 
of different protein isoforms in those tissues [84].
Export of mRNA from the nucleus and localisation in the cytoplasm
Only a small proportion of RNA that is synthesized ever leaves the nucleus. 
The quality control system of RNA production ensures that only completely 
processed RNA is exported, whereas incompletely processed or damaged RNA stays 
in the nucleus, where eventually gets degraded [85]. However, there are known 
examples of incompletely processed transcripts that are selectively transported 
to the cytoplasm in a regulated manner. In the best-studied example, during HIV-1
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infection, this is controlled by a protein which binds specifically to viral unprocessed 
transcript and then interacts with a nuclear export receptor, causing the transcript 
translocation through the nuclear pore [86].
Once in the cytoplasm, mRNA that passes the nonsense-mediated decay (NMD) 
assessment, which is responsible for degradation of mRNAs containing premature 
termination signals [87], gets translated. The future localisation of the protein is very 
often determined by signal sequences within the mRNA. In many cases they are 
present in the coding region of the mRNA and direct the newly translated protein 
to the right cell compartment after start of translation [88]. Sometimes, however, 
especially in large polarized cells, mRNA itself is transported to a particular part 
of the cell prior to translation. In the known examples, it is 3'UTR of mRNAs that is 
responsible for their transport and often also inhibition of translation until the mRNA 
reaches its destination [89]. The exact mechanisms are not well-understood yet, but it 
is clear that the localisation of mRNA may be influenced by presence of certain 
proteins (such as those responsible for recognition or directional movement 
of mRNAs) or 3'UTR modifications during the transcript processing.
mRNA stability and translation
Number of copies of an mRNA available for translation may be controlled 
at the levels of transcription, transcript processing and intracellular transport, and also 
its turnover. Degradation and translation rate of a particular mRNA depend on 
multiple positive and negative regulatory signals. Interestingly, both processes seem 
to be closely interrelated: poorly translated transcripts are more likely to be degraded,
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as polyA tail shortening and decapping enzymes, crucial for mRNA destabilisation, 
directly compete with the translational machinery [90].
Information necessary for regulation of specific mRNA stability and translation is 
very often located in untranslated regions (UTRs) of the mRNA. These are lengths 
of sequence 5' and 3' to the coding sequence (CDS, that part of the mRNA coding 
for protein). Specific motifs within UTRs are recognised and interpreted by factors 
present in cells, including proteins and non-coding RNA molecules [91].
Among factors regulating mRNA degradation and translation, a particularly important 
example are recently discovered small RNAs, called microRNAs, which bind to 
mRNA and reduce protein output. I shall discuss them in detail later in this chapter. 
Other well-described modes of translational regulation include alternative choice 
of translation initiation site, use of the so-called internal ribosome entry sites (IRES) 
for cap-independent translation, and enzymatic extension of the polyA tail 
(cytoplasmic polyadenylation) [92, 93]. These can have important consequences 
for protein output. For example, alternative sites of translation initiation may result 
in synthesis of proteins with different N-terminus or selection of another open reading 
frame, IRES-mediated translation is not susceptible to most general inhibitors 
of translation, and enzymatic extension of polyA tail may increase half-life 
of the mRNA and stimulate its translation [92, 93].
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1.3.3 Posttranslational control
Finally, it often happens that a polypeptide chain, following translation, requires some 
kind of modification for activity, or alternatively needs to be temporarily inactivated. 
This is particularly beneficial step for regulation of genes which may be needed 
immediately in response to a signal. The required protein is ready in the cell and gains 
its special properties typically in a single reaction.
The most usual posttranslational modifications include addition of functional groups, 
such as phosphate, acetyl, methyl groups, various lipids and carbohydrates [94]. There 
might be also modifications changing the chemical nature of amino acids 
(e.g. glutamine or asparagine may be converted into glutamic acid or aspartic acid, 
respectively [94]), involving formation of disulfide bridges within a protein, 
or proteolytical cleavage. A classic example of the latter two is insulin, which is 
synthesised as a larger inactive protein called proinsulin and becomes active after 
folding, formation of two disulfide bridges, and specific cleavage and removal 
of a large part of proinsulin by a proteolytic enzyme [95, 96]. Proteolytical cleavage 
of the first methionine residue (encoded by the AUG start codon) from newly 
produced polypeptide chains is also very common, so that mature proteins rarely 
begin with the methionine [97].
Another possibility to regulate gene expression after translation is control of a protein 
localisation. Enzymes, in particular, may be kept in a cell compartment apart from 
their potential but undesirable substrates, until they may be required (like for example 
proteases in neutrophil granules) [98].
Lastly, when there is a need to reduce amount of a certain protein in a cell, ubiquitin may 
be covalently linked to it, directing the protein for degradation by proteasomes [94].
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1.4 MicroRNAs in regulation of gene 
expression
In the past few years, hardly any area of biology has been transformed so deeply 
as RNA molecular biology. In particular, it was the discovery of small, 
20-30 nucleotide long, RNA species: microRNAs (miRNAs), short interfering RNAs 
(siRNAs), and piwi-interacting RNAs (piRNAs), that contributed greatly 
to the revolution. Among them, microRNAs have been shown to play an important 
role in regulation of expression of a large proportion of genes in almost all eukaryotic 
organisms investigated so far in both somatic and germline lineages. Rapid advances 
in understanding their biogenesis and mechanisms of action, together with microRNA 
expression patterns available now for many tissues and clinical conditions, have 
profound implications for basic biology as well as disease diagnosis and treatment.
1.4.1 MicroRNA discovery
The discovery of short non-coding RNAs as regulators of gene expression started 
about 17 years ago, when researchers screening for genes that control developmental 
timing in the nematode Caenorhabditis elegans found the first microRNA, lin-4, able 
to inhibit translation of mRNA of a different gene, lin-14, by binding 
to complementary sites within its 3'UTR [99, 100]. Although this was considered 
a beautiful and interesting finding, it was the discovery in the year 2000 that another 
microRNA involved in larval development in C. elegans, let-7, was conserved from
35
nematodes to mammals, that made the importance of that new class of gene 
expression regulators widely appreciated [101, 102].
1.4.2 MicroRNA expression
Since the discovery of let-7, many more microRNAs have been identified in worms, 
flies, mammals and plants. There are even known examples of eukaryotic unicellular 
organisms, in which microRNAs can be found [103]. Furthermore, certain viruses 
also express microRNAs [104].
Many microRNAs are well conserved in evolution, being probably part of crucial 
ancient pathways of gene regulation, whereas other microRNAs are more restricted 
in their phylogenetic distribution [105]. Comparisons of animals with increasingly 
complicated bodies suggest that the number of microRNA genes is correlated 
with developmental complexity; according to the miRBase release 14 [106], there 
have been 718 human microRNAs identified, 216 in zebrafish, and 174 in the genome 
of C. elegans.
Furthermore, some microRNAs have unique tissue-specific or developmental 
expression patterns, which are especially intensively studied in humans, so that 
in many cases it is possible now to identify tissue of origin on the basis 
of the microRNA profile of the sample [107].
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1.4.3 Biogenesis of microRNAs in animals
The biogenesis of microRNAs, although similar among different classes of organisms, 
differs to a certain extent. All the experiments in this thesis were performed on human 
cells or tissues; therefore, here I will focus on the discoveries made in animal systems. 
The overview of the canonical pathway of microRNA biogenesis in animals is shown 
on Figure 1.3, and described in some detail below.
Transcription of primary microRNAs (pri-microRNAs)
Transcription of microRNA genes is usually performed by RNA polymerase II, 
resulting in capped and polyadenylated primary microRNA transcripts 
(pri-microRNA) [108]. There are some animal microRNAs individually generated 
from separate transcription units. The majority, however, are produced from 
transcription units that generate more than one product: a few microRNAs, 
or alternatively one or more microRNAs and a protein (with microRNAs most 
typically located within introns) [109]. A wide range of RNA polymerase II- 
associated transcription factors, together with promoter methylation status, regulate 
microRNA gene transcription, facilitating their expression in specific conditions 
and cell types [110, 111].
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Nuclear processing by Drosha and export of pre-microRNA
Within the pri-microRNA, the mature microRNA is localised to an approximately 
70-nucleotide long fragment that can form a stem-loop hairpin structure, known 
as precursor microRNA (pre-microRNA). Once the pri-microRNA is transcribed, 
the so-called Microprocessor complex, the essential part of which constitute 
the RNase III enzyme Drosha and its co-factor DiGeorge syndrome critical region 
gene 8 (DGCR8), recognises and cleaves it specifically so that the pre-microRNA is 
liberated [112].
Once the pre-microRNA is excised from the primary transcript, it is recognised 
by the nuclear export factor Exportin-5 (Exp5), which, together with Ran-GTP, 
transports it through the nuclear pore to the cytoplasm [113].
Cytoplasmic processing by Dicer and miRISC loading
Following the nuclear export, pre-microRNA is processed by the second 
RNase Ill-type protein Dicer, which cleaves off the loop and releases about 
22-base-pair-microRNA duplex [114]. Subsequently, with help of the proteins 
including Dicer, TRBP and PACT, the double-stranded RNA unwinds and one 
of the strands (the guide strand or mature microRNA) is selectively loaded into a large 
complex, called the microRNA-induced silencing complex (miRISC). This contains 
an Argonaute protein as the main component [108]. Then, the microRNA is ready 
to perform its function.
38
Although it has been thought for a long time that the processing pathway described 
above is universal for all animal microRNAs, it is becoming clear that processing 
of different microRNAs may differ substantially, and there is more than a single way 
to produce a mature microRNA. For example, some intronic microRNAs called 
mirtrons, do not require processing by Drosha. Their precursors form a hairpin-like 
pre-microRNA immediately after splicing [115, 116]. Among Drosha-dependent 
microRNAs, on the other hand, there is a large group of microRNAs that are 
processed by the Microprocessor complex (i.e. Drosha and DGCR8 alone). There is 
also a subset of microRNAs that are processed by a larger and more efficient 
complex, containing additionally the RNA helicases p68 and p72, double-stranded 
RNA-binding proteins, heterogeneous nuclear ribonucleoproteins and Ewing’s 
sarcoma proteins [117, 118]. Furthermore, TGF-beta signalling has been shown to 
specifically increase the rate of pri-miR-21 processing by recruitment of p68 
and SMAD protein to the Microprocessor complex [119]. Finally, individual 
microRNA precursors may be a subject of RNA editing, which could then affect 
the processing [120, 121] or specificity of the resulting mature microRNA [122].
1.4.4 Modes of action of animal microRNAs
The initially described and best-studied microRNA function in animals is 
posttranscriptional repression of gene expression. To accomplish this, a mature 
microRNA that has been loaded into the miRISC complex recognises and binds 
to specific mRNA targets. The choice of the targets depends on the presence, usually 
within their 3'UTRs, of sequences at least partially complementary to the microRNA.
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Due to the structure of the miRISC complex, the 5' end of the microRNA (termed 
‘seed’) is particularly well exposed and therefore plays the major role in the target 
recognition [123].
In animals, the great majority of microRNA:mRNA interactions are based 
on imperfect complementarity, and result in inhibition of translation
and/or the mRNA destabilisation [124]. The exact mechanism of translational 
repression by microRNA is still unclear. Some reports suggest that microRNAs affect 
the initiation stage of translation (by competition for cap binding, competition for 
eIF6, or block of mRNA circularisation) while others point at inhibition of elongation 
(by ribosome drop-off) [124]. These discrepancies cannot be simply explained by 
technical or experimental differences. They rather reflect the fact that different 
microRNAs use distinct mechanisms to inhibit translation, or alternatively that 
mechanism may be cell type- or stage-dependent.
In contrast to the first studies, showing that microRNAs reduce protein output without 
influencing the amount of the target mRNA, it has since become clear that in many 
cases lower protein synthesis is accompanied by loss of the mRNA [125]. Further 
investigations have revealed that microRNAs can direct their target mRNAs 
to the cytoplasmic foci called P-bodies, where the mRNAs are not translated but, 
following decapping and polyA tail removal, slowly degraded by exonucleases [126]. 
In addition to what appears to be their major action: mRNA destabilisation 
and inhibition of translation through binding to the 3'UTRs, animal microRNAs have 
been also implicated in other kinds of regulation of gene expression. For instance, 
it has been reported that they can activate or repress translation of specific genes 
in a cell-cycle-stage-dependent manner [127]. Moreover, two independent groups 
have found examples of microRNAs that activate translation of specific target
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mRNAs by binding to their 5'UTRs [128, 129]. A functional microRNA-binding site 
has been also identified within a CDS [130]. Interestingly, a recent computational 
analysis suggests that conserved and very likely functional microRNA-binding sites 
are common in 5'UTRs and CDSs of animal mRNAs [131]. Finally, following 
discoveries of the role of siRNAs and plant microRNAs in regulation of transcription, 
a few animal microRNAs involved in transcriptional gene silencing have been 
identified [132, 133].
1.4.5 MicroRNA role in health and disease
Since only a very short sequence on the target mRNA is necessary for recognition 
by a microRNA, it has been speculated, and since experimentally confirmed, that one 
gene may be regulated by more than just one microRNA. Conversely, one microRNA 
can target many different mRNAs [105]. A highly convincing confirmation 
of the latter comes from two studies that use mass spectrometry to analyse a few 
thousand proteins at once. They show that about one thousand of them are changed, 
in most cases subtly, by introduction or inhibition of a single microRNA 
in a cell [125, 134]. In line with the prediction that they regulate about 30% of human 
genes, microRNAs emerge as one of the most important regulatory systems, greatly 
contributing to the complexity of gene expression. It is not surprising then that they 
play important roles in nearly all biological processes, physiological as well 
as pathological, investigated so far.
The failed attempts to generate a Dicer knockout mouse (the embryos died 
7.5-12 days after fertilisation) are a highly convincing demonstration of importance
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of microRNAs early in mammalian development [135]. Subsequent numerous studies 
examining inactivation of Dicer in selected tissues or manipulation of expression 
of individual microRNAs have shown that microRNAs play crucial roles also in late 
development and normal function of various organs [136-138].
Predictably, microRNAs have been also linked to a range of human diseases, from 
cancer through neurodegenerative diseases to immune disorders, as reviewed 
elsewhere [139]. Their role in cancer has been studied particularly intensively. 
Deregulation of microRNA expression is remarkably widespread in cancers. 
Typically, most of them are downregulated [140]. Interestingly, such expression 
pattern closely resembles that of early mammalian development, suggesting 
an important role in cellular differentiation [140]. To confirm that the change 
in microRNA expression actually played a role in cancer, global downregulation 
of microRNA expression in a cancer cell line was studied. This resulted in increased 
colony formation in culture, and increased tumour growth in nude mice [141]. Not all 
microRNAs, however, have tumour suppressor properties. Some microRNAs act 
as oncogenes. The best-established example is miR-21, which targets apoptosis 
related genes [142]. The enormously quick progress in microRNA research is very 
likely to bring some new diagnostic, prognostic, and therapeutic strategies against 
cancer and other diseases soon.
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1.5 MicroRNAs in the kidney 
and in fibrotic diseases
As microRNAs became a subject of intensive studies just recently, at the beginning of 
the project in 2006 there was very little microRNA data available specifically relevant 
to the kidney or fibrotic diseases. Therefore, it is important to recognise that the vast 
majority of work discussed in this section has been published towards the end or after 
my own practical studies.
MicroRNAs in the kidney
To date, microRNA expression profile in the kidney has been characterised in human 
and mouse tissue [143-146]. One of those reports suggested that some microRNAs, 
namely miR-192, miR-194, miR-204, miR-215, and miR-216, are enriched 
in the kidney when compared with other tissues [143]. Moreover, microRNA 
expression profiles have been also studied separately in renal cortex 
and medulla [147]. In that experiment, the authors not only demonstrated 
a differential expression of several microRNAs in those regions, but also linked that 
to the differences in expression of their target genes [147].
Recent work clearly shows that microRNAs are functional in the kidney. Conditional 
Dicer knockout in murine podocytes leads to proteinuria and finally death within 
a few weeks after birth [148-150] and is associated with various abnormalities 
exhibited by podocytes and glomeruli. However, specific microRNAs and their 
targets responsible for the damage have not been identified.
43
In addition to their role in normal renal physiology, microRNAs have been also 
implicated in a variety of kidney disorders. The first report regarding the role 
of microRNAs in diabetic nephropathy appeared in 2007 [151]. The authors 
demonstrated an increase in miR-192 expression in glomeruli isolated from animal 
models of diabetic nephropathy. Moreover, they found that miR-192 upregulation 
by TGF-beta in murine mesangial cells led to increased collagen 1-alpha 2 synthesis. 
The proposed mechanism included a direct inhibition of ZEB2, one 
of the transcriptional repressors of collagen 1-alpha 2, by miR-192 [151]. A recent 
study from the same laboratory shows that in addition to the collagen gene, miR-192 
indirectly regulates expression of two other microRNAs, miR-216a and miR-217, 
both of which target PTEN, an inhibitor of Akt activation [152].
Another group looking at a role of microRNAs in diabetic nephropathy has reported 
that miR-377 is upregulated both in a mouse model of diabetic nephropathy, 
and in mesangial cells stimulated with TGF-beta or high concentration 
of glucose [153]. The upregulation of miR-377 resulted in an increase in the matrix 
protein fibronectin via downregulation of p21-activated kinase and superoxide 
dismutase.
So far, there has been no data published on microRNA expression in diabetic 
nephropathy in humans. Similarly, the role of microRNAs in proximal tubular 
epithelial cell response to profibrotic factors has not been well-explored yet. The only 
work devoted to this subject that I am aware of has been presented at the American 
Society of Nephrology Meeting in November 2008 [154]. The authors reported that 
TGF-beta causes significant downregulation of miR-192 and miR-215 in mesangial 
and proximal tubular epithelial cells, but not in podocytes. Furthermore, they found 
that miR-192 and miR-215 were decreased in the kidney of diabetic mice.
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Several studies aimed to investigate microRNA functions in other renal pathologies. 
A number of microRNAs have been found to be deregulated in a rat model 
of polycystic kidney disease [155]. Additionally, expression of a few selected 
microRNAs (the miR-200 family, miR-205, and miR-192) has been examined 
inpatients with immunoglobulin A nephropathy [156] and hypertensive 
nephrosclerosis [157]. The authors have reported significant changes in expression 
of some of the tested microRNAs in those conditions and found very weak 
but significant correlations between their expression and clinical parameters. 
For more details of the role of microRNAs in renal non-malignant diseases 
see Table 1.2.
Due to a greater availability of renal tumour tissue and overwhelming evidence that 
microRNAs are very important in cancers, renal cancer has been the most intensively 
studied kidney disease in that context so far. A few groups have performed 
microRNA expression profiling experiments to find microRNAs differentially 
expressed in renal cell carcinoma [158-162] (for summary see Table 1.3). Although 
each study has identified a subgroup of microRNAs that are altered in renal tumours, 
the overlap between the results is unexpectedly small. This may be in part explained 
by differences in experimental design or techniques. In particular, small number 
of tissue samples tested in individual studies may be responsible for the discrepancy. 
Additionally, the use of non-tumourous tissue adjacent to tumours as control provokes 
a question, whether the microRNA expression profile considered “normal” in those 
studies is the same as of the kidney from a healthy person. Overall, the results suggest 
that it is too early now to rely on a microRNA expression pattern for diagnosis 
of renal cancers.
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Finally, two independent groups have investigated microRNA expression in acute 
rejection after renal transplantation [163, 164]. Considering the differences between 
the two studies, it is not very surprising that microRNAs identified as under- 
or overexpressed in acute rejection biopsies also differ greatly. The first group 
compared microRNA expression in the renal allograft after acute transplant 
rejection (n=3) with non-tumourous tissue adjacent to renal tumours (n=3) [163]. 
The second study included more samples (twelve acute rejection samples and twenty 
one controls), and used normal renal allograft tissue as a control [164]. Furthermore, 
the authors have demonstrated that acute rejection and allograft function can be 
predicted based on allograft microRNA expression profile. They have also shown that 
a few of the overexpressed microRNAs are highly expressed in monocytes 
and lymphocytes, suggesting that the observed altered microRNA expression pattern 
in acute rejection is caused by infiltrating immune cells [164].
MicroRNAs in fibrotic diseases
In addition to renal fibrosis, there are dozens of other fibrotic diseases, characterised 
by excessive production and deposition of extracellular matrix. They include 
for instance pulmonary fibrosis, liver cirrhosis, scleroderma, atherosclerosis 
and myocardial fibrosis. Some data on the role of microRNAs in those diseases have 
been already published.
The best-established example is miR-133 function in cardiac disease. It has been 
reported that miR-133 is downregulated in two rodent models of heart disease 
and in human pathological left ventricular hypertrophy [165]. Furthermore, 
the authors have demonstrated that CTGF, a powerful inducer of extracellular matrix
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production (see 1.2.4), is a direct target of miR-133 [165]. Consistent with this, 
another group has shown that miR-133 knockout mice develop severe fibrosis 
and heart failure [166].
Although such findings are certainly interesting, they are usually less relevant to my 
work than the kidney-related data. This is because of different microRNA expression 
patterns in the kidney and other organs/tissues, i.e. many of the microRNAs identified 
to be important in those diseases are not expressed in the kidney.
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1.6 Aim of this thesis
When I started the project, there was no published data regarding microRNA function 
in renal fibrosis, while mounting evidence suggested that microRNAs are enormously 
important factors in regulation of gene expression, and they contribute to various 
physiological and pathological processes. The aim of this thesis was to establish 
if they play an important role also in the kidney, in particular in renal fibrosis.
Specifically, in this thesis I addressed the following questions:
- Which microRNAs are expressed in the kidney or in cultured proximal tubular 
epithelial cells, and which are altered by profibrotic stimuli (microRNA profiling 
experiments)?
- What is the function of all expressed microRNAs in proximal tubular epithelial cells 
(global downregulation of all microRNAs by knockdown of microRNA-processing 
enzymes)?
- What is the function of the differentially expressed microRNAs (manipulation 
of expression of individual microRNAs)?
- Is TGF-beta directly regulated by microRNAs?
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Figure 1.1. The kidney. (A) Human kidneys in situ. (B) Cross-section of the right 
kidney revealing the renal cortex and medulla. (C) Nephron. The renal corpuscule 
(glomerulus, Bowman’s capsule) and the renal tubule (proximal convoluted tubule, 
loop of Henle, distal convoluted tubule) are shown. The illustrations were adapted 
from Encyclopaedia Britannica Online [167] (A,B) or UpToDate [168] (C).
Distal
convoluted
tubule
Collecting 
tu b u le  —
Cortex
Medulla
49
NUCLEUS
ONA
RNA
transcript
transcriptional
control processing
c o n tr o l
inactive  mRNA
CYTOSOL mRNA
degradation 5 
control
mRNA
3
RNA
transport
and
localization
control
translation
control
protein
activity
control
protein
inactive
protein
active
protein ^
Figure 1.2. Control of gene expression in eukaryotic organisms. The steps 
of the DNA-to-protein pathway which may be regulated include: (1) transcription, 
(2) mRNA maturation, (3) mRNA export from the nucleus, (4) translation, 
(5) mRNA degradation, and (6) post-translational modifications influencing 
the protein activity. The scheme was adapted from [68].
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Figure 1.3. The canonical microRNA biogenesis pathway. MicroRNAs are 
transcribed from genomic DNA in the nucleus as long primary microRNAs 
(pri-microRNA). They are processed by Drosha in association with DGCR8 into 
~70 nt precursor microRNAs (pre-microRNA), which are then exported through 
the nuclear pore by Exportin-5. In the cytoplasm, pre-microRNAs are cleaved by 
Dicer into double-stranded RNA complexes. The mature microRNAs (single­
stranded RNA) are incorporated into the miRISC complexes and are ready to interact 
with specific mRNA targets. The scheme was adapted from [169].
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Stage eGFR
(ml/min per 
1.73 m2)
Description Treatment
1 90+
Normal kidney function, but 
urine findings, structural 
abnormalities, or genetic trait 
point to kidney disease
Observation, control of blood 
pressure
2 60-89
Mildly reduced kidney 
function, and other findings 
(as for stage 1) point to 
kidney disease
Observation, control of blood 
pressure and risk factors
3 30-59 Moderately reduced kidney function
Observation, control of blood 
pressure and risk factors
4 15-29 Severely reduced kidney function
Planning for end-stage renal 
failure
5 < 15 Very severe or end-stage renal failure
Control of blood pressure, 
monitoring for uremic 
symptoms, initiation of renal 
replacement therapy
Table 1.1. The stages of chronic kidney disease. The table was adapted from [170], 
eGFR -  estimated glomerular filtration rate.
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Kidney
disease MicroRNA Expression/Function Ref
miR-192, -194, 
-204, -215, -216 Enriched in the kidney. [143]
miR-192,-194, 
-203, -450, -34a Enriched in the cortex.
let-7e, miR-24, 
-30c, -27a, -23, 
-27b, -200b, -99a, 
-125a, -200c,-125b
Enriched in the medulla.
[147]
miR-192
Upregulated in glomeruli of diabetic mice; 
upregulated by TGF-beta in mesangial 
cells; directly targets ZEB2; increases 
collagen 1-alpha 2 synthesis in mesangial 
cells.
[151]
miR-215 Downregulated by TGF-beta in mesangial cells.
Diabetic
nephropathy miR-377
Upregulated in the kidey of diabetic mice;
upregulated by high concentration of 
glucose and TGF-beta in mesangial cells; 
directly targets PAK1, SOD1, and SOD2; 
causes increase in fibronectin in 
mesangial cells.
[153]
miR-192, -215
Downregulated in the kidney of diabetic 
mice; downregulated by TGF-beta in 
mesangial and proximal tubular epithelial 
cells.
[154]
miR-216a, -217
Upregulated in glomeruli of diabetic mice; 
upregulated by TGF-beta in mesangial 
cells; directly target PTEN.
[152]
Polycystic 
kidney disease
miR-31, -217, 
-34b, -126*, -7, 
-128, -136, -99a, 
-448, -380, -20, 
-96, -7b, -379, 
-203, -147, -196a, 
-335, -216, -30a, 
-181b,-346,-377
Downregulated in the kidney of a rat 
model of polycystic kidney disease.
[155]
miR-21 Upregulated in the kidney of a rat model of polycystic kidney disease.
IgA miR-200c Downregulated in renal biopsy samples. [156]nephropathy miR-141 ,-205,-192 Upregulated in renal biopsy samples.
Hypertensive
nephrosclerosis
miR-200a, -200b, 
-141,-429, -205, 
-192
Upregulated in renal biopsy samples. [157]
Table 1.2. MicroRNAs in the kidney and in renal non-malignant diseases.
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Type of 
experiment 
(total number of 
microRNAs 
tested)
Nunn
0
sam
iber
f
pies
Downregulated 
microRNAs 
(total number)
Upregulated 
microRNAs 
(total number)
Ref
C* N*
Hybridisation-based 
microarray (245) 20 3 -
(4)
miR-28, miR-185, 
miR-27, let-7f
[158]
Hybridisation-based 
microarray (470) 16 6
(37; top 10 are 
shown) 
miR-141, miR-200c, 
miR-138, miR-514, 
miR-411, miR-183, 
miR-381, miR-184, 
miR-648, miR-368
(6)
miR-373*, miR-210, 
miR-452*, miR-122a, 
miR-224, miR-155
[159]
Hybridisation-based 
microarray (331) 11 11
(26; examples are 
shown) 
miR-214, miR-422a, 
miR-145, miR-320, 
miR-494
(50; examples are 
shown) 
miR-27a, miR-221, 
miR-34a, miR-103, 
miR-143, miR-15a, 
miR-16, miR-17_5p, 
miR-24, let-7g, 
miR-21
[160]
Hybridisation-based 
microarray (677) 3 3
(12)
miR-200c, miR-720, 
miR-150, miR-214, 
miR-1826, miR-182, 
miR-200b, miR-199a, 
miR-532_5p, miR- 
378, miR-191, miR- 
26a
(21; top 10 are 
shown) 
miR-122, miR-210, 
miR-101, miR-19b, 
miR-489, miR-20b, 
miR-340, miR-15a, 
miR-424, miR-106a
[161]
qRT-PCR-based 
array (384) 28 28
(26; top 10 are 
shown) 
miR-141, miR-200c, 
miR-514, miR-429, 
miR-377, miR-135a, 
miR-154, miR-200a, 
miR-200b, miR-204
(9)
miR-185, miR-34a, 
miR-34b, miR-224, 
miR-592, miR-21, 
miR-142_3p, 
miR-155, miR-210
[162]
* C -  cancer, N -  normal (adjacent non-tumourous) tissue
Table 1.3. Summary of microRNA profiling experiments using renal cell 
carcinoma samples.
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CHAPTER TWO:
M e t h o d s
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2.1 Samples
2.1.1 Cell culture
2.1.1.1 Cell lines 
HK-2
The vast majority of in vitro experiments were performed on the human proximal 
tubular epithelial cell line HK-2 (human kidney-2) [171]. This cell line was 
established by transduction of primary proximal tubule cells from adult human kidney 
with human papilloma virus (HPV 16) E6/E7 genes. These genes facilitate 
proliferation, but do not change cells as profoundly as for example malignant 
transformation. Typically, cells immortalised by them retain many features 
of the primary cells. In particular, they are not tumourigenic in experimental animals, 
do not grow in soft agar, and exhibit contact inhibition [171, 172].
HK-2 cells have previously been shown to be very much like the primary proximal 
tubular cells in terms of both their phenotype and function. For instance, they are 
positive for alkaline phosphatase, gamma-glutamyltranspeptidase, leucine 
aminopeptidase, acid phosphatase, cytokeratin, integrin alpha-3 beta-1, 
and fibronectin; but negative for factor VUI-related antigen, 6.19 antigen and CALLA 
endopeptidase. They also exhibit characteristic for proximal tubular cells sodium- 
dependent, phlorizin-sensitive sugar transport, and produce more cAMP in response
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to parathyroid, but not to antidiuretic, hormone. Moreover, many aspects of proximal 
tubular cell biology, including those relevant directly to this project, have been 
studied in this laboratory in both HK-2 and the primary cells, always giving similar 
results [173, 174].
U937
Posttranscriptional regulation of TGF-beta by an unknown mechanism, similar 
to microRNA action, was reported in U937 cell line 20 years ago [175]. For that 
reason, U937 cells were used in the present study, together with HK-2 cells, when 
investigating the potential role of microRNAs in TGF-beta regulation (Chapter Six). 
The U937 cell line was derived by Sundstrom and Nilsson in 1974 from malignant 
cells obtained from the pleural effusion of a patient with histiocytic lymphoma [176]. 
The cells resemble monocytes, and can differentiate into macrophage-like cells after 
stimulation with phorbol esters, vitamin D3, gamma interferon, TNF, and other 
factors [177-179].
2.1.1.2 Culture conditions
Both cell lines were cultured at 37°C in a humidified incubator (Cell House 170, Heto 
Holten, Derby, UK) in an atmosphere of 5% CO2. Conditions for culture differ 
between HK-2 and U937 cell lines, and were as follows.
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HK-2
A single frozen aliquot of HK-2 cells were obtained from ATCC (LGC Standards, 
Teddington, UK). After three passages, stock cells were prepared as described below 
and stored in liquid nitrogen. Cells were used in experiments up to the passage 30.
Cells were maintained in a 1:1 mixture of Dulbecco’s Modified Eagle’s Medium 
(GIBCO/Invitrogen, Paisley, UK) and Ham’s F12 (Sigma, Poole, UK), supplemented 
with 10% (v/v) fetal calf serum (FCS) (biosera, Ringmer, UK), 20 mM HEPES, 
2 mM L-glutamine, 5 jLig/ml insulin, 5 pg/ml transferrin, 5 ng/ml sodium selenite, 
and 0.4 pg/ml hydrocortisone (Sigma). Fresh growth medium was added to cells 
every three days until confluent. Then they were used in experiments, or subcultured 
at the ratio 1:5.
For subculture, cells were incubated at 37°C with trypsin/EDTA lOx solution 
(Sigma), diluted with PBS (1:10). After ten minutes, equal volume of culture medium 
containing 10% (v/v) FCS was added, cell suspension transferred to a tube, and 
centrifuged for seven minutes at 150 ref at room temperature. The cells were 
resuspended in culture medium and seeded into new culture flasks or plates.
To store frozen in liquid nitrogen, cells were detached from a culture flask 
with trypsin/EDTA, as described above. After centrifugation cells were resuspended 
in culture medium supplemented with 10% (v/v) DMSO and 20% (v/v) FCS, and 
transferred to CryoTube Vials (Nunc/VWR International, Leics, UK). Following
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incubation for 30 minutes at room temperature to allow DMSO enter the cells, the 
tubes were moved to -80°C. Next day, they were transferred to liquid nitrogen.
U937
U937 cells of unknown passage number were in use in the department. Unstimulated 
U937 cells grow in suspension. They were cultured in Roswell Park Memorial 
Institute 1640 medium (GIBCO) supplemented with 2 mM L-glutamine, 
20mMHEPES, and 5% (v/v) FCS. Cell density was maintained between 104 
and 106 cells/ml. Fresh medium was added every three days.
For subculturing, cells were collected from the culture flask and gently centrifuged 
in a long tube for seven minutes at 70 ref at room temperature, so that any dead cells 
or cell debris remained in the supernatant and could be discarded. Cells from 
the pellet were resuspended in the culture medium and part of them (usually 1/20) 
transferred to a new flask.
2.1.1.3 Determination of cell number and viability
To determine total cell number and proportion of dead cells, Trypan Blue stain (BDH 
Chemicals, Poole, UK) was used in conjunction with a hemocytometer. Trypan Blue 
is a negatively charged dye, which does not react with cells unless the membrane is 
damaged. Thus, it can be used to distinguish between live and dead cells. 
The procedure was as follows. Cells in suspension were mixed with 0.4% (w/v) 
Trypan Blue in PBS. Approximately 10 jil was transferred to both chambers
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ofNeubauer hemocytometer by capillary action. Cells were observed under 
microscope (using lOOx magnification) and counted in 5 of 9 squares (1 mm x 1 mm) 
in each chamber. Of cells touching the outer lines, only cells touching top and bottom 
lines were calculated. Viable and non-viable cells were counted separately. If there 
were fewer than 20 or more than 50 cells per square, the dilution of the samples was 
adjusted and the procedure repeated. To calculate the density of cells in the original 
suspension (cells/ml), average number of cells per square was multiplied by dilution 
factor and by 104.
The second method used for examination of relative cell number and/or viability was 
AlamarBlue assay. This employs a non-toxic, cell permeable, blue 
and non-fluorescent dye, resazurin, converted to the pink and fluorescent dye 
resorufin in response to metabolic activity of cultured cells. The fluorescent and 
colorimetric signal is proportional to the number of living cells in the sample. 
To perform the assay, cells were incubated at 37°C with 10% (v/v) solution 
of AlamarBlue reagent (BioSource/Oxford Biosystems, Oxon, UK) in culture 
medium. Typically, after one hour the medium was transferred to a black 96-well- 
plate (100 pl/well) and the fluorescent signal was monitored using 544 nm excitation 
wavelength and 590 nm emission wavelength. Medium with 10% (v/v) AlamarBlue 
reagent, kept in the incubator for one hour before the measurement, was used as a 
blank.
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2.1.1.4 Cell stimulations
Stimulation of HK-2 cells with profibrotic factors
Two main profibrotic factors were used in this study. The first one was the elevated 
concentration of glucose, 25 mM instead of normal 5 mM, in the culture medium. 
This is a concentration in the order of that detected in the blood of diabetic patients, 
and is a standard concentration adopted by many investigators in the study 
of pathological changes elicited by glucose.
The second profibrotic stimulus was recombinant TGF-beta (R&D Systems, 
Abingdon, UK). It was used at the final concentration of 10 ng/ml unless stated 
otherwise. Previous work from this department has characterised phenotypic changes 
in HK-2 cells in response to TGF-beta, with maximal changes observed at this 
dose [174].
Additionally, in some experiments PMA also known as TPA 
(12-O-Tetradecanoylphorbol 13-acetate, Sigma) at the concentration of 160 nM was 
used to stimulate cells. This mostly applies to experiments in which TGF-beta 
secretion to medium was examined, so the use of TGF-beta as a stimulus was not 
ideal, and an alternative profibrotic stimulus was required.
In each case, confluent HK-2 cells were growth-arrested (kept in the medium without 
FCS) for 48 hours before addition of the profibrotic factor, also in FCS-free medium. 
The duration of the stimulation varied from one hour to seven days, depending 
on the experiment design. In longer experiments, medium was replaced every 
48 hours. Unstimulated cells were used as a control. They were treated similarly; 
the only deliberate difference was lack of the stimulus in their medium.
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U937 monocyte differentiation into macrophages
U937 cells at the density 5 x 105 cells/ml in medium with 5% (v/v) FCS were plated 
(900 pl/well on a 12-well-plate) and PMA in FCS-free medium (1.6 pM, 100 pl/well) 
was added, so that the final concentration was 160 nM. After 48 hours, cells were 
stuck to the plastic and bigger, and their number was visibly smaller than 
in the corresponding control wells, in keeping with PMA-dependent 
transformation/activation [177].
2.1.1.5 Transfections
HK-2 cells are easy to transfect, like many other adherent and quickly proliferating 
cell lines. Previously, in this laboratory, they have been successfully transfected 
with small RNA and plasmid DNA using cationic liposomal or polyamine-based 
reagents.
Transient transfections with small RNA molecules
For this project HK-2 cells were transfected with three distinct classes of small RNA 
molecules. These were: siRNAs, synthetic microRNAs, and microRNA inhibitors 
(anti-microRNAs). All were purchased from Ambion (Ambion/Applied Biosystems, 
Warrington, UK). Details of the small RNAs used in the study are given in Table 2.1.
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Transfection reagents
The small RNAs were delivered to the cells using siPORT Amine (Ambion). 
Efficiency of the transfection was occasionally confirmed by use of a very effective 
siRNA designed to silence CD44 (i.e. cause cleavage and subsequent degradation 
of its mRNA). In these experiments the remaining CD44 mRNA was typically less 
than 5% of the control expression, as assessed by quantitative RT-PCR (see 2.2.2), 
suggesting that at least 95% of the cells were successfully transfected (Figure 6 .8A).
Transfection procedure
Cells were trypsinised as described above (see 2.1.1.2). After centrifugation they were 
resuspended in culture medium containing 10% (v/v) FCS, at the density 105 cells/ml. 
During preparation of transfection complexes, the cell suspension was stored at 37 °C. 
Small RNAs were diluted in Opti-MEM I medium (Invitrogen). When transfection 
was performed in 12-well-plates, typically 30 pmol of small RNA was mixed with 
Opti-MEM I at the total volume of 50 pi, so that the final concentration (after 
the transfection complexes are mixed with cells) was 30 nM, as recommended 
by the manufacturer. In a separate tube, 5 pi siPORT Amine was added to 45 pi 
of Opti-MEM I medium, and incubated for exactly ten minutes at room temperature. 
Then, diluted RNA and diluted siPORT Amine were mixed and incubated another 
ten minutes to allow transfection complexes to form. Subsequently, 100 pi 
of the transfection complexes were transferred to culture plate wells, and 900 pi 
of the cell suspension was added. Transfected cells were incubated at 37°C until ready 
to assay.
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Transient transfections with DNA plasmids
Two main kinds of plasmids were used (see Table 2.2). The first group constitute 
plasmids for expression of relatively short RNA molecules: short hairpin RNAs 
(shRNA) or microRNA precursors (pre-microRNA). These plasmids were generated 
as described below, based on siSTRIKE vector (Figure 2.1 A, Promega, 
Southampton, UK), utilizing the human U6 promoter, which is recognised by the 
RNA polymerase III.
Reporter plasmids represent the second kind. The plasmid containing four 
SMAD-binding elements (SBEs) in the promoter region of the firefly luciferase gene, 
useful to study TGF-beta signaling, was a kind gift from Aristidis Moustakas, Ludwig 
Institute for Cancer Research, Uppsala University, Uppsala, Sweden [180]. Two other 
plasmids with 3'UTR of ZEB1 or ZEB2 downstream the firefly luciferase coding 
sequence, to study posttranscriptional regulation of those genes, were constructed as 
described below by modification of the pGL3 plasmid (Figure 2.2A, Promega). 
As a control for transfection efficiency in reporter assays, a plasmid encoding Renilla 
luciferase under a strong constitutive promoter (SV40), the pRL plasmid (Promega), 
was routinely cotransfected with the firefly luciferase-expressing reporter 
plasmids (ratio 1:9).
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Construction o f siSTRIKE U6-based plasmids for expression o f shRNAs
or pre-microRNAs
The plasmids for expression of shRNA or pre-microRNA were generated by ligation 
of annealed DNA oligonucleotides A and B (for sequences see Table 2.2) into 
the siSTRIKE U6 vector, in accordance with the manufacturer’s advice.
Oligonucleotide design
The first oligonucleotide (A) contained the overhang ACCG (complementary to the 
sticky ends in the siSTRIKE U6 plasmid; the G nucleotide is the transcription start 
site); a hairpin sequence (for shRNA expression this is -  19-nucleotide-long fragment 
of the mRNA target sequence, the recommended loop sequence AAGTTCTCT, 
and the sequence complementary to the target; for pre-microRNA-expressing 
plasmids this is the pre-microRNA sequence as found in the miRBase 
release 10 [106]); the U6 termination sequence (TTTTT); an additional C residue (to 
form a new Pstl restriction site upon ligation of the insert; to distinguish the plasmids 
containing the insert from those without it).
The second oligonucleotide (B) began with the overhang TGCA (complementary 
to the sticky ends in the siSTRIKE U6), and the rest of the sequence was 
complementary to the oligonucleotide A, except for the last four nucleotides.
Oligonucleotide annealing
The oligonucleotides A and B were annealed by incubation at 90°C for three minutes, 
followed by incubation at 37°C for 15 minutes in the Oligo Annealing Buffer 
(Promega) at the final concentration of 40 ng/jil each.
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After the annealing, the oligonucleotides formed double-stranded DNA 
with 5' overhangs (different on each end), complementary to the overhangs 
in siSTRIKE U6, to enable effective and directional ligation.
Ligation o f the annealed oligonucleotides into siSTRIKE U6 vector
The annealed oligonucleotides (4 ng each) were mixed with the linear siSTRIKE U6
vector (50 ng) and T4 DNA ligase (3 units, Promega) in the Rapid Ligation Buffer
(Promega) in the total volume of 10 pi. Ligation was carried out for one hour at room
temperature.
Transformation o f  Escherichia coli
Chemically competent Escherichia coli (BIOLINE, London, UK) were thawed on ice. 
Subsequently, 2.5 pi of ligation reaction was added to 50 pi of bacteria suspension, 
and incubated on ice for 30 minutes. The tube was then placed at 42°C for 45 seconds, 
and chilled on ice for two minutes. Following addition of 500 pi SOC medium 
(Invitrogen), the tube was incubated for one hour at 37°C with shaking. Usually, 
100 pi of cell transformation mixture was spread on an YTx2 agar plate containing 
100 pg/ml ampicilin, and incubated at 37°C overnight.
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Plasmid amplification in E. coli and purification
Plasmids were purified using HiSpeed Plasimd Purification Kit (QIAGEN, 
Crawley, UK), according to manufacturer’s instructions. Briefly, a selected colony 
from the agar plate was transferred to a tube containing 5 ml YTx2 broth 
with 100 jig/ml ampicilin, and incubated in an orbital shaker at 37°C for four to eight 
hours. Then, 800 pi of the bacterial culture was mixed with 200 pi of glycerol, and 
stored frozen at -80°C. The rest (-4  ml) was moved to a conical with 100 ml YTx2 
broth with ampicilin. After overnight incubation at 37°C with vigorous shaking, 
bacteria were centrifuged for 30 minutes at 3000 ref at 4°C. The bacterial pellet was 
resuspended in 6 ml of resuspension buffer (Buffer PI), and 6 ml of lysis buffer 
(Buffer P2) was added. After five minutes at room temperature, 6 ml of cold 
neutralization buffer (Buffer P3) was added. The mixture was poured into the barrel 
of the QIAfilter Cartridge, and left for ten minutes, until a precipitate (containing 
proteins, genomic DNA, and detergent) formed a layer on top of the solution. The cell 
lysate was then filtered into a HiSpeed Tip, pre-equilibrated with 4 ml of equilibration 
buffer (Buffer QBT). The filtrate was allowed to enter the resin by the gravity flow. 
Subsequently, the HiSpeed Tip was washed with 20 ml of wash buffer (Buffer QC), 
and DNA was eluted with 5 ml of elution buffer (Buffer QF). The DNA was 
precipitated by addition of 3.5 ml of room temperature isopropanol. After five 
minutes, the eluate/isopropanol mixture was filtered through a QIAprecipitator 
module. The DNA in the QIAprecipitator was then washed with 2 ml of 70% (v/v) 
ethanol, dried by pressing air through the QIAprecipitator, and eluted with 500 pi 
of water. All plasmids were stored at -20°C.
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Verification o f the plasmid identity
A new Pstl restriction site is created in the siSTRIKE U6 plasmid as a result 
of a successful ligation. The plasmid before ligation already contains one Pstl site. 
Thus, the plasmids containing the inserts after digestion with Pstl give two products 
(-3.0 and 1.4 kbp). The diagnostic digestion of newly created plasmids with Pstl was 
routinely performed as follows.
Plasmid concentration was quantified with a UV spectrophotometer, as described 
in more detail for RNA (see 2.2.1.1), except that in the equation used for calculation 
of DNA concentration, A260nm is multiplied by the factor of 50 rather than 40 (total 
RNA) or 33 (small RNA). Usually 1 pg of plasmid DNA was digested with 20 units 
of Pstl in the recommended buffer at 37°C for four hours. Then, the samples were 
separated on a 1% (w/v) agarose gel as described in detail for RNA electrophoresis 
(see 2.2.1.1). Samples without the enzyme were processed similarly and run on the 
same gel. A typical outcome is shown on Figure 2.IB.
Additionally, in all cases, the plasmid sequences were confirmed by sequencing 
by the Sequencing Service at the University of Dundee.
Construction o f oGL3-based reporter plasmids with 3'UTR ofZEBl or ZEB2
Modification o f pGL3 vector
As a preparatory step before generation of reporters with ZEB1 or ZEB2 3'UTR 
downstream of luciferase coding sequence, pGL3 vector, which originally has only 
one restriction site downstream of the firefly luciferase CDS (for Xbal), was modified 
to facilitate directional cloning.
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Digestion of pGL3 vector with Xbal was performed like the siSTRIKE U6 plasmid 
digestion with Pstl described above. After the digestion Xbal was inactivated 
by incubation at 60°C for 20 minutes. A short insert (two annealed oligonucleotides, 
see Table 2.2), containing one restriction site for EcoRl and destroying the second 
restriction site for Xbal, was ligated as described above into the A7?al-digested pGL3 
vector. E. coli transformation with the ligation products, followed by plasmid 
amplification and purification, was carried out as described above.
As the insert could be ligated into the plasmid in both directions with equal 
probability, the inserts additionally contained part of the PshAI restriction site, which 
formed the full functional PshAl restriction site only when ligated in the desired 
direction, i.e. with Xbal restriction site followed by the ZscoRI site. The second PshAl 
restriction site was already present in the pGL3 vector, so the properly modified pGL3 
vector (called later pGL3-Xbal/EcoRl) would give two bands on a gel (576 bp 
and 4711 bp) when digested with PshAl, one band (distinct from the undigested 
plasmid) when incubated with Xbal, and one band (distinct from the undigested 
plasmid) after digestion with EcoRl (Figure 2.2B)
Insertion ofZEBl or ZEB2 3'UTR into the modified pGL3 vector 
To generate the reporters with ZEB1 or ZEB2 3'UTR downstream of the firefly 
luciferase CDS, based on the pGL3-XbaUEcoKL vector, those regions 
(-1.7 or -1.4 kbp, respectively) were PCR-amplified from HK-2 cell genomic DNA.
The genomic DNA was isolated from -6  x 106 unstimulated HK-2 cells, which were 
trypsinised and centrifuged as described above (see 2 .1.1.2), and resuspended 
in 400 pi Digestion Buffer and 4 pi Protease (both from the Recover All Total Nucleic
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Acid Isolation Kit, Ambion, used mainly for isolation of RNA from FFPE samples, 
see 2.2.1.2). After overnight incubation at 50°C, the cell lysate was mixed 1:1 (v/v) 
with basic-phenol:chloroform containing 1% (v/v) isoamyl alcohol, and centrifuged 
for five minutes at 13000 ref at room temperature. The upper (aqueous) phase was 
collected and mixed with 500 pi of chloroform, and centrifuged again. DNA from 
the aqueous phase was precipitated in a new tube by addition of 500 pi 
of isopropanol. After one hour at 4°C, the precipitate was pelleted by centrifugation 
for three minutes at 13000 ref at 4°C, washed twice with 70% (v/v) ethanol, air-dried 
for 15 minutes, and 100 pi of water was added, before dissolving in water overnight 
at4°C. Subsequently, the genomic DNA concentration was measured as described 
above for plasmid DNA, and stored frozen at -20°C in small aliquots.
The genomic DNA was used subsequently as a template for amplification of ZEB1 
and ZEB2 3'UTR by PCR. For the PCR, high-fidelity Platinum Pfx DNA Polymerase 
(Invitrogen) was used, together with the recommended buffer. The optimal PCR 
conditions were slightly different for ZEB1 and ZEB2 3'UTRs, and were as follows 
(per 50 pi reaction):
Components Plasmid pGL3-Xbal/EcoRl
ZEB1 3'UTR ZEB 2 3'UTR
lOx PCR Buffer 10 pi 5 pi
2.5 mM dNTP 6 pi 6 pi
50 mM MgS04 1 pi 1 pi
Water 19 pi 14 pi
Pfx Polymerase 1 pi 1 pi
Genomic DNA 10 pi (80 ng/pl) 20  pi (10  ng/pl)
10 pM F-PCR-primer 1.5 pi 1.5 pi
10 pM R-PCR-primer 1.5 pi 1.5 pi
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The PCR-primers (listed in Table 2.2) for ZEB2 3'UTR contained Xbal and EcoRl 
restriction sites, and for ZEB1 3'UTR -  SpeI and EcoRl (Xbal could not be used, 
because there is additional Xbal site within the ZEB1 3'UTR; Spe I generates the same 
sticky ends as Xbal, but recognises different sequence).
The cycling conditions were as recommended by the manufacturer. The template was 
denatured for three minutes at 94°C. That was followed by 30 (ZEB1) or 35 cycles 
(ZEB2) of: 15 seconds at 94°C, 30 seconds at 55°C, two minutes at 68°C. Finally, 
the reactions were chilled at 4 °C.
The PCR products were gel-purified using the QIAquick Gel Extraction Kit 
(QIAGEN) according to manufacturer’s instructions. Briefly, the PCR products were 
separated on a 1% (w/v) agarose gel, as described for RNA (see 2.2.1.1). The DNA 
bands were excised from the gel using a clean scalpel. The fragments were weighed, 
and three volumes of Buffer QG were added to one volume of gel (assuming that 
1 mg of gel is -1 pi). Following ten minute incubation at 50°C, one volume 
of isopropanol (Sigma) was added. To bind DNA, the samples were transferred to 
a QIAquick spin column placed in a centrifuge tube, and centrifuged for one minute 
at 13000 ref. The flow-through was discarded and the column washed with 750 pi 
of Buffer PE. The DNA was finally eluted with 50 pi of water.
The purified PCR products were digested with the appropriate restriction enzymes, 
as described above for digestion with Pstl. Subsequently, they were incubated 
for 30 minutes at 37°C with shrimp alkaline phosphatase, to prevent ligation of two 
or more inserts. Then, the enzyme was inactivated by ten minute incubation at 65°C, 
and the cut PCR products were gel-purified again with the QIAquick Gel Extraction 
Kit, as described above, except that the DNA was eluted with 30 instead of 50 pi 
of water.
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The modified pGL3 (pGL3 -X&aLEcoRI) plasmid was digested with Xbal and EcoRl, 
and gel-purified. Subsequently, 1 pi of pGL3-Xbal/EcoKL was mixed with 7 pi 
of the PCR products (3’UTR of ZEB1 or ZEB2, with appropriate sticky ends). 
The ligation, transformation of E. coli, and all the following steps were performed 
as described above. Confirmation that the obtained plasmids are as expected came 
initially from the digestion of the plasmids with Xbal and EcoRl (ZEB2 3’UTR), 
or BamHl and Pstl (ZEB1 3’UTR, choice of restriction enzymes explained 
in the figure legend) and estimation of size of the cut fragments (Figure 2.3). 
Ultimately, their sequence was confirmed by the Sequencing Service at the University 
of Dundee.
Transfection reaeents
As there are a few commercially available transfection reagents for DNA plasmid 
delivery, before starting the main experiments, I compared four of them in terms 
of transfection efficiency and their effect on HK-2 cells: FuGENE 6 (Roche, Burgess 
Hill, UK), Lipofectamine LTX with or without PLUS Reagent, and Lipofectamine 
2000 (all from Invitrogen) (Figure 2.4). The results suggested that the best 
transfection reagent for my experiments will be Lipofectamine LTX together 
with PLUS Reagent, as it is much more effective than FuGENE 6, and does not cause 
any visible effect on HK-2 cell viability, unlike Lipofectamine 2000.
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Transfection procedure
Lipofectamine LTX with (or without) PLUS Reagent
One day before transfection, cells were trypsinised and plated on a 12-well-plate, 
so that they were -70% confluent at the time of transfection. For each transfection 
sample, 1 pg of plasmid DNA was diluted in 200 pi Opti-MEM I. After mixing, 1 pi 
of PLUS Reagent was added (or not). The sample was mixed and incubated for five 
minutes at room temperature. Then, 2.5 pi of Lipofectamine LTX was added to the 
tube. The sample was mixed and incubated for 30 minutes at room temperature. 
Subsequently, 200 pi of the transfection mix was added to wells with cells, and they 
were incubated at 37°C until ready to assay.
Lipofectamine 2000
One day before transfection, cells were trypsinised and plated on a 12-well-plate, 
so that they were -90% confluent at the time of transfection. For each transfection 
sample, 1.6 pg of plasmid DNA was diluted in 100 pi Opti-MEM I medium. 
In a separate tube, 4 pi of Lipofectamine 2000 was diluted in 100 pi Opti-MEM I. 
After five minutes, the diluted DNA and diluted Lipofectamine 2000 were combined 
and incubated for 20 minutes at room temperature. Then, the transfection complexes 
were added to cells in 800 pi FCS-free medium per well. Before testing, the cells 
were incubated at 37°C for 48 hours.
FuGENE6
One day before transfection, cells were trypsinised and plated on a 12-well-plate, 
so that they were -70% confluent at the time of transfection. For each transfection
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sample, 1.5 pi of FuGENE 6 was mixed with 50 pi FCS-free HK-2 cell medium. 
After five minutes, 0.5 pg of plasmid DNA was added, and transfection complexes 
were allowed to form for 15 minutes at room temperature. Subsequently, 50 pi 
of transfection mix was added to cells in 500 pi FCS-free medium per well. The cells 
were then incubated for 48 hours at 37°C.
Transient transfections with small RNAs and with DNA plasmids
Occasionally, there was a need to cotransfect HK-2 cells with both small RNAs 
and DNA reporter plasmids.
Transfection reaeents
Of the transfection reagents available, only Lipofectamine 2000 has been 
recommended for transfection of small RNA molecules and/or DNA plasmids. 
The design of the experiments facilitated assessment of the efficiency of delivery 
of both the small RNAs and the plasmids.
Transfection procedure
One day before transfection, cells were trypsinised and plated on a 12-well-plate, 
so that they were -80% confluent at the time of transfection. For each transfection 
sample, 1 pg of plasmid DNA and 40 pmol of small RNA were diluted in 100 pi 
Opti-MEM I medium. In a separate tube, 4 pi of Lipofectamine 2000 was diluted in 
100 pi Opti-MEM I. After five minutes, the diluted nucleic acids and diluted 
Lipofectamine 2000 were combined and incubated for 20 minutes at room
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temperature. Subsequently, the transfection complexes were added to cells in 800 pi 
medium with 10% (v/v) FCS. The cells were then incubated at 37°C before testing.
Stable transfections
In some experiments, prolonged expression of shRNA or pre-microRNA was desired. 
As these were expressed from the siSTRIKE U6 plasmid, which contains a puromycin 
resistance gene, it was possible to establish modified HK-2 cell lines that stably 
express the desired RNA molecules.
Characterisation o f the toxic effect o f puromycin on HK-2 cells 
As a prerequisite for stable transfections, the toxic effect of puromycin on HK-2 cells 
was examined (Figure 2.5). The cells were seeded on 96-well-plates in various 
densities (from 3 to 12 thousand cells per well), and (immediately or 24 hours later) 
they were treated with increasing concentrations of puromycin within 
the recommended range for mammalian cell lines: 1-10 pg/ml. Their viability was 
assessed 72 hours after addition of puromycin by the AlamarBlue assay (as described 
in 2.1.1.3). The puromycin concentration of 9 pg/ml was chosen for the subsequent 
selection of stably transfected cells.
Transfection reasents and procedure
Transfection was carried out exactly as described above for transient transfection 
with DNA plasmids using Lipofectamine LTX and PLUS Reagent.
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Selection o f transfected cells
Stably transfected cells were selected by addition of puromycin (9 jxg/ml) to medium 
48 hours after transfection, and were kept in medium with puromycin afterwards. 
Untransfected cells (or in some experiments cells transfected with plasmids without 
the puromycin resistance gene) were used as a negative* control. All these cells died 
within one week after addition of puromycin, as did the large proportion of cells 
transfected with siSTRIKE U6-based vector. Many of the latter cells died later, 
presumably because of the protective effect of the transient expression 
of the puromycin resistance gene. Approximately three weeks after transfection, 
stably transfected cells formed colonies, and there were enough cells for storage in 
liquid nitrogen, and for precise calculation of cell number.
Isolation o f sinsle lines
The cells were plated to a mean density of 0.5 cells per well on 96-well-plates, 
and cultured until colonies were easily visible under the microscope (approximately 
three weeks). Then, typically, six different wells were selected (forming large or small 
cell colonies, as the RNA expressed could potentially affect cell growth/proliferation). 
100 pi of Trypsin/EDTA was added to the chosen wells. Following 15 minutes 
at 37°C, equal volume of culture medium (containing 10% (v/v) FCS and puromycin) 
was added, and the cells were transferred to a 12-well-plate containing 1 ml 
of the complete medium. A few days later, when they became confluent, they were 
transferred to bigger cell culture dishes, to facilitate subsequent preparation 
of samples for liquid nitrogen storage (see 2 .1.1.2), cell line characterisation 
by qRT-PCR (see 2.2.2 and 2.2.3.2), and cell maintenance for later experiments.
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2.1.2 Tissue samples
Formaldehyde-fixed, paraffin-embedded (FFPE) kidney biopsy samples of 40 patients 
with diabetic nephropathy, previously characterised by Lewis et al. [181] were 
examined.
In the previous work, a computer search was performed on the archive 
of the Histopathology Department, University Hospital of Wales, to identify renal 
biopsies with the term diabetes in the diagnosis list. After leaving out the biopsies that 
showed dual pathology and transplant kidney biopsies, 40 renal biopsies taken 
between 1992 and 2000 were included in the study.
Official biopsy reports were obtained on all the samples, providing information about 
renal function, defined as the eGFR (see 1.2.2), at the time of the biopsy, 
and in the following years if possible. Additionally, in the preceding study, 
the samples were characterised structurally. In particular, fibrosis scores were 
determined using the grading system of Shih [182].
Patients were divided into three groups [181]. Those who had chronic kidney disease 
stage 5 (see 1.2.2) or requiring renal replacement therapy within six months of their 
renal biopsy were referred to as late presenters. Patients who had deterioration 
of > 5ml/min/year in their eGFR in follow up (which also equated to a > 10% change 
in the starting eGFR), were termed progressors, and those who did not satisfy these 
criteria were termed non-progressors. Mean duration of follow up was longer for 
non-progressors than progressors (6.11+2.75 years vs. 3.67+2.85 years), suggesting 
that differences between groups did not reflect an inadequate period of follow-up.
The patient information, including age, sex, date of the biopsy, eGFR at the time 
of the biopsy, subsequent change in eGFR, fibrosis score, is given in Table 2.3.
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2.2 RNA analysis
2.2.1 RNA extraction, quantification, and 
quality control
2.2.1.1 Cell culture samples 
RNA extraction
Some of the traditional methods for RNA isolation are not suitable for small RNA 
analysis. Therefore, the RNA extraction method commonly used in this laboratory 
(TRI Reagent, Sigma) was compared with the method designed specially to recover 
small RNAs (mirVana miRNA Isolation Kit, Ambion).
RNA extraction with TRI Reaeent
TRI Reagent is an improved version of the RNA isolation reagent developed 
by Chomczynski [183]. It combines phenol and guanidine thiocyanate to facilitate 
the immediate inhibition of RNase activity. A biological sample is lysed in TRI 
Reagent and the lysate is separated into aqueous and organic phases by chloroform 
addition and centrifugation. RNA remains in the aqueous phase, whereas DNA 
and proteins relocate to the interphase or the organic phase, respectively. RNA is 
precipitated from the aqueous phase by addition of isopropanol, washed with ethanol 
and solubilised. The detailed procedure was as follows.
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At the end of the experiment, cells were washed with PBS, and TRI Reagent was 
added to the wells (600 pl/well on 12-well-plates, or 1 ml/well on 6-well-plates). 
After ten minutes at room temperature, the lysate was transferred to a tube, and 
chloroform (Sigma) was added (200 pi to 600 pi of the lysate, or 300 pi to 1 ml). 
Following vigorous vortexing, the sample was incubated for five minutes at room 
temperature, and then centrifuged for 45 minutes at 13000 ref at 4°C. The upper 
(aqueous) phase was transferred to a new tube and mixed with 400 pi or equal volume 
(whichever is greater) of isopropanol (Sigma). The sample was then kept overnight 
at -80°C. The precipitated RNA was pelleted by centrifugation for 45 minutes 
at 13000 ref at 4°C, and the pellet was washed three times with 1 ml of 70% (v/v) 
ethanol. After final centrifugation (15 minutes at 13000 ref at 4°C), the pellet was air- 
dried for 15 minutes in the fume hood, and resuspended in 20-35 pi of water (so that 
the RNA concentration was approximately 200 ng/pl). The RNA was then stored 
at -80°C.
RNA isolation with mirVana miRNA Isolation Kit
RNA isolation with the mirVana miRNA Isolation Kit starts with an organic 
extraction step, similar to the previous method. Then, RNA is immobilised and further 
purified on a glass-fiber filter. Depending on the ethanol concentration used 
in the immobilisation step, total, large (> 200 nt) or small (< 200 nt) RNA fractions 
can be obtained.
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Total RNA isolation
To isolate total RNA using this method, after a wash with PBS, cells were lysed 
with 600 (il of Lysis/Binding Solution, and transferred to a tube. 60 j l l I  of miRNA 
Homogenate Additive was added and the sample mixed vigorously. After ten minutes 
on ice, 600 pi of Acid-Phenol:Chloroform was added and the sample was vortexed 
for one minute. The sample was centrifuged for ten minutes at 10000 ref at room 
temperature. The upper (aqueous) phase was transferred to a new tube, and mixed 
with 1.25 volumes of room temperature 100% ethanol. The mixture (700 pi 
at the time) was transferred onto a Filter Cartridge in a centrifuge tube. 
After centrifugation for 15 seconds at 10000 ref, RNA was bound to the filter, while 
the other substances passed through and were discarded. That was repeated until all 
the sample mixture had passed through the filter. RNA bound to the filter was washed 
once with 700 pi Wash Solution 1, and then twice with 500 pi Wash Solution 2/3. 
RNA was eluted with 100 pi pre-heated to 95°C water and stored at -80°C until 
needed.
Small or large RNA isolation
To obtain small (< 200 nt) or large (> 200 nt) RNA fractions, after organic extraction 
(as described above for total RNA isoloation), the aqueous phase was mixed with 1/3 
volume of room temperature 100% ethanol. The mixture was placed onto a Filter 
Cartridge in a centrifuge tube. After centrifugation for 15 seconds at 10000 ref, large 
RNA was bound to the filter, while small RNA, because of relatively low ethanol 
concentration in the mixture, passed through. The large RNA fraction was recovered 
from the filter using the procedure for total RNA. The small RNA in the filtrate was 
mixed with 2/3 volumes of room temperature 100% ethanol, and applied to a new
79
Filter Cartridge. With a higher concentration of ethanol, small RNA molecules were 
now bound to the filter, and were washed and eluted as described above for total 
RNA. To confirm that the obtained fractions contained RNA of the expected size, 
the isolated RNA was separated on an agarose gel as described below (Figure 2.6).
For comparison of the two methods, total RNA obtained with either of them was 
quantified as described below, and 1 pg of each sample was separated on an agarose 
gel (Figure 2.7A). Additionally, a model microRNA, miR-16, was quantified 
by qRT-PCR (see 2.2.3.2) in both the RNA preparations (Figure 2.7B). No difference 
was seen in the small RNA fraction on the gel and in miR-16 expression 
by qRT-PCR. Thus for the majority of subsequent experiments RNA was isolated 
using the cheaper option, TRI Reagent. mirVana miRNA Isolation Kit was used 
for preparation of RNA for microRNA profiling using the mirVana miRNA 
Bioarrays (see 2.2.3.1).
RNA quantification and quality control
RNA concentration was measured using a UV spectrophotometer. Absorbance 
at the wavelength 260 nm (A260nm) was assessed to calculate the nucleic acid 
concentration, using the following equations (for total and small RNA preparations):
[RNA] = A260nm* 40 * dilution factor Total RNA
(pg/ml)
[RNA] = A260nm* 33 * dilution factor Small RNA
(pg/ml)
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To ensure accuracy, the samples were diluted prior to the measurement, so that 
the absorbance value fell between 0.1 and 1.0.
In addition to the reading at 260 nm, the absorbance at 280 nm (A280nm) was also 
measured. The ratio of A260nm to A280nm indicated whether the sample was heavily 
contaminated with other molecules, such as proteins. Only the samples with a ratio 
above 1.5 were used for further analysis.
Alternatively, RNA concentration in diluted samples was measured using a more 
sensitive, fluorescence-based method, Quant-iT RNA Assay (Invitrogen). The assay 
is highly selective for RNA and exhibits a linear detection range between 5 ng 
and 100 ng RNA. The quantification was performed according to the manufacturer’s 
instructions. Briefly, Quant-iT RNA reagent was mixed with Quant-iT RNA 
buffer 1:200. To 200 pi of that mixture 1-20 pi of RNA standards or my 
RNA samples were added. After two minute incubation at room temperature, 
fluorescence was measured with the Qubit fluorometer (excitation/emission 
wavelengths: -644/673 nm).
To determine RNA integrity, 0.5 to 1 pg of RNA was routinely separated on 3% (w/v) 
agarose gel. Before loading the RNA samples into the gel, they were mixed with the 
gel loading buffer (Ambion). The gel was prepared by dissolving of agarose in TAE 
buffer (Promega) containing 0.5 pg/ml ethidium bromide. Electrophoresis was carried 
out in TAE buffer usually for one hour at 100 V. The presence of ethidium bromide in 
the gel made possible subsequent visualisation of RNA in UV light. Typically, two 
strong distinct bands (28S and 18S rRNA) were visible.
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2.2.1.2 Tissue samples
RNA extraction
RNA extraction from 40 FFPE kidney biopsy samples (see 2.1.2) was performed 
using the RecoverAll Total Nucleic Acid Isolation Kit (Ambion), especially designed 
for isolation of RNA and DNA from FFPE samples. Prior to the main experiment, this 
method was tested on 4 FFPE renal biopsy samples not included in the study.
For RNA isolation with the RecoverAll Total Nucleic Acid Isolation Kit, FFPE 
samples were processed according to the manufacturer’s instructions. Briefly, they 
were deparaffinised using a series of xylene and ethanol washes. Subsequently, they 
were digested with a protease. Then, RNA was purified using a rapid glass-fiber filter 
methodology, including an on-filter treatment with a DNase, and were eluted into 
water. The detailed procedure was as follows.
The FFPE renal tissue blocks were cut into 20 pm sections (as recommended 
for maximum microRNA recovery), using a microtome in the Histopathology 
Department by the Cardiff University School of Medicine Central Biotechnology 
Services (CBS). From each sample, five sections were taken, the outer one was 
discarded, and RNA was isolated from the remaining four slices.
To remove paraffin, the sections were incubated with 1 ml of 100% xylene (Sigma) 
for three minutes at 50°C, and then centrifuged for two minutes at 13000 ref at room 
temperature. The pellet was washed twice with 1 ml of 100% ethanol, and air-dried 
for 15 minutes.
Subsequently, 400 pi of Digestion Buffer and 4 pi of Protease were added per sample, 
and the samples were incubated at 50°C for three hours.
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For RNA isolation, 480 j l l I  of Isolation Additive was added to each sample, mixed, 
and then 1.1 ml of 100% ethanol was added. The mixture (700 pi at the time) was 
placed onto a Filter Cartridge in a centrifuge tube. After centrifugation for 30 seconds 
at 10000 ref, the nucleic acids present in the mixture were bound to the filter, while 
the other substances passed through and were discarded. That was repeated until all 
the sample mixture was through the filter.
The nucleic acids bound to the filter were washed once with Wash 1 buffer, and then 
with Wash 2/3 buffer. DNA was removed from the preparation by incubation with 
60 jllI of DNase mix (containing 6 pi of lOx DNase Buffer, 4 |il DNase, and 50 pi 
water) for 30 minutes at room temperature.
The filter was washed again with Wash 1 buffer, and then twice with Wash 2/3 buffer. 
RNA was eluted by addition of water pre-heated to 95°C (2x 30 pi). Small aliquots of 
all the samples were taken for quality control, and the rest was stored at -80°C until 
analysis.
RNA quantification and quality control
As the RNA amount isolated from FFPE kidney biopsies was expected to be very 
small, to assess RNA yield and quality in the samples, microfluidics analysis was 
performed by CBS. For that, they used Agilent’s 2100 bioanalyser together with 
the RNA PicoChip Kit (Agilent Technologies, Stockport, UK). Each RNA chip 
contains an interconnected set of microchannels that is used for separation of nucleic 
acid fragments based on their size as they are driven through it electrophoretically. 
The data obtained by this method are analogous to those from RNA agarose gels,
83
but as little as 0.2 ng of RNA is sufficient for the analysis. Moreover, it also estimates 
RNA concentration of a sample.
Additionally, to determine suitability of the samples for microRNA detection 
by qRT-PCR, expression of miR-16, known to be expressed in many tissues and cell 
lines, including HK-2 cells, was analysed by qRT-PCR (see 2.2.3.2).
Before proceeding with array-based quantitation of microRNAs, detailed analysis 
of the 4 extra FFPE samples was performed, to establish that the extraction procedure 
was effective, and to determine an optimal method for quality control of subsequent 
samples. Firstly, the RNA concentrations were determined by PicoChip, 
and compared with the values obtained with the Quant-iT RNA Assay (see 2.2.1.1) 
(Figure 2.8A,B).
Subsequently, relative expression of miR-200b and miR-16 was evaluated 
by qRT-PCR. A constant ratio of miR-200b to miR-16 was seen in the samples 
(Figure 2.8C,D). Moreover, for both microRNAs, 5x and 25x dilution of the samples 
resulted in expected ~5x and -25x reduction in microRNA expression (Figure 2.8F), 
suggesting that the assays work properly and no PCR inhibitors are present in RNA 
preparations.
Finally, the qRT-PCR assay for miR-16 quantification developed for this study, used 
for miR-16 detection in all the 40 FFPE samples, gave almost identical results 
to the miR-16-specific TaqMan assay supplied by Applied Biosystems 
(Figure 2.8C,E). That was further confirmed using the both assays on HK-2 cell RNA 
samples (Figure 2.1 ID).
84
2.2.2 Messenger RNA detection
Messenger RNA (mRNA) was measured in cell culture samples by two-step 
quantitative reverse transcription -  polymerase chain reaction (qRT-PCR).
2.2.2.1 Reverse transcription
Reverse transcription (RT) was performed using High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). Briefly, 1 pg of total RNA in 10 pi of water 
was added to 10 pi of the RT mix containing: 3.2 pi water, 2 pi lOx RT Buffer, 
2 pi lOx Random Primers, 0.8 pi 100 mM dNTP Mix, 1 pi RNase Inhibitor, 
and 1 pi MultiScribe Reverse Transcriptase. Two types of negative control for RT 
step were used:
- Non-template control (RT-NTC), which did not contain RNA;
- RT-negative control, which did not contain MultiScribe Reverse Transcriptase.
The following thermal profile in a thermal cycler was used: ten minutes at 25°C, 
two hours at 37°C, five seconds at 85°C, and cooling to 4°C.
After the reaction, samples (cDNA) were diluted (5x) by addition of 80 pi of water, 
and used in quantitative polymerase chain reaction (qPCR) or stored at -20°C, 
as recommended by the manufacturer.
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2.2.2.2 Quantitative polymerase chain reaction
There are two main chemistries used to detect PCR products in qPCR:
- TaqMan chemistry, which uses a fluorogenic probe, binding specifically to the target 
mRNA between the PCR-primers;
- SYBR Green chemistry, which uses SYBR Green dye, binding non-specifically 
to double-stranded DNA.
Both types of qPCR were used in the study. For a full list of the TaqMan assays and 
primers used see Table 2.4.
TaqMan assays
Master mix for every gene tested was prepared by combining together a gene-specific 
set of PCR-primers and TaqMan probe (designed and supplied by Applied 
Biosystems) (1 pl/reaction), water (5 pl/reaction), and 2x TaqMan Universal PCR 
Master Mix (Applied Biosystems) (10 pl/reaction), containing a thermostable DNA 
polymerase, deoxynucleotides, optimized concentration of ions, and the passive 
reference dye ROX.
Gene-specific master mix was distributed to appropriate wells on an Optical 96-Well 
Fast Plate (Applied Biosystems) (16 pl/well). Subsequently, 5x diluted cDNA 
(or water for PCR-NTC) was added (4 pl/well).
The plate was sealed with a MicroAmp Optical Adhesive Film (Applied Biosystems) 
and qPCR performed on an Applied Biosystems 7900HT Fast Real-Time PCR
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System, using the recommended conditions: ten minutes at 95°C, followed 
by 40 cycles of 15 seconds at 95°C and one minute at 60°C.
SYBR Green-based assays
The SYBR Green-based assays were performed as described for TaqMan assays, with 
a few modifications:
- SYBR Green-containing master mix (Power SYBR Green Master Mix, Applied 
Biosystems) was used.
- Instead of the primer/TaqMan probe mix, PCR-primers (custom DNA 
oligonucleotides obtained from Invitrogen) were used at the final concentration 
of 300 nM each.
- After the last PCR cycle, the fluorescence was measured while the temperature was 
slowly increasing from 60 to 95 °C for subsequent melting curve analysis (to ensure 
that only a single PCR product is present).
Primer design
The majority of SYBR Green-based assays used for this project were designed using 
the Primer3 program [184] and BLAST [185]. The mRNA sequences were taken from 
the NCBI database. In case of genes known to have two or more splicing variants, 
the primers were designed in a common part, so that all mRNA variants are detected. 
The length of the PCR product was ideally between 75 and 150 bp (and for all primer 
pairs designed, it was 50-200 bp). The annealing temperature for all the designed 
primers was 60°C, so that the standard cycling conditions could be used, and TaqMan 
assays could be run together with SYBR Green-based assays on one plate. To avoid
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detection of genomic DNA, if possible, primers were in different exons or bound 
to exon-exon junctions.
New pairs of primers were routinely tested for PCR efficiency. For that qPCR was 
performed on serially diluted cDNA (usually 5x). Relation between Ct (see 22.2.3) 
and template starting copy number was plotted. After addition of the logarithmic 
trendline, the PCR efficiency was calculated using the following formula 
(from Stratagene/Agilent Technologies Technical Toolbox, modified):
Efficiency = -l+e("1/dope)
Only the pairs with the efficiency between 90 and 110% (as recommended by Applied 
Biosystems), and giving a single PCR product, as determined by melting curve 
analysis, were used in experiments.
22.23  Quantitative RT-PCR data analysis
For qPCR data analysis, Applied Biosystems SDS v2.3 software and Microsoft Excel 
were used. Relative expression was calculated using the 2'AACT method [186]. 
Ct, or the threshold cycle, is a number of PCR cycles needed to detect fluorescence 
associated with the amplification of a specific product (Figure 2.9). If efficiency 
of the reaction is 100%, with every PCR cycle the number of copies of the product 
is doubled. Therefore, one cycle difference (ACt=1) between two samples means that 
there was initially 2-fold difference in expression of a particular gene between those 
samples. The difference of two cycles (ACt=2) means 4-fold (22) difference 
in expression, ACt=3 means 8-fold (23) difference, and so on.
To normalise for differences in the starting amount of RNA in RT between 
the samples (or inaccuracy during subsequent steps), in addition to a gene of interest 
(target gene), expression of a gene not influenced by experimental treatment 
(endogenous control) is assessed.
In the first step of the 2'AACT method, for each sample the difference between Ct 
obtained for a target gene and C t for an endogenous control is calculated 
(ACt=CtTARGHT-Ct endogenous control). Subsequently, one sample is chosen 
as a calibrator (its expression will be equal 1), and AACt is calculated by subtraction 
of aC t calibrator from ACt of every other sample. The last step is calculation 
of 2'aact, which for each sample will give the target gene expression, normalised 
to the endogenous control, relative to the calibrator.
2.2.3 MicroRNA detection
2.2.3.1 MicroRNA profiling
There are two main types of arrays used currently to examine expression of large 
number of microRNAs in biological samples. These are hybridisation-based 
microarrays and qPCR-based arrays (so called TaqMan Low-Density Arrays). Both 
were used in this study.
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MicroRNA profiling in HK-2 cells using mirVana miRNA Bioarrays
The qPCR-based microRNA arrays became available in 2008. Therefore, the only 
option for early microRNA profiling experiments was a hybridisation-based array. 
That was carried out twice by Asuragen Services (formerly Ambion Services, Austin, 
US), using the mirVana miRNA Bioarrays platform (Ambion).
Before the start of my studies, microRNA expression was analysed in control HK-2 
cells and those cultured with high concentration of glucose (25 mM) for 
48 or 96 hours, using the mirVana miRNA Bioarrays vl. The analysis was repeated 
one year later, after review of the data from the first microRNA microarrays 
with Asuragen. They suggested a potential technical error with the high-glucose 
arrays and agreed to repeat the microRNA profiling on new samples (control 
and 25 mM glucose for 48 hours), using new version (v2) of Ambion mirVana 
miRNA Bioarrays. Version 2 included probes to all human (328), mouse (266), 
and rat (238) miRNAs in the miRBase release 8.0 [106], 152 additional unpublished 
human miRNAs, and 61 control probes for accurate data normalization.
Stimulation of HK-2 cells was carried out as described above (see 2.1.1.4). 
Subsequently, total RNA was isolated using the mirVana miRNA Isolation Kit 
(see 2.2.1.1). Approximately 30 pg of total RNA for each sample (control and high- 
glucose-treated HK-2 cells, in triplicate) was sent frozen to Asuragen.
Sample preparation by Asuragen included quality assessment of the supplied total 
RNA, and microRNA enrichment using the flashPAGE Fractionator and Reaction 
Clean-up Kit (Ambion). The 3' ends of RNA molecules were then labeled using 
the mirVana miRNA Labeling Kit (Ambion), according to the manufacturer’s 
instructions. Amine-modified nucleotides were incorporated during polyadenylation
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reaction. Subsequently, Cy3 succinimide esters were conjugated to the amine moieties 
on the small RNAs. Hybridisation to the mirVana miRNA Bioarrays was performed 
using the mirVana miRNA Bioarray Essentials Kit (Ambion). The Cy3 fluorescence 
was scanned at excitation wavelength of 532 nm, using a GenePix 4200AL scanner 
(Molecular Devices). The fluorescent signal associated with the probes and local 
background was extracted using GenePix Pro (version 6.0, Molecular Devices). 
Thresholding, signal scaling, and normalization were performed using algorithms 
selected by Asuragen.
MicroRNA profiling in tissue samples by TaqMan Low-Density 
Arrays
Since the amount of RNA isolated from FFPE kidney biopsy samples was 
not sufficient for microRNA profiling using hybridisation-based arrays, a qPCR-based 
array was used. The TaqMan Low-Density Array Human MicroRNA Panel vl.O 
(Applied Biosystems) is a 384-well microfluidic card that contains primers and probes 
for 365 different human microRNAs. It is used in conjunction with the Human 
Multiplex RT Set vl.O (Applied Biosystems), so that all 365 microRNAs (if they are 
expressed) are reverse-transcribed in eight separate RT reactions, using eight distinct 
RT-primer pools (containing up to 48 RT-primers each). The principles of microRNA 
detection by this method are analogous to the detection of individual microRNAs 
by stem-loop qRT-PCR, and are explained below (see 2.2.3.2). The microRNA 
profiling using this method in FFPE kidney biopsy samples from patients 
with diabetic nephropathy was performed by CBS.
The procedure was in accordance with the manufacturer’s instructions. Briefly, 
for each group of patients (non-progressors, n=9; progressors, n=9; late presenters,
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n=4), total RNA, isolated and quantified as described above (see 2.2.1.2), was pooled. 
Multiplex reverse transcription reactions (with 8 different sets of microRNA-specific 
RT-primers) were carried out using 25 ng of the pooled RNA. Each RT reaction was 
diluted 62.5x with water, and 55 pi was combined with 55 pi of TaqMan 2x Universal 
PCR Master Mix. Subsequently, 100 pi of the mixture for each of 8 Multiplex RT 
pools was loaded into appropriate filling ports of the microfluidic card. The array was 
then centrifuged and mechanically sealed with the Applied Biosystems sealer device. 
qPCR was carried out on an Applied Biosystems 7900HT Fast Real-Time PCR 
System, using the recommended cycling conditions. The relative microRNA 
expression was calculated as described above for mRNA quantification by qRT-PCR 
(see 2.2.2.3). Detection limit was set to Ct=33, according to the manufacturer’s 
recommendations.
2.2.3.2 Individual microRNA detection
There are several methods available for individual microRNA detection. These are 
mainly northern blot, solution hybridisation, and RT-PCR-based methods. 
As RT-PCR-based methods are thought to be more sensitive, can better differentiate 
between similar sequences, do not involve using radiolabeled reagents, and also can 
be quantitative, they were considered first for the project.
Due to the small size of microRNAs (-22 nt), they cannot be detected in a common 
RT-PCR reaction, routinely used for mRNA detection. Recently, two ingenious 
quantitative RT-PCR systems, suitable even for detection of very short RNA 
molecules, have been described [187, 188]. These are stem-loop qRT-PCR (used
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originally in Applied Biosystems TaqMan MicroRNA Assays) and polyadenylation- 
based qRT-PCR (Invitrogen NCode miRNA Detection System).
MicroRNA detection by stem-loop qRT-PCR
This involves two steps (Figure 2.10):
- RT with a microRNA-specific RT-primer. This primer contains a few nucleotides 
complementary to the 3' end of the mature microRNA, and a long unrelated sequence 
forming a stem-loop structure, so that it cannot interact with other RNA molecules 
present in the RT reaction.
- qPCR with one PCR-primer identical with the 5' end of microRNA, and the second 
identical with a part of the long stem-loop RT-primer. Fluorescence signal, needed 
for quantitative detection, comes from a TaqMan probe, binding to the junction 
between the microRNA and RT-primer.
The detailed procedure was as follows.
To prepare RT master mix, 4.16 pi water, 1.5 pi lOx Reverse Transcription Buffer, 
0.15 pi 100 mM dNTP, 0.19 pi 20 u/pl RNase Inhibitor, 1 pi 50 u/pl MultiScribe 
Reverse Transcriptase, and 3 pi 5x RT-primer per one reaction were combined. 
10 pi of the RT master mix was then added to 5 pi of RNA, typically containing 10 ng 
total RNA, and incubated on ice for at least five minutes. Negative controls used at 
this step were RT-NTC (with water instead of RNA) and RT-negative control 
(without MultiScribe Reverse Transcriptase). The following thermal cycler profile 
was used: 30 minutes at 16°C, 30 minutes at 42°C, five minutes at 85°C, and cooling 
to 4°C.
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The cDNA was diluted with water 1:3, and 4 pi were used in qPCR, performed 
as described for mRNA detection with TaqMan assays (see 2.22.2). The data were 
analysed using the 2'MCT method [186] (see 2.2.2.3).
The accuracy of microRNA detection with this system was assessed for three 
microRNAs of varying abundance levels in HK-2 cells according to the microarray 
results: miR-16 (the highest expression), miR-29a, and miR-128a (the lowest 
expression) (Figure 2.11 A). For miR-16 and miR-29a assays, relationship between 
the fluorescence signal and the RNA amount used for reaction (between 2 and 250 ng) 
was as expected, with the efficiency of the reactions close to 100% (Figure 2.1 IB). 
The efficiency was calculated as described above (see 2.2.2.2). In case of the assay 
for miR-128a, the least abundant of the selected microRNAs, the signal was not 
strictly dependent on RNA amount used in RT, especially when higher concentrations 
of RNA were used. To minimize competition of miR-128a with other RNA 
molecules, small RNA fraction (< 200 nt), isolated with mirVana miRNA Isolation 
Kit (see 2.2.1.1), was used in qRT-PCR instead of total RNA (Figure 2.11C). 
That modification, however, was not sufficient to allow for quantitative miR-128a 
detection in HK-2 cells. Therefore, for subsequent experiments microRNAs 
of relatively high expression in HK-2 cells were preferentially chosen, 
and the efficiency of new assays was routinely estimated.
Design o f SYBR Green-based stem-bop qRT-PCR assays for microRNA detection 
In order to examine expression of recently described microRNAs (like those studied 
in Chapter Six), for which no pre-designed qRT-PCR assays were available, 
stem-loop qRT-PCR assays were designed in house. In those new assays, the protocol
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and the reagents from the commercial system were used, except for microRNA- 
specific primers for RT and PCR, and SYBR Green-containing qPCR master mix 
(Power SYBR Green Master Mix, Applied Biosystems).
As it was conceivable that those new microRNAs may not be expressed by HK-2 
cells, the first assay was designed for detection of miR-16, which is highly expressed 
and easily measured with the TaqMan assay in HK-2 cells. Assays for other 
microRNAs were designed later in a similar manner, except for miR-663, which 
is highly GC-rich and requires special conditions, as described below. For all primer 
sequences see Table 2.4.
Design o f miR-16-specific stem-loop RT-primer and PCR-primers
Sequence of the mature human miR-16 (as deposited in the miRBase [106])
is as follows:
5' UAGCAGCACGUAAAUAUUGGCG 3'
Optimisation experiments showed that, for this microRNA, the RT-primer worked 
best if it contained in its 3' end 5 nucleotides complementary to 3' end of miR-16 
(in bold).
The rest of the primer is intended to increase the length of miR-16 cDNA, so that 
it can be subsequently detected by qPCR. Chen et al. [187] have reported that these 
RT-primers work better (in terms of both specificity and sensitivity), if the long part 
forms a secondary structure, such as a stem-loop.
For good PCR efficiency, this structure is not supposed to be stable during qPCR 
(i.e. at 60°C or above), one of the PCR-primers should interfere effectively with its 
re-formation, and bind only to one site on the RT-primer complement. This suggested 
that a more complicated secondary structure than a simple stem-loop may be superior.
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Therefore, a random sequence, not highly similar to any human mRNA, as confirmed 
by BLAST [185], served as a base for design of a DNA oligonucleotide, forming 
a stem-double-loop structure with one mismatch in the stem at the temperature 
oftheRT reaction (42°C). This was confirmed by MFOLD [189] (Figure 2.12A). 
The oligonucleotide, combined with the 5 nucleotides complementary to miR-16, 
created the miR-16-specific RT-primer (from 5' to 3'):
ATCAAGCGTCGCAGGAACATCACCCACATGTTACGATTGATCGCCA (46 nt) 
This primer was used in RT at the optimised final concentration of 50 nM.
For detection of the 63-nucleotide-long miR-16 cDNA by qPCR, two primers were 
designed. The first (forward) primer has identical sequence (with T instead of U) 
as the mature miR-16, except that it does not include the last two nucleotides: 
TAGCAGCACGTAAATATTGG. Ideally, there would be no overlap between 
RT- and PCR-primer, however the already very low annealing temperature of that 
forward PCR-primer (50.6°C, calculated using Primer Express, Applied Biosystems) 
did not allow for further shortening.
The second (reverse) PCR-primer is identical with a part of RT-primer (in italics): 
AGCGTCGCAGGAACATCA. Most of this fragment of the RT-primer localises 
to the mismatched region and forms the loops, so the PCR-primer would bind only 
to one strand and prime only in the desired direction. Moreover, the reverse 
PCR-primer binding may prevent the formation of the secondary structure within 
the template.
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Validation o f the new assay fo r  miR-16
First of all, the amplification of a single product was confirmed by melting curve 
(see2.2.2.2) (Figure 2.12C) and agarose gel (see 2.2.1.1) analyses. The latter also 
showed that the product is approximately of the expected size: 59 bp. Subsequently, 
efficiency of the new SYBR Green-based stem-loop qRT-PCR assay for miR-16 was 
tested, and was 98% (Figure 2.12D). Additionally, its performance was compared 
with the TaqMan assay in both HK-2 cell culture samples (Figure 2.12D) and renal 
tissue samples (Figure 2.8C,E), giving almost identical results.
Design o f miR-663 assay
Since miR-663 is very GC-rich (AGGCGGGGCGCCGCGGGACCGC), it was very 
likely that at temperatures used in a standard stem-loop qRT-PCR it would interact 
with other RNA species and form stable double-stranded RNA structures, interfering 
with the detection. Therefore, the procedure was altered as follows.
The RT-primer was longer (60 nt vs. 46 nt) and the secondary structure was more 
stable (Tm 78.3°C vs. 61.7°C) than of the primer used for miR-16 detection 
(Figure 2.12B). This allowed for an additional step before RT: sample RNA 
and the stem-loop RT-primer were mixed together and heated for five minutes at 
65°C, then chilled. The RT mix was then added and the RT reaction was carried out 
for one hour at 42°C. In the following qPCR, the annealing/extension step was set 
at75°C instead of standard 60°C; otherwise the RT-primer would form a stable 
secondary structure that would affect the efficiency of the reaction.
The primer sequences are given in Table 2.4, and the performance of the assay was 
evaluated in Chapter Six.
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Polyadenylation-based qRT-PCR
Before trying to design stem-loop qRT-PCR assays for newly described microRNAs, 
the other microRNA detection method, NCode SYBR Green qRT-PCR Kit 
(Invitrogen), was tested. This was a modification of qRT-PCR, which employed
a polyadenylation reaction prior to RT [188].
Unfortunately, the system did not work as expected. Assays for miR-16 and miR-29a 
were far less sensitive than the TaqMan assays (approximately 10-cycle increase in Ct 
for both microRNAs). Furthermore, fluorescence signal depended neither
on the concentration of RNA used for RT, nor cDNA in qPCR. In addition, strong 
signal was observed in negative controls without the polyadenylation step. Therefore, 
the method was not used for this project.
2.3 Protein analysis
2.3.1 Western blot
Detection of Dicer by Western blot was used to evaluate performance of Dicer- 
specific siRNA. Additionally, this method was used (together
with Immunofluorescence, see 2.3.2) to assess E-cadherin expression in HK-2 cells 
stably overexpressing miR-192 at the protein level.
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Cell lysis
Whole cell extracts were prepared with RIPA Lysis Buffer (Santa Cruz 
Biotechnology, Heidelberg, Germany). After washing cells with cold PBS, RIPA 
Lysis Buffer was added (200 pl/well on 6-well-plates), and incubated for 15 minutes 
on ice with frequent agitation. Then, the lysate was transferred to a tube 
and centrifuged for 30 minutes at 16000 ref at 4°C. The supernatant was then 
collected, divided into aliquots, and stored frozen at -80°C until needed.
Protein quantification by Bradford Assay
The BioRad Protein Assay, based on the method of Bradford, is a dye-binding assay 
in which the absorbance maximum for an acidic solution of Coomassie Brilliant Blue 
G-250 dye shifts from 465 nm to 595 nm when binding to protein occurs.
To quantify proteins in the lysates, the standard curve of bovine serum albumin (BSA) 
was prepared (2-fold serial dilutions in the range: 1000-15.6 ng/pl) and the lysates 
appropriately diluted. Bradford Reagent 5x was diluted with water 1:5, 
and 200 pl/well added to a 96-well-plate containing in separate wells 5 pi of water 
(blank), BSA standards, or samples (all in triplicate). Absorbance at 595 nm was 
measured five minutes later, using a FLUOstar OPTIMA plate reader.
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SDS-PAGE
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed by the method of Laemmli [190].
Composition of the resolving and stacking gels was as follows:
Components Resolving gel 7.5% (w/v) Stacking gel
Water 7.275 ml 6.1 ml
Buffer
1.5 M Tris-HCl pH 8.8 
3.75 ml
0.5 M Tris-HQ pH 6.8 
2.5 ml
10% (w/v) SDS 150 pi 100 pi
Mix of Acrylamide 29.2% (w/v) 
and Bisacrylamide 0.8% (w/v) 3.75 ml 1.3 ml
10% Ammonium Persulphate 
(0.05 g in 500 pi water) 75 pi 75 pi
TEMED 7.5 pi 10 pi
Protein samples were thawed on ice, a constant amount (usually 15 pg) mixed with 
3x Reducing Loading Buffer (see Appendix), and heated at 95°C for five minutes. 
Then, samples were cooled on ice, and loaded in the gel. Additionally, 15 pi of a mix 
of dye-conjugated standards (See Blue Plus Two, Invitrogen) was loaded in one 
of the wells. The electrophoresis was carried out in a BioRad Mini Protein II 
apparatus, in Running Buffer (see Appendix), at 100 V for 20 minutes 
and subsequently at 150 V for one hour.
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Protein transfer to a nitrocellulose membrane
The separated proteins were transfeired onto a nitrocellulose membrane 
(GE Healthcare, Amersham, UK), using a BioRad Mini Blot II apparatus. 
The membrane, filter paper, and pads were pre-soaked in Transfer Buffer 
(see Appendix). The transfer cassette was assembled in the following order:
(negative charge)-pad-paper-gel-membrane-paper-pad-(positive charge)
The cassette was placed in the holder, and then in the transfer apparatus filled 
to the top with pre-chilled Transfer Buffer, and containing an ice pack and stirring 
bar. The transfer was performed for 1-1.5 hours at 100 V.
Incubation with antibodies
The nitrocellulose membrane was blocked (to prevent non-specific antibody binding) 
for one hour with 5% (w/v) skimmed milk in Tris-buffered saline (TBS) pH 7.4 
containing 0.1% (v/v) Tween-20. Subsequently, the membrane was incubated 
overnight at 4°C with primary antibodies in TBS with 1% (w/v) BSA and 0.1% (v/v) 
Tween-20. After three washes with 0.1% (v/v) Tween-20 in TBS (15 minutes each), 
the membrane was transferred to appropriate horseradish peroxidase (HRP)- 
conjugated secondary antibody solution in TBS with 1% (w/v) BSA and 0.1% (v/v) 
Tween-20. Following one hour incubation at room temperature, and three more 
washes, the membrane was ready for the detection step.
For details about the antibodies and dilutions used in this study see Table 2.5.
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Detection
Antibody binding was visualised using enhanced chemiluminescence (ECL) detection 
(Luminogen, GE Healthcare). The substrate for HRP was prepared by mixing 
reagents A and B, and added to the drained membrane and left for one minute. Then, 
the membrane was wrapped in cling film and exposed to Amersham Hyperfilm ECL 
(GE Healthcare) for 0.5-15 minutes, as required.
Membrane stripping and reprobing
To ensure equal protein load in each lane, membranes were stripped by incubation 
in Stripping Buffer (see Appendix) at 50°C for 30 minutes. Adequacy of the stripping 
was confirmed by lack of signal from the membrane after incubation with HRP 
substrate and 30 minute exposure to a film. After extensive washes and quick 
blocking, the membrane was reprobed with anti-GAPDH antibody. Incubation 
with appropriate secondary antibody and detection were performed as described 
above.
2.3.2 Immunofluorescence
Immunofluorescence was used to confirm increase of E-cadherin at the protein level 
in cells stably overexpressing miR-192.
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Cells on glass Lab-Tek Chamber Slides (Nunc) were washed with FCS-free medium, 
and fixed with 3.7% (w/v) PFA in PBS containing 1 mM CaCh for ten minutes 
at room temperature. After three washes with PBS, the slides were blocked with 
1% (w/v) BSA in PBS for 45 minutes at room temperature. E-cadherin was probed 
with a murine monoclonal antibody (HECD-1, abeam) diluted 1:50 with 0.1% (w/v) 
BSA in PBS. Following overnight incubation at 4°C, the slides were washed three 
times with 0.1% (w/v) BSA in PBS, and incubated for one hour at room temperature 
with Alexa Fluor 555-conjugated anti-mouse secondary antibody (Molecular 
Probes/Invitrogen) diluted 1:1000 in PBS containing 0.1% (w/v) BSA. The slides 
were washed twice with 0.1% (w/v) BSA in PBS. Hoechst 33258 (Sigma) was used 
at the concentration of 0.5 pg/ml to stain nuclei. After the final wash, the glass 
coverslip was mounted on the slide using FluorSave Reagent (Calbiochem/Merck 
Chemicals, Nottingham, UK). Cells were observed on a Leica DMLA fluorescent 
microscope, and pictures were taken with a Zeiss Axiocam MRc digital camera.
2.3.3 Enzyme-linked immunosorbent assay
A commercially available TGF-beta enzyme-linked immunosorbent assay (ELISA) 
development kit (R&D Systems) was used to quantify TGF-beta secreted 
to the medium by HK-2 cells. The antibodies in the kit recognise TGF-beta 1, 
and the cross-reactivity with TGF-beta2 and TGF-beta3 is below 1%, as determined 
by the manufacturer.
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Ultra High Binding 96-well-plates (Immulon, Thermo Fisher Scientific, 
Loughborough, UK) were coated with anti-TGF-beta capture antibody (2 pg/ml 
in PBS, 100 pl/well) overnight at room temperature. Wells were washed three times 
with 0.05% (v/v) Tween-20 in PBS, using a Denley Wellwash 4 plate washer. 
The plate was blocked with 200 pi 5% (v/v) Tween-20 in PBS for one hour at room 
temperature.
During that incubation, samples and standards were prepared. The antibodies 
in the kit recognise the active form of TGF-beta. Previous work in this laboratory 
suggested that if there is any active TGF-beta in HK-2 cell medium, it is below 
the detection limit of this method, therefore all cell culture supernatant samples were 
acid-activated before detection. To each 100 pi of sample 20 pi of 1 M HC1 was 
added. After ten minutes, the samples were neutralised with 20 pi of 1.2 M NaOH 
in 0.5 M HEPES. In parallel, supplied TGF-beta standards were serially diluted 
(2-fold dilutions in the range: 2000-31.25 pg/ml) in Reagent Diluent (1.4% (w/v) 
delipidised BSA, 0.05% (v/v) Tween-20 in PBS).
The standards and acid-activated samples were transferred to the plate (100 pl/well) 
and incubated for two hours at room temperature. Following three washes, 
anti-TGF-beta detection antibody was added (300 ng/ml in Reagent Diluent, 
100 pl/well). After 2 hours, the plate was washed three times, and HRP-conjugated 
streptavidin was added (diluted 1:200 in Reagent Diluent, 100 pl/well). The plate was 
incubated in the dark for 20 minutes, then washed three times. Finally, HRP substrate, 
freshly prepared by mixing equal volumes of Reagent A with Reagent B, was added. 
The plate was incubated in the dark for 20 minutes and the reaction was stopped 
by addition of Stop Solution (2 M H2SO4). The absorbance was read at 450 nm. 
TGF-beta concentrations in the samples were calculated using a standard curve.
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2.3.4 Luciferase activity
All reporter plasmids used in this study utilised firefly (Photinus pyralis) luciferase 
CDS, and were routinely cotransfected with a control plasmid coding for Renilla 
(Renilla reniformis) luciferase. Firefly and Renilla luciferases, because of their 
distinct evolutionary origins, have different structures and substrate requirements. It is 
therefore possible to discriminate between their respective bioluminescent reactions. 
With the Dual-Luciferase Reporter Assay System (Promega), the activities of both 
luciferases can be measured sequentially in a single sample. The detailed procedure, 
recommended by the manufacturer, was as follows.
Transfected cells were washed with PBS, and 200 pi of Passive Lysis Buffer 
(diluted 1:5 in water) was added per well (12-well-plate). After 30 minutes at room 
temperature with constant agitation, the lysates were transferred to tubes. For each 
sample, 20 pi aliquot was transferred to a well on a white 96-well-plate. 
Subsequently, 100 pi of Luciferase Assay Reagent II (substrate for firefly luciferase) 
was added, and luminescence measured for five seconds on a FLUOstar OPTIMA 
plate reader. That was followed by addition of 100 pi of Stop & Glo Reagent 
(quenching the previous reaction and providing a substrate for Renilla luciferase), 
and measurement of luminescence for five seconds. Lysates from untransfected cells 
were used to determine the background. Unless stated otherwise, the presented results 
are ratio of firefly to Renilla luciferase activities.
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2.4 Bioinformatics
2.4.1 MicroRNA target prediction
To find microRNAs that may regulate a gene of interest, or to identify potential 
targets of a particular microRNA, microRNA target prediction programs are 
commonly used. One of the most popular programs, PicTar [191], was used in this 
study to help to identify microRNAs potentially involved in tubulointerstitial fibrosis. 
The PicTar algorithm may be summarised as follows. Input to PicTar consists 
of multiple alignments of 3'UTRs from eight vertebrate genomes, and a set of mature 
microRNAs. PicTar starts the identification of the microRNA targets by searching 
the 3’UTRs for the perfect and imperfect complementarities to the microRNA ‘seed’ 
regions (defined here as seven nucleotides starting with the first or second nucleotide 
from the 5’ end). Then, free energy of the putative microRNA:target site complexes 
is calculated. Highly probable sites that survive the optimal free energy filter and are 
conserved between species are then scored. The model accounts for synergistic effect 
of multiple binding sites of one microRNA, or several microRNAs acting together. 
Additionally, it takes into consideration microRNA and target gene expression 
profiles. The estimated false positive rate for PicTar is approximately 30%.
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2.4.2 Identification of human microRNAs 
similar to miR-LAT
For identification of human microRNAs similar to the viral microRNA miR-LAT, 
which could similarly bind to the GC-rich region of TGF-beta 3'UTR, a few on-line 
tools were employed.
To begin with, the miRBase Sequence Database release 9.1 [106] was searched for 
mature microRNAs of similar sequence to miR-LAT, using S SEARCH, 
an implementation of the Smith-Waterman algorithm [192]. SSEARCH does 
a rigorous search for similarity between a query sequence and a group of sequences 
of the same type. Compared to BLAST, it is much slower. However, it may be 
the most sensitive method available for similarity searches. It is recommended 
for finding a short sequence within a library, in this case the miRBase Sequence 
Database.
The chance that the identified microRNAs interact with TGF-beta 3'UTR was 
assessed using RNA22 [193], a microRNA target prediction program. RNA22 uses 
a different approach to microRNA target discovery than PicTar. This is so called 
pattern-based approach. It first finds common motifs (“patterns”) in a set 
of microRNAs (354, at the time of the original publication of the method). Then, 
it predicts possible microRNA binding sites in a given target sequence, and assigns 
candidate microRNAs to those sites.
To visualise the potential interactions of the identified microRNAs with 3'UTR 
of TGF-beta, RNAfold program from Vienna RNA Secondary Structure 
Package [194] was used. The program reads an input RNA sequence, calculates its 
minimum free energy structure, and produces a graph of this structure. As it can
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process only one RNA molecule at a time, microRNA and its binding site within 
TGF-beta 3'UTR were linked with the linker sequence GCGGGGACGC, used 
similarly in RNA22 program [193].
2.4.3 Other applications.
Construction/modification of plasmids (see 2.1.1.5) was facilitated by the on-line 
tools available at New England BioLabs website (http://www.neb.com). Particularly 
useful was the NEBcutter, which finds restriction sites in a given sequence. 
Additionally, NEB Enzyme Finder made possible quick searches of the restriction 
enzyme database for a particular recognition sequence, an overhang produced after 
cleavage, or simply enzyme name to find its recognition sequence and recommended 
digestion conditions.
To identify a suitable endogenous control for microRNA expression studies in renal 
biopsy samples, or mRNA analysis of HK-2 cell response to TGF-beta, geNorm VBA 
applet for Microsoft Excel [195] was used. geNorm determines the most stable 
reference genes from a set of tested genes in a given set of samples. It calculates the 
gene expression stability measure M for a reference gene as the average pairwise 
variation V for that gene with all other tested reference genes. Stepwise exclusion of 
the gene with the highest M value allows ranking of the tested genes according to 
their expression stability. The underlying principles and calculations are described in 
Vandesompele et al. [195].
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The use of Primer3, NCBI database, the miRBase Sequence Database, BLAST, 
Primer Express, and MFOLD for primer design was described above (see 22.2.2 
for primers for mRNA detection, or 2.23.2 for stem-loop microRNA qRT-PCR 
assays).
2.5 Statistical analysis
The statistical analysis of data from the microRNA profiling experiment using 
mirVana miRNA Bioarrays (see 2.2.3.1) was carried out by Asuragen, as part 
of the microRNA Standard Service Premium. To check if there were any 
differentially expressed microRNAs between control HK-2 cells and cells cultured 
in high-glucose medium, t-test was performed for every microRNA. A multiplicity 
correction was conducted to control false discovery rate at 5% using a step-up 
approach, as described by Benjamini and Hochberg [196].
Pearson Correlation Coefficients were calculated for fibrosis score or eGFR 
and miR-192 in kidney biopsies from patients with diabetic nephropathy using SPSS 
version 14.0 software.
Statistical evaluation was otherwise by t-test, using Microsoft Excel, with p < 0.05 
assumed to be significant.
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Figure 2.1. The siSTRIKE U6 vector (Promega). (A) Plasmid map. (B) Typical 
result of the diagnostic digestion with Pstl. A second Pstl restriction site is created 
in the plasmid as a result of a successful ligation. Two products (~3 kbp 
and ~ 1.4 kbp) of the digestion with Pstl indicate that the plasmid contains the insert.
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Figure 2.2. The pGL3-ControI vector (Promega). (A) Plasmid map. 
(B) Identification of the properly modified plasmid containing sequential 
XbaVEcoRI restriction sites instead of Xbal site downstream the luciferase CDS. 
Unlike the unmodified pGL3-Control, the desired plasmid would be cut once by 
£coRI. Additionally, a second PshAI restriction site would appear in plasmids with 
Xbal preceding EcoRl (rather than the other way round, which was equally 
probable), giving two products: 576 bp and 4711 bp. Of the four tested colonies, 
only Colony D contained the expected plasmid.
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Figure 2.3. Construction of reporter plasmids with ZEB1 or ZEB2 3'UTRs 
downstream the luciferase CDS. ZEB1 and ZEB2 3'UTRs were PCR-amplified 
from genomic DNA and ligated into the pGL3-Xbal/EcoRl plasmid using Xbal 
and EcoKl sites. To confirm the ligation of the insert, the new plasmids were cut 
with Bam HI and Pstl for ZEB1 3’UTR (A), or Xbal and EcoRl for ZEB2 3'UTR (B). 
The later digestion released -1.4 kbp ZEB2 3'UTR insert from the plasmids. Since 
ZEB1 3'UTR contains a Xbal site, the PCR product was digested with Spel and the 
ligation destroyed the Xbal site. Therefore, Pstl site from the ZEB1 3'UTR together 
with BamHl site on the plasmid (758 bp apart after successful ligation) were used. 
All tested plasmids were as desired.
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Figure 2.4. Selection of an optimal transfection method for plasmid DNA 
delivery to HK-2 cells. HK-2 cells were transfected with a mix of two reporter 
plasmids (one containing four SBEs in the promoter of the firefly luciferase gene, 
and one for high constitutive expression of Renilla luciferase) at 3:1 ratio. Following 
48 hour incubation, Dual Luciferase Assay was used to measure firefly (A)and 
Renilla (B) luciferase activities. Additionally, as an indirect measure of cell viability 
after transfection, total protein concentration in lysates was estimated with Bradford 
assay (C). The experiment was performed in triplicate; SEM is shown.
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Figure 2.5. H K -2  cell resistance to puromycin. HK-2 cells were plated at three 
different densities on 96-well-plates. Various concentrations of puromycin were 
added to medium immediately after plating the cells (A), or 24 hours later (B). 
To assess the effect of puromycin on the cell viability, AlamarBlue test was 
performed 72 hours later. The experiment was performed in triplicate; SEM is 
shown.
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Figure 2.6. RNA extraction using mirVana miRNA Isolation Kit (Ambion).
Total, large (> 200 nt), and small (< 200 nt) RNA fractions were isolated from 
HK-2 cells (control or treated with high concentration of glucose for 48 hours), 
as described in the text. The RNA fractions were separated on a 3% (w/v) agarose 
gel containing ethidium bromide, and visualised in UV light. The same gel 
photographed with low (A) or high (B) light intensity is shown. The two rRNA 
species: 28S and 18S, and the small RNA fraction (quickly migrating RNA, not 
detected in the large RNA preparations) are indicated.
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Figure 2.7. Comparison of two RNA isolation methods. Total RNA was isolated 
from HK-2 cells (control or treated with high concentration of glucose for 48 hours) 
using mirVana miRNA Isolation Kit (Ambion) or TRI Reagent (Sigma). 
The extracted RNA was separated on an agarose gel and photographed with low or 
high light intensity (A). Additionally, both RNA preparations were used for miR-16 
quantification by stem-loop qRT-PCR (B).
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Figure 2.8. Preliminary analysis of RNA isolated from FFPE renal biopsy 
samples. RNA was isolated from four FFPE samples with RecoverAll Total Nucleic 
Acid Isolation Kit. Subsequently, RNA concentration was estimated using Agilent’s 
2100 bioanalyser with PicoChip (A) or Invitrogen Quant-iT RNA Assay (B). 
Additionally, miR-16 (C) and miR-200b (D) expression in those samples was 
measured with TaqMan stem-loop qRT-PCR. The performance of a new SYBR 
Green-based assay for detection of miR-16 was tested in those samples (E). Finally, 
miR-16 (lighter bars) and miR-200b (darker bars) were measured after 5 or 25-fold 
dilution of cDNA to demonstrate that the detection is quantitative and there were no 
PCR inhibitors present in the samples.
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Figure 2.9. Amplification plot features. Seven amplification curves are shown; 
the red one represents a sample with the highest expression of the tested gene, while 
the dark green -  a sample with the lowest expression. A typical amplification curve 
starts with the phase of low^ackground fluorescence, followed by the exponential 
phase (please note that the scale on the Y axis is logarithmic), the linear phase, 
and finally the plateau. The threshold is the point at which a reaction reaches 
a fluorescent intensity above background. For the most accurate reading, it is set at 
the exponential phase of the amplification. The PCR cycle at which the sample 
reaches the threshold is known as the threshold cycle (Cx). For example, CT 
of the sample represented by the light green amplification curve is approximately 17, 
and CT of the sample with the lowest expression of the gene of interest (dark green) 
is close to 36. As explained in the text, the fold-difference in the gene expression 
between these two samples equals 2(36_17)=524288. The amplification plot comes 
from the work by N. Walker [197].
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Figure 2.10. Schematic overview of the stem-loop qRT-PCR microRNA 
detection system. Quantification of microRNAs with this method consists of two 
steps. The first includes an RT reaction with a long RT-primer, forming a stem-loop 
structure, containing at the 3' end a few nucleotides complementary to the 3' end of a 
particular microRNA. The second step is a quantitative PCR with a forward primer 
specific to the microRNA, and a reverse primer of the same sequence as a fragment 
of the long RT-primer. In TaqMan MicroRNA Assays (Applied Biosystems), a 
source of fluorescence is a TaqMan probe, binding to the region between the two 
PCR primers. The scheme was taken from the article originally describing this 
method [187].
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Figure 2.11. Evaluation of the performance of TaqMan MicroRNA Assays 
(Applied Biosystems). Three microRNAs were selected for analysis based on their 
expression in HK-2 cells according to the microarray results (A). The reactions were 
performed on 2, 10, 50, or 250 ng of total RNA isolated from HK-2 cells (B). 
The efficiencies were as follows: 101% for miR-16, 103% for miR-29a, and 237% 
for the least abundant of the three, miR-128a. The assay was then used with 6, 30, 
or 150 ng of small RNA (C). The calculated efficiency of miR-128a detection was 
6196%, while miR-16, used here as a positive control, was amplified 
with the efficiency 97%.
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Figure 2.12. Design and validation of SYBR Green-based stem-loop qRT-PCR 
for microRNA detection. Predicted secondary structures of RT-primers for miR-16 
(A) and miR-663 (B) detection are shown. (C) Melting curve analysis following 
miR-16 quantification with the new assay, demonstrating that only a single product 
is amplified. (D) Comparison of performance of the new miR-16 assay (red 
diamonds) with the TaqMan MicroRNA Assay (blue diamonds).
Name Sequence (5* -> 3') Comments
siRNA
CD44 CGTGGAGAAAAATGGTCGC ID: n/a
Dicerl T GCTTG AAGC AGCT CTGG A [198]
Dicer2 CCATATGAGCGACAGCAGT ID: 137010
Dicer3 GCAAATCTTTCATCTCAAT ID:137012
SMAD3 n/a ID:115717
TRBP T CT ACG AAATT C AGT AGG A [199]
Scrambledl GCGTATCGTAAGCAGTACT Negative Control #1
Synthetic microRNAs (Pre-miR miRNA Precursors)
miR-608 AGGGGTGGTGTTGGGACAGCTCCGT
miR-663 AGGCGGGGCGCCGCGGGACCGC
miR-LAT GTGGCGGCCCGGCCCGGGGCC
MicroRNA inhibitors (Anti-miR miRNA Inhibitors)
miR-192 GGCT GT CAATT CAT AGGT CAG
miR-200b T CAT CATT ACCAGGC AGT ATT A
Negative Control n/a Negative Control #1
Table 2.1. Small RNA used in this study. All molecules were ordered from Ambion. 
For double-stranded RNA, only sequence of the sense strand is given.
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Plasmid Inserts or PCR-primers (5' -> 31)
psiSTRIKE U6-Puromycin (Promega)
shDicer
(short-hairpin RNA silencing Dicer 
based on Dicer3 siRNA)
A: ACCGC AAAT CTTT CAT CT C AAT AAGTT CT CTATT GAG AT G 
AAAGATTTGC1 1 1 1 1C
B :TG CAG AAAAAGCAAAT CTTT CAT CT CAAT AG AG AACTTAT 
TGAGATGAAAGATTTG
shGW182
(short-hairpin RNA silencing GW182 
based on siRNA from [200])
A: ACCG AAATGCT CTGGT CCGCT AAAGTT CT CTTAGCGGAC 
CAGAGCATTTCI 1 1 1 1C
B :TGC AG AAAAAG AAAT G CT CTGGT CCGCT AAG AG AACTTTA 
GCGGACCAGAGCATTT
pre-miR-192
(miR-192 stem-loop precursor)
A:ACCGTGCACAGGGCTCTGACCTATGAATTGACAGCCAGT 
GCT CT CGT CT CCCCT CTGGCT GCCAATT CCAT AGGT C ACAG 
GTATGTTCGCCI 1 1 1 1C
B:TGCAGAAAAAGGCGAACATACCTGTGACCTATGGAATTG 
GCAGCCAGAGGGG AG ACG AGAGCACT GGCTGT CAATT CAT 
AGGTCAGAGCCCTGTGCA
pre-miR-200b
(miR-200b stem-loop precursor)
A:ACCGCTCGGGCAGCCGTGGCCATCTTACTGGGCAGCAT 
TGGATGGAGTCAGGTCTCTAATACTGCCTGGTAATGATGAC 
GGCGGAGCCCTGCAC1 1 1 1 1C
B :TGCAG AAAAAGTGCAGGGCT CCGCCGT CAT CATT ACCAG 
GCAGTATTAGAGACCTGACTCCATCCAATGCTGCCCAGTAA 
GATGGCCACGGCTGCCCGAG
shScrambledl
('negative control based on 
Scrambledl siRNA)
A: ACCGCGTAT CGT AAGCAGT ACT AAGTTCT CTAGTACTGCT 
TACGATACGCI 1 1 1 1C
B :TGCAGAAAAAGCGT AT CGTAAGCAGTACT AGAGAACTT A 
GTACTGCTT ACGATACG
shScrambled2
(negative control based on the 
reversed miR-16 sequence)
A: ACCGAT CGT CGTGCATTTAT AACCGCAAGTT CT CTGCGG 
TTATAAATGCACGACGATCI 1 1 1 1C 
B :TG CAG AAAAAG AT CGT CGTGC ATTT ATAACCGC AG AG AA 
CTTGCGGTTATAAATGCACGACGAT
shScrambled3
(negative control based on miR-192 
scrambled by siRNA Wizard v2.6, 
InvivoGen)
A: ACCGCCAAT CT CGT AGCCT AT AG AAAGTTCT CTT CT ATAG 
GCTACGAGATTGGC1 1 1 1 1C
B :TG CAG AAAAAGCC AAT CT CGT AG CCTAT AG AAG AG AACTT 
T CT AT AGGCT ACG AG ATT GG
pGL3-Control (Promega)
pGL3-Control-Xbal/Eco Rl A:CT AG AACTGG AG AGT ACGT G AATT CTATT GA B :CT AGT CAAT AG AATT CACGT ACT CT CCAGTT
3VTRZEB1
(~1.7 knt 3 ’UTR of ZEB1 PCR- 
amplified from HK-2 qenomic DNA)
F :CAT CG AACT AGT CAAAAT AAAT CCGGGTGTGCCT 
R :GTCCT AG AATT C AC AGCAGTT C AGGCTT GTTG A
3VTRZEB2
(~1.4 knt 3’UTR of ZEB2 PCR- 
amplified from HK-2 genomic DNA)
F:CATCGATCTAGATAAACTACTGCA 1 1 1 1AAGCTTCCTATT 
R:GTCCTAGAATTCAGTTTGGCTACA 1 1 1 1 IATTCGAG
Table 2.2. Plasmids generated for this study and sequences of the 
oligonucleotides used in cloning. The bold letters A and B indicate inserts, while F 
and R precede sequences of PCR-primers.
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Sample
no Biopsy
Group
* Age Sex
Date
of
biopsy
eGFR
ml/min
A eGFR 
ml/min/yr
Fibrosis
score
1 H2016.92 NP 66 M 1992 70 4.38 1.29
2 H529.92 NP 39 M 1992 48 4.55 -
3 H098.92 P 42 F 1992 56 5.7 1.29
4 H2636.92 LP 73 M 1992 5 n/a 1.29
5 H2627.92 NP 56 M 1992 59 0.58 0.86
6 H503.93 P 69 M 1993 14 9 2.14
7 H368.93 LP 75 M 1993 7 n/a 2.57
8 H264.94 NP 76 F 1994 17 1.02 1.14
9 H005.94 P 27 F 1994 12 7 1
10 H1232.93 LP 60 F 1993 6 n/a 2.86
11 H278.94 NP 72 F 1994 13 4.01 -
12 H488.94 P 55 F 1994 12 7.1 1.86
13 H342.94 LP 40 M 1994 7 n/a 1.86
14 H267.95 NP 49 M 1995 57 0.3 0.29
15 H173.95 P 74 M 1995 20 10.1 -
16 H260.95 LP 35 F 1995 5 n/a 1.71
17 H068.96 NP 52 M 1996 59 4.75 1
18 H213.96 P 59 F 1996 15 10.3 2.71
19 H062.97 NP 62 M 1997 49 2.37 0
20 H314.96 P 52 M 1996 92 11 1.14
21 H065.97 NP 58 M 1997 43 2.6 0.29
22 H053.98 NP 51 M 1998 36 0.71 0.71
23 H045.97 P 55 M 1997 93 9.53 0
24 H277.96 LP 50 M 1996 8 n/a 2
25 H102.98 NP 40 F 1998 67 1.1 0.43
26 H081.97 P 62 M 1997 46 9.24 1.143
27 H073.97 LP 53 M 1997 6 n/a 1.86
(Continued on the next page)
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(Continued)
Sample
no Biopsy Group* Age Sex
Date
of
biopsy
eGFR
ml/min
A eGFR 
ml/min/yr
Fibrosis
score
28 H123.98 NP 52 M 1998 32 0.5 0.6
29 H145.97 P 58 M 1997 61 6.2 0.57
30 H354.97 LP 45 M 1997 9 n/a 2.29
31 H184.99 NP 25 M 1999 45 3.8 0.71
32 H064.98 P 48 M 1998 27 16 -
33 H069.99 LP 77 M 1999 10 n/a 1.71
34 H196.99 NP 60 M 1999 25 1.8 1
35 H183.99 P 44 M 1999 24 7 1.57
36 H191.00 NP 59 M 2000 31 0.9 1.29
37 H248.99 P 57 M 1999 30 7 1
38 H202.00 NP 47 M 2000 60 0.75 0.43
39 H130.00 P 29 M 2000 28 14.1 1.29
40 H196.00 P 77 F 2000 17 10 1.43
* NP - non-progressors, P - progressors, LP- late presenters
Table 2.3. Patient characteristics. Samples used in the microRNA profiling 
experiment are in italics. eGFR -  estimated glomerular filtration rate.
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G e n e A s s a y  I D /  P r i m e r  S e q u e n c e s  (5' - >  3 ’) C o m m e n t s
1. T a q M a n  a s s a y s
mRNA detection
CD44 ID: Hs00174139_ml
E-cadherin ID: HsOOl70423_ml
RPLPO PN: 4326314E
microRNA and small RNA detection
let-7a ID: 000377
miR-16 ID: 000391
miR-26a ID: 000405
miR-29a ID: 002112
miR-106b ID: 000442
miR-128a ID: 002216
miR-192 ID: 000491
miR-200b ID: 002251
miR-608 ID: 001571
snRNA U6 ID: 001093
II. S Y B R  G r e e n  a s s a y s
mRNA detection
ACTB F : GACCCAGATCATGTTTGAGACCTT,R:CAGAGGCGTACAGGGATAGCA
B2M F : ATGAGTATGCCTGCCGTGTG,R:CATGTCTCGATCCCACTTAACTATCTT
Dicer F : TTGGGG AAT ACT CAAACCT AGAAG, R : GCGACATAGCAAGT CAT AAT GAGA
E-cadherin F : TCCCAATACATCTCCCTTCACA, R : ACCCACCTCTAAGGCCATCTTT
GAPDH F : CCTCTGACTTCAACAGCGACAC, R : TGTCATACCAGGAAATGAGCTTGA
HPRT1 F : GCAGTATAATCCAAAGATGGTCAAG, R : TCAAGGGCATATCCTACAACAAAC
PAI-1 F : TCTCTGCCCTCACCAACATTC,R:CGGTCATTCCCAGGTTCTCT
SMAD3 F :ACCACGCAGAACGTCAACA,R:CGATGGGACACCTGCAAC by D.D.Luo
TBP F : CACAGTGAATCTTGGTTGTAAACTTG, R: GGTTCGTGGCTCTCTTATCCTC
TFRC F : GGCACAGCTCTCCTATTGAAAC, R: CACTCCAACTGGCAAAGATAATG
TGF-beta F : CCTTTCCTGCTTCTCATGGC,R:ACTTCCAGCCGAGGTCCTTG by D.Fraser
TRBP F : GGCCCTCAAACACCTCAAAG,R:GGAATGTCCTCAGGCAGTGAA
Vimentin F :GGAGAAATTGCAGGAGGAGATG,R :AAGGTCAAGACGTGCCAGAGA
ZEB1 F : CAGGCAGATGAAGCAGGATGT,R:TGACAGCAGTGTCTTGTTGTTGTAG
ZEB2 F :CCTTCTGCGACATAAATACGAACA,R:AGTACGAGCCCGAGTGTGAGA
microRNA and small RNA detection
miR-16 R T :ATCAAGCGTCGCAGGAACATCACCCACATGTTACGATTGATCGCCA 
F :TAGCAGCACGTAAATATTGG,R :AGCGTCGCAGGAACATCA
miR-21 R T :ATCAAGCGTCGCAGGAACATCACCCACATGTTACGATTGATTCAAC 
F :TAGCTTATCAGACTGATGTTG,R:CGTCGCAGGAACATCACC
miR-29a R T :ATCAAGCGTCGCAGGAACATCACCCACATGTTACGATTGATTAACC 
F :TAGCACCATCTGAAATCGG,R:CGTCGCAGGAACATCACC
miR-34a R T: ATCAAGCGTCGCAGGAACATCACCCACATGTTACGATTGATACAACC 
F :TGGCAGTGTCTTAGCTGG,R:CGTCGCAGGAACATCACC
miR-663 RT:AGCCACCGTGCAGGCGGCACTGACTACGCACCCACGCGTAGGCCGACGATGGCTGCGGTC 
F : AGGCGGGGCGCCGCGGGA,R:CCACCGTGCAGGCGGCACTGACTACGCACC
snRNA U6 F :CGCTTCGGCAGCACATATAC,R:CAGGGGCCATGCTAATCTT b y  [ 2 0 1 ]
Table 2.4. Quantitative PCR assays used in this study. TaqMan assays were 
purchased from Applied Biosystems. All SYBR Green assays were designed as 
described in Methods, unless stated otherwise.
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Antibody Supplier (ID) Dilution
Immunofluorescence
10 Mouse monoclonal (HECD-1) 
to E-cadherin
abeam (ab1416) 1:50
2° Alexa Fluor 555 goat anti­
mouse IgG
Molecular Probes / Invitrogen 
(A-21424)
1:1000
Western blot
1 “Mouse monoclonal (13D6) to 
Dicer
abeam (ab14601) 1:100
2° HRP goat anti-mouse IgG Santa Cruz Biotech, (sc-2005) 1:1000
10 Rabbit polyclonal (H-108) to 
E-cadherin
Santa Cruz Biotech, (sc-7870) 1:1000
1 ° Rabbit polyclonal to GAPDH abeam (ab9485) 1:1000
2° HRP goat anti-rabbit IgG abeam (ab6721) 1:10000
Table 2.5. Antibodies used for immunofluorescence and Western blot. The source 
of antibodies and optimal dilutions are shown.
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CHAPTER THREE:
Ch a n g e s  in  m ic roR N A  e x p r e ssio n
IN RESPONSE TO PROFIBROTIC STIMULI 
IN  VITRO AND IN  VIVO
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3.1 Introduction
Several lines of evidence suggest that microRNAs compete with each other 
for the components of the miRISC complex. Moreover, it has been reported that 
microRNA turnover rates depend on availability of their target mRNAs [202]. Thus, 
a microRNA abundance in a cell or tissue very likely reflects its actual activity there. 
It is no surprise then that the most common strategy to identify microRNAs important 
in a particular process relies on evaluation of microRNA expression. Before the start 
of my project, there had been approximately 400 known human microRNAs and very 
limited data available regarding their expression in the kidney or in fibrotic processes 
(for more details see 1.5).
Previous extensive characterisation of proximal tubular epithelial cell responses 
to high concentration of glucose and other stimuli potentially related to diabetic 
nephropathy had taken place in this and other laboratories, as laid out 
in the introduction. Other investigators had shown extensive mRNA changes 
in proximal tubular epithelial cells in response to elevated glucose [203]. Before 
I started this project, the laboratory had collaborated with Ambion in a beta test 
of a novel array for microRNA profiling. It was decided to study effects of glucose 
on microRNA expression in the immortalised human proximal tubular epithelial cell 
line, HK-2.
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Preliminary experiments done before the start of my project
To characterise expression of 212 human microRNAs in HK-2 cells, and evaluate 
changes in response to glucose, an analysis with a new microRNA microarray 
(mirVana miRNA Bioarray VI, Ambion) was performed by Asuragen, Inc. 
(Figure 3.1). The results demonstrated expression of approximately 50% (105) 
of the tested human microRNAs in HK-2 cells. Furthermore, high concentration 
of glucose induced profound changes in microRNA expression. In particular, 
31 microRNAs were significantly, and more than 2-fold changed (all downregulated) 
in HK-2 cells cultured for 48 hours in medium containing high concentration 
of glucose.
The aim of this chapter was to determine the significance of those data, as well as to 
further characterise changes in microRNA expression in response to profibrotic 
stimuli in vitro and in vivo.
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3.2 Results
3.2.1 MicroRNA expression in proximal tubular 
epithelial cells
MicroRNA expression in response to high concentration of glucose
In order to validate the preliminary results, five microRNAs (miR-16, miR-26a, 
miR-29a, miR-106b, and miR-128a) were selected. The choice was based both 
on their expression, according to the microarray data, and target predictions 
by PicTar. Their relative abundance, change in expression after 48 hour culture 
in medium with high concentration of glucose, and potential targets implicated 
in renal fibrosis are listed in Table 3.1.
For quantitative detection of the selected microRNAs in HK-2 cells, stem-loop 
qRT-PCR system was chosen and its accuracy verified, as described in Methods 
(see 2.2.3.2). Detection of the least abundant of the chosen microRNAs, miR-128a, 
using that assay was not quantitative. Therefore, the results presented below 
demonstrate expression only of the other four microRNAs.
Expression of miR-16, miR-26a, miR-29a, and miR-106b was examined in HK-2 
cells exposed to 25 or 5 mM glucose for indicated time points (Figure 3.2A). Instead 
of expected 86-89% decrease, no statistically significant differences in microRNA 
expression between high-glucose treated and control cells were found.
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Additionally, in separate experiments, cells were growth-arrested for 72 instead 
of 48 hours, cultured in medium without insulin, in different culture dishes 
or in different volume of medium, exposed to 35 mM glucose, or to 25 mM glucose 
from three independent sources, in all cases giving similar results (Figure 3.2B-G). 
Having noticed the discrepancy between the preliminary data (7-9 fold change 
in response to glucose) and the qRT-PCR results (no difference between the two 
experimental groups), it was important to establish whether the cells responded 
to 25 mM glucose in a previously characterised way. Therefore, TGF-beta secretion 
to medium by HK-2 cells exposed to 25 or 5 mM glucose for four to seven days was 
measured by ELISA (Figure 3.3). The cells cultured in high-glucose medium secreted 
significantly more TGF-beta than control cells, reproducing published data [55]. 
Review of the data from the first microRNA microarrays with Asuragen, Inc. led 
them to suggest a potential technical error with the arrays, and to agree to repeat 
the microRNA profiling on new samples (three control and three from HK-2 cells 
treated with 25 mM glucose for 48 hours), using a new version (V2) of Ambion 
mirVana miRNA Bioarray.
The results showed no significant difference in expression of any of 328 tested human 
microRNAs in response to glucose (Figure 3.4), consistent with the qRT-PCR results. 
Nevertheless, the microarrays provided a list of 103 microRNAs expressed by HK-2 
cells, which was used in later experiments. A complete listing of expression data 
is available online as a supplementary material for my paper [204].
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MicroRNA expression in response to TGF-beta
The above data suggested that glucose alone did not alter microRNA expression 
in HK-2 cells in short-term culture. Extensive data implicates TGF-beta as a key 
mediator of renal fibrosis, induced by glucose and many other stimuli, as laid out 
in Chapter One. To examine if TGF-beta can influence microRNA expression 
in HK-2 cells, the four previously selected microRNAs, miR-16, miR-26a, miR-29a, 
and miR-106b, were quantified by stem-loop qRT-PCR in TGF-beta-treated cells 
(Figure 3.5). Two of them, miR-26a and miR-29a, were substantially (-50%) 
and significantly downregulated by treatment with 10 ng/ml TGF-beta for four days. 
Encouraged by those results, I selected five additional microRNAs for analysis. These 
were: let-7a, miR-21, miR-34a, miR-192, and miR-200b. They were all detected 
in HK-2 cells in the microarray experiment, and had some interesting properties, 
as found in literature (Table 3.2). Their expression was measured by qRT-PCR 
in HK-2 cells following stimulation with 10 ng/ml TGF-beta for four days (Figure 
3.6A). Three of them were significantly changed by TGF-beta. The biggest, over 60% 
difference was found in miR-192 expression, which decreased in stimulated cells, 
while expression of miR-200b was only -30% lower than in control cells. The only 
microRNA significantly upregulated by TGF-beta was miR-21. No statistically 
significant change was found in let-7a and miR-34a expression.
To ensure that equal amounts of RNA were used in both experimental groups, total 
RNA concentration prior to the stem-loop RT step was measured with Qubit 
fluorometer. Additionally, the small nuclear RNA U6 was measured by stem-loop 
qRT-PCR (Figure 3.6B). In all the future experiments involving HK-2 cell stimulation
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with TGF-beta, miR-16, found to be stable in those conditions, was used 
for microRNA normalisation.
To get more insight into the regulation of the two most promising microRNAs, 
miR-192 and miR-21, HK-2 cells were stimulated with 1 or 10 ng/ml TGF-beta 
or 25 mM glucose for 12, 24, 48, or 96 hours. Then RNA was isolated and miR-192 
and miR-21 expression was measured using stem-loop qRT-PCR (Figure 3.7). 
Consistent with the repeated microarray data, there was no substantial difference 
in expression of the tested microRNAs in response to high concentration of glucose. 
On the other hand, TGF-beta caused profound changes in miR-192 and miR-21 
expression, increasing gradually with time. The greatest down- or upregulation 
of miR-192 or miR-21, respectively, was observed at the longest time-point 
examined, when using the higher dose of TGF-beta.
3.2.2 MicroRNA expression in kidney biopsies 
from patients with diabetic nephropathy
In parallel to the investigation of TGF-beta-induced changes in microRNA expression 
in vitro, I had an extraordinary opportunity to look at microRNA expression 
in formalin-fixed, paraffin-embedded (FFPE) renal biopsy samples from patients 
with diabetic nephropathy.
This opportunity arose because of the recent work of an MD student in the laboratory 
(Dr Aled Lewis) who had recruited 40 patients who had previously undergone a renal 
biopsy and had a diagnosis of diabetic nephropathy, and had performed a detailed 
histopathologic study of the archived biopsy material. The data is reported
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in Lewis etal. [181]. The patients had been divided by Dr Lewis into three groups, 
depending on the rate of loss of renal function (as established by calculation of eGFR; 
see 1.2.2) in follow up. These were non-progressors (loss of eGFR < 5 ml/min/year), 
progressors (> 5 ml/min/year), and late presenters (eGFR at the time of biopsy 
<15 ml/min). For more details on the samples and patients see 2.1.2.
RNA was isolated from 40 FFPE samples (cut into 20 pm sections by CBS), using 
a technique allowing for maximum recovery of microRNAs, as described in Methods 
(2.2.1.2). Agilent’s 2100 bioanalyser together with the RNA PicoChip Kit was used 
then by CBS to assess RNA diversity between samples in terms of its integrity 
and concentration (Figure 3.8A). Although the RNA concentrations varied greatly, 
the electropherograms were similar for all samples, showing that the majority 
of the isolated RNA was relatively short (< 200 nt), with no sign of large RNA 
species such as rRNA.
Subsequently, expression of miR-16, which is highly and stably expressed in HK-2 
cells, was examined by stem-loop qRT-PCR in those samples in order to establish 
if they were suitable for microRNA analysis by that method (Figure 3.8B). 
As in the reactions a constant volume was used, rather than constant RNA amount, 
the differences in quantity of detected miR-16 between individual samples were large, 
but the signal was of good quality. Interestingly, when the RNA concentration 
determined with Agilent’s 2100 bioanalyser was compared with the relative 
expression of miR-16 in those samples, the ratio of RNA concentration to miR-16 
appeared constant for all biopsies collected after 1996 (Figure 3.8C). In older 
samples, however, miR-16 expression was disproportionally low. Therefore, further 
analysis was performed on the biopsies obtained in 1996 or later.
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RNA from the three patient groups: non-progressors (n=9), progressors (n=9), 
and late presenters (n=4), was pooled, so that the pooled samples for each group 
contained 200 ng of RNA, with proportionately equal representation of each biopsy. 
The pooled RNA was subjected to microRNA profiling using a qPCR-based array 
(TaqMan Low Density Array, Applied Biosystems), performed by CBS. Of 365 
microRNAs examined, 103 were detected. The microRNA expression patterns varied 
across the groups (Figure 3.9A,B). The greatest difference in microRNA expression 
was observed for miR-192, which was over 3-fold downregulated in late presenters 
compared to both non-progressors and progressors (Figure 3.9C).
To validate the array data, miR-192 was quantified in all 22 individual biopsy samples 
with stem-loop qRT-PCR (Figure 3.10A). miR-16 was identified by geNorm [195] 
(see 2.4.3) as one of the three most stably expressed microRNAs in the array; 
therefore, it was used for normalisation of miR-192 expression. miR-192 was 67% 
lower in late presenters than in the other two groups, in keeping with data from 
the pooled array studies, and suggesting loss of miR-192 in advanced diabetic 
nephropathy.
Subsequently, association between miR-192 expression and structural or functional 
clinical parameters, obtained by Lewis et al. [181], was tested. Significant correlations 
were found between fibrosis score and miR-192 expression (Figure 3.1 OB, Pearson 
Correlation Coefficient: -0.704, p < 0.001), and between eGFR and miR-192 
expression (Figure 3.10C, Pearson Correlation Coefficient: 0.768, p < 0.001).
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3.3 Discussion
This chapter was intended to provide a starting point for investigation of microRNA 
role in renal fibrosis. Since at the beginning of the project microRNA expression 
in normal or fibrotic kidney was not well explored, an ideal strategy was to look 
for microRNAs regulated by profibrotic stimuli among all microRNAs discovered 
in humans. As in the middle of 2006 there were already over 400 different human 
microRNAs described (the miRBase release 8.1 [106]), a special high-throughput 
technique was needed to accomplish that.
The first generation of commercially available microRNA arrays were hybridisation- 
based arrays, similar to the typical microarrays used for mRNA detection. The main 
disadvantage of that method was the requirement of large quantities of good quality 
RNA. That excluded the possibility of global analysis of microRNA expression 
in non-surgically obtained renal samples. Surgical nephrectomy specimens, 
on the other hand, would provide enough RNA, but as profound changes 
in microRNA expression had been reported following a prolonged period of tissue 
hypoxia [205], they were not ideal for the study. Therefore, initially, microRNA role 
in the kidney was investigated in the well-established and successfully used 
in the department in vitro model of renal fibrosis, employing immortalized proximal 
tubular epithelial cells stimulated with profibrotic stimuli, typically high concentration 
of glucose or TGF-beta.
MicroRNA profiling by hybridisation array was a relatively new and challenging field 
at that time, mostly due to the size of the microRNAs. Optimal probe characteristics, 
array printing, sample preparation and labeling, and hybridisation also needed to be
137
determined. Ambion, and their daughter company Asuragen, the company with which 
the collaborative beta test was performed, remain an industry leader in microRNA 
technology. At their first review of the initial array studies, no technical problems 
were identified. However, subsequent re-analysis gave clear pointers of technical 
issues with the arrays.
For the repetition of the microRNA profiling approximately one year later, 
the company used an optimized procedure and a new version of Ambion mirVana 
miRNA Bioarrays. The new arrays contained more probes for human microRNAs 
(328 vs. 212) and more control probes (61 vs. 4).
The array data together with the individual qRT-PCR assay results showed that high 
concentration of glucose in the short term did not influence microRNA expression 
in proximal tubular epithelial cell line. This was a rather unexpected finding, since 
elevated glucose had been reported to cause significant alterations in HK-2 cell gene 
expression [203]. The other available data suggest, however, that most of the effects 
on HK-2 cells can be observed after longer culture in high glucose medium than 
48 hours, and often may be attributed to newly synthesized TGF-beta [206]. Further 
experiments confirm that in a short term TGF-beta may be necessary to see a change 
in microRNA expression in those cells.
The enormous progress rate in the microRNA field in the recent years has influenced 
the final outcome of this chapter in two ways. Firstly, the accumulating literature 
about function of individual microRNAs in various systems enabled a fine selection 
of candidate microRNAs that might be involved in fibrotic processes in the kidney, 
when a screen for TGF-beta-regulated microRNAs using a high-throughput technique 
could not be employed for economic reasons. Secondly, at the beginning of 2008
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another method for global microRNA expression studies became available. That was 
a qRT-PCR-based array (TaqMan Low Density Array, TLDA, Applied Biosystems), 
allowing for simultaneous detection of 365 human microRNAs. Importantly, 
the technique was much more sensitive than hybridisation-based arrays; only 80 ng 
of sample RNA was needed for analysis. This made microRNA profiling theoretically 
feasible in FFPE renal biopsy samples collected over years from nephrology patients 
for routine evaluation. Such samples from 40 patients with diabetic nephropathy had 
been previously characterised histologically in the department and were available for 
further study. Although it was highly probable that there would be enough RNA from 
those samples, its quality, after fixation procedure and long storage (8-16 years), 
might have made them unsuitable for analysis.
The encouragement came from two reports comparing microRNA profiles in FFPE 
and fresh frozen tissue samples, demonstrating that microRNAs were well-preserved 
in the FFPE samples and could be successfully detected by hybridisation-based array 
or qRT-PCR [207, 208]. Preliminary analysis done on the 40 FFPE kidney biopsy 
samples confirmed that the isolated microRNAs can be easily detected by qRT-PCR. 
However, in older samples, eventually excluded from further analysis, the qRT-PCR 
signal compared with RNA concentration was remarkably low, suggesting that 
microRNAs in those old samples were damaged, possibly by oxidation during 
prolonged storage. Alternatively, the older fixation procedure might have been less 
efficient or included some inhibitors of PCR reaction. Very similar observations 
to mine have been made recently in a study comparing microRNA expression 
in FFPE lymph nodes from three decades [209].
The final microRNA profiling experiment using the qRT-PCR-based array, 
in addition of being the first demonstration that microRNAs can be globally analysed
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in archival FFPE kidney biopsy samples, revealed multiple differences in microRNA 
expression depending on the rate of disease progression in follow up period 
(comparison: non-progressors vs. progressors) or severity of fibrosis
at the presentation (late presenters vs. combined non-progressors and progressors). 
Renal biopsy is a complex mixture of cells that might vary depending for example 
on the relative amounts of cortex vs. medulla, or tubules vs. glomeruli vs. blood 
vessel, in each biopsy. In spite of this, one of the microRNAs identified in the array 
experiment as differentially expressed between early and late stages of diabetic 
nephropathy, miR-192, when examined in individual samples was still downregulated 
in the late presenters group and its expression inversely correlated with fibrosis 
and decrease in eGFR. Furthermore, the subsequent work in the department revealed 
that this was relatively specific to miR-192, since expression of another microRNA, 
miR-200b, in the biopsies did not correlate with either fibrosis or eGFR [204]. 
In addition, miR-192 loss in advanced diabetic nephropathy was confirmed by in situ 
hybridisation, which also demonstrated presence of miR-192 mostly in glomeruli 
and tubules [204].
These results suggest that miR-192 is a potential new biomarker in diabetic 
nephropathy, and validate the approach of measuring microRNAs in routinely 
processed renal biopsy tissue, analogously to studies of microRNA expression 
in cancer specimens, no less complex, that are soon to enter clinical practise. The data 
also imply that the other changes in microRNA expression found in the experiment 
are very likely to be meaningful and will be a fruitful area for further investigations. 
Sadly, limitations in time and materials permitted a detailed characterisation only 
of one of many microRNAs potentially important in renal fibrosis, miR-192, in this 
thesis.
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Expression of miR-192 has been previously reported to be relatively specific 
to the kidney [143], and to be present in the renal cortex rather than medulla [147]. 
Its expression has been studied also in diabetic nephropathy. Surprisingly, two groups 
working on this subject came to the opposite conclusions [151, 154]. Kato et al. 
observed upregulation of miR-192 in glomeruli from mouse models of diabetic 
nephropathy as well as in vitro in mesangial cells treated with TGF-beta [151]; 
whereas Kantharidis et al. presented results consistent with mine. Namely, he noted 
downregulation of miR-192 in mouse diabetic kidney, and in cultured mesangial 
and proximal tubular epithelial cells stimulated with TGF-beta [154]. Additionally, 
two recent papers from one laboratory pointed to a potential role of miR-192 in other 
renal disorders [156, 157]. The authors reported that in patients with IgA nephropathy 
miR-192 was upregulated when compared with control, inversely correlated 
with the rate of decline in eGFR and with glomerulosclerosis [156]. In patients with 
hypertensive nephrosclerosis they noticed an increase in miR-192, as well as its 
correlation with proteinuria [157]. The discrepancies between the existing data 
suggest that miR-192 regulation and role in the kidney is complex and, very likely, 
worth investigating.
Surprisingly, miR-215, miR-216a, and miR-217, the other microRNAs that have been 
implicated in diabetic nephropathy (see Table 1.2), were not detected in the renal 
biopsy tissue (and miR-377 was not examined). Since control samples from 
the normal kidney were not available for this study, it is conceivable that miR-215, 
decreased in the kidney of diabetic mice and in TGF-beta-treated mesangial 
and proximal tubular epithelial cells [151, 154], could potentially be expressed 
in the normal kidney and would be lost during the course of diabetic nephropathy. 
This, however, would not explain the lack of miR-216a and miR-217, which have
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been found upregulated in glomeruli of diabetic mice and in TGF-beta-treated 
mesangial cells [152]. Most likely, distinct techniques, parts of the kidney/cell types 
investigated, and perhaps differences between species account for the inconsistency.
The results presented in this chapter identified microRNAs for further study, 
and suggested that microRNA quantification might provide useful prognostic 
information for patients with diabetic nephropathy. The major finding was 
the identification of miR-192 as downregulated by profibrotic factors both in short 
term in vitro, following stimulation of proximal tubular epithelial cell line with 
TGF-beta, and in long term in vivo, in course of diabetic nephropathy. Investigation 
of miR-192 function in the fibrotic process in the kidney will be the focus of Chapter 
Five.
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Figure 3.1. Preliminary experiments done before the start of my project. HK-2 
cells were cultured in control medium or 25 mM glucose for 48 or 96 hours before 
RNA extraction. MicroRNA profiling was performed by Asuragen as part of a beta 
test for a new microRNA microarray (Ambion mirVana miRNA Bioarray VI).
(A) Expression of 385 (including 212 human) microRNAs in HK-2 cells is 
represented on a heat map, with dark blue being low/no expression, and red being 
maximum expression. Samples and microRNAs were grouped according to 
unsupervised Bicluster Analysis. (B) Volcano Plot showing the relationship between 
change in microRNA expression between two groups (25 mM glucose and control) 
and statistical significance. Horizontal red line represents p = 0.05 threshold. 
(C) Expression of 40 microRNAs most altered by 25 mM glucose at 48 hours 
displayed as in (A).
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Figure 3.2. Expression of selected microRNAs in H K -2  cells cultured in medium 
with high glucose concentration. After 48-hour-culture in medium without FCS, 
confluent HK-2 cells were cultured in control medium (blue bars) or medium with 
25 mM glucose (green bars) for 48 hours unless stated otherwise. Expression 
of miR-16, miR-106b, miR-26a, and miR-29a was examined using stem-loop 
qRT-PCR, as described in Methods. (A) Cells were stimulated with 25 mM glucose 
for 1 to 96 hours, as indicated on the graph. (B) Glucose used for stimulation came 
from two other independent sources. (C) Cells were plated before the experiment on 
T25 flasks instead of usual 6-well-plates. (D) Cells were growth-arrested for 72 
rather than 48 hours. (E) Higher concentration of glucose (35 mM) was used.
(F) Cells were stimulated with 25 or 45 mM glucose in medium without insulin.
(G) Smaller volume (1 ml rather than usual 2 ml) of culture medium was used. Error 
bars (where shown) represent SEM, n=3. No significant change in microRNA 
expression between samples cultured in control and high glucose medium was 
found.
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Figure 3.3. TGF-beta secretion by HK-2 cells cultured with 25 mM glucose.
HK-2 cells were cultured on a 6-well-plate. After 48 hours without FCS, they were 
cultured in 1.2 ml medium containing 5 mM (blue bars) or 25 mM glucose (green 
bars) for four days (A) or as indicated on the chart (B). Medium was replaced every 
second day until the day 4, and then was collected after 24, 48, or 72 hours. 
The concentration of latent TGF-beta in medium was measured by ELISA. The error 
bars (A) represent SEM, n=3. An asterisk indicates p < 0.05.
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Figure 3.4. MicroRNA profiling in proximal tubular cells. HK-2 cells were 
cultured in 25 mM glucose or control medium for 48 hours before RNA extraction. 
MicroRNA profiling was done by Asuragen using Ambion mirVana miRNA 
Bioarray V2. (A) Expression of 640 (including 328 human) microRNAs in HK-2 
cells is represented on a heat map scale, with dark blue being low/no expression, 
and red being maximum expression. Samples and microRNAs were grouped 
according to unsupervised Bicluster Analysis. (B) Volcano Plot shows 
the relationship between change in microRNA expression between the two groups 
(25 mM glucose and control) and statistical significance (-log of uncorrected 
p-values). Horizontal red line represents p = 0.05 threshold.
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Figure 3.5. Expression of selected microRNAs in HK-2 cells stimulated with 
TGF-beta. After 48-hour-culture in medium without FCS, confluent HK-2 cells 
were cultured in control medium (blue bars) or stimulated with TGF-beta at the final 
concentration of 1 ng/ml (yellow bars) or 10 ng/ml (red bars) for indicated time 
points (A,B) or 96 hours (C,D). Expression of miR-16 (A), miR-106b (B), miR-26a 
(C), and miR-29a (D) was examined using stem-loop qRT-PCR. Error bars (C,D) 
represent SEM, n=3. Statistical significance is indicated with asterisks as follows: 
* p <0.05, ***p<  0.0005.
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Figure 3.6. Expression of newly selected microRNAs in HK-2 cells stimulated 
with TGF-beta. After 48-hour-culture in medium without FCS, confluent HK-2 
cells were cultured in control medium (blue bars) or stimulated with 10 ng/ml 
TGF-beta (red bars) for 96 hours. (A) Expression of let-7a, miR-21, miR-34a, 
miR-192, and miR-200b was examined using stem-loop qRT-PCR. (B) RNA amount 
used in RT reactions (intended 10 ng) was quantified in each sample using Quant-iT 
RNA Assay (Invitrogen). Additionally small nuclear RNA U6 was quantified using 
stem-loop qRT-PCR. The experiment was performed in triplicate; SEM is shown. 
** indicates p < 0.005.
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Figure 3.7. Expression of miR-192 and miR-21 in HK-2 cells stimulated with 
profibrotic stimuli. After 48-hour-culture in medium without FCS, confluent HK-2 
cells were cultured in control medium (blue bars), medium with 25 mM glucose 
(green bars), or stimulated with TGF-beta at the final concentration of 1 ng/ml 
(yellow bars) or 10 ng/ml (red bars) for indicated time points. Expression 
of miR-192 (A) and miR-21 (B) was examined using stem-loop qRT-PCR. miR-16 
was used for normalisation.
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Figure 3.8. Quantification and quality control of RNA isolated from FFPE renal 
biopsy tissue from patients with diabetic nephropathy. RNA was isolated from 
FFPE renal tissue from 40 patients with diabetic nephropathy. (A) Microfluidics 
analysis of RNA integrity was performed by CBS using Agilent’s 2100 bioanalyser 
together with the RNA PicoChip Kit. A representative electropherogram is shown. 
On the right the results are displayed as they would appear on an agarose gel.
(B) miR-16 expression was measured in the 40 samples by stem-loop qRT-PCR. 
Amplification plot and melting curves are shown, demonstrating proper amplification 
and a single product of the reaction in all samples, but not in negative controls.
(C) Comparison of RNA concentration estimated with RNA PicoChip and expression 
of miR-16 by stem-loop qRT-PCR. The red box indicates samples which were used in 
further experiments (from the biopsies taken in or after 1996, except for samples 32 
and 36 with very low RNA concentration).
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Figure 3.9. TaqMan Low Density Array determination of microRNA expression 
in renal biopsy tissue from patients with diabetic nephropathy. Renal biopsies 
from diabetic nephropaths were separated into three groups on the basis of progression 
following biopsy: non-progressors (NP, n=9), progressors (P, n=9), and late presenters 
(LP, n=4). Expression of 365 microRNAs was quantified in pooled RNA for each 
group using TaqMan Low Density Array Human MicroRNA Panel vl.O (Applied 
Biosystems). Fold-expression values are displayed for microRNAs detected (Cx < 33). 
(A) Comparison of P vs. NP. (B) Comparison of combined earlier stage biopsies 
(NP+P) vs. LP. (C) Amplification plot demonstrating lower miR-192 expression in LP 
in comparison with NP and P.
154
A
1.5
CMO !
I
DC
E
0.5 J
p < 0.005
NS p < 0.05
i  r
N o n -P rogressors P ro g resso rs Late P r e se n te r s
B
CMO)
3
2.5
2
1.5
1
0.5
0
0 0.5 1.5 2 2.5 31
Fibrosis score
CMO)
DC
E
3
2.5
2
••
1
0.5
0
0 20 40 60 80 100
eGFR
Figure 3.10. Expression of miR-192 in individual kidney biopsies and its 
correlation with severity of kidney disease. (A) miR-192 was examined 
in individual samples pooled for use in microRNA profiling (9 non-progressors, 
9 progressors, 4 late presenters) by stem-loop qRT-PCR, using miR-16 as an 
endogenous control. Mean ± SEM is shown. (B) Plot of miR-192 expression 
vs. fibrosis score, Pearson Correlation Coefficient -0.704, p < 0.001. (C) Plot 
of miR-192 expression vs. eGFR, Pearson Correlation Coefficient 0.768, p < 0.001. 
Fibrosis score and eGFR were determined by Lewis et al. [181].
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MicroRNA
Array
signal*
(Control)
Expression
ratio*
(Glucose
5/25mM)
Som e predicted microRNA targets implicated 
in renal fibrosis**
miR-16 13.1 6.857
activin A receptor, type II (ACVR2), TGFB-induced factor 2 
(TALE family homeobox) (TGIF2), collagen, type XII alpha 1, 
and type XXIV alpha 1 (COL12A1, COL24A1), SMAD, 
mothers against DPP homolog 5, 3 and 7 (Drosophila) 
(SMAD5, SMAD3, SMAD7), PAI-1 mRNA-binding protein 
(PAI-RBP1), laminin gamma 1 (LAMC1), hyaluronan 
synthase 2 (HAS2), serum/glucocorticoid regulated kinase 
(SGK), bone morphogenetic protein receptor, type IA 
(BMPR1A), transforming growth factor, beta receptor III 
(TGFBR3), insulin-like growth factor 2 receptor (IGF2R)
miR-26a 11.2 8.414
SMAD, mothers against DPP homolog 1 and 4 (Drosophila) 
(SMAD1, SMAD4), PAI-1 mRNA-binding protein (PAI- 
RBP1), platelet-derived growth factor receptor, alpha 
polypeptide (PDGFRA), collagen, type XXII alpha 1, and 
type I alpha 2, and type XIX alpha 1 (COL22A1, COL1A2, 
COL19A1), hyaluronan synthase 2 (HAS2)
miR-29a 9.7 7.581
collagen, type I alpha 1, and type IV alpha 5, and type III 
alpha 1, and type I alpha 2, and type IV alpha 1, and type V 
alpha 2, and type II alpha 1, and type IX alpha 1, and type II 
alpha 1, and type XXII alpha 1, and type XV alpha 1, and 
type VII alpha 1, and type VI alpha 3, and type V alpha 3, 
and type XIX alpha 1 (COL1A1, COL4A5, COL3A1, 
COL1A2, COL4A1, COL5A2, COL2A1, COL9A1, COL2A1, 
COL22A1, COL15A1, COL7A1, COL6A3, COL5A3, 
COL19A1), serum/glucocorticoid regulated kinase (SGK), 
transforming growth factor beta 1 induced transcript 4 
(TGFB114), platelet derived growth factor C (PDGFC), 
transforming growth factor, beta 3 (TGFB3), laminin gamma 
1 (LAMC1)
miR-106b 9.0 8.704
hyaluronan binding protein 4 (HABP4), peroxisome 
proliferative activated receptor, alpha (PPARA), BMP and 
activin membrane-bound inhibitor homolog (Xenopus laevis) 
(BAMBI), SMAD, mothers against DPP homolog 6, 7and 5 
(Drosophila) (SMAD6, SMAD7, SMAD5), hyaluronan 
synthase 2 (HAS2), platelet-derived growth factor receptor, 
alpha polypeptide (PDGFRA), bone morphogenetic protein 
receptor, type II (BMPR2), activin A receptor, type IB 
(ACVR1B), TGF-beta induced apotosis protein 2 (TAIP-2), 
TGFB inducible early growth response 2 (TIEG2), collagen, 
type IV, alpha 3 (Goodpasture antigen) (COL4A3)
miR-128a 6.2 5.687
bone morphogenetic protein receptor, type II (BMPR2), 
epidermal growth factor receptor (EGFR), peroxisome 
proliferative activated receptor, gamma (PPARG), latent 
transforming growth factor beta binding protein 1 (LTBP1), 
collagen, type III alpha 1 (COL3A1), platelet-derived growth 
factor receptor, alpha polypeptide (PDGFRA), insulin 
receptor (INSR), hyaluronan and proteoglycan link protein 1 
(HAPLN1), activin A receptor, type I (ACVR1), insulin 
receptor substrate 1 (IRS1)
* Results obtained before the start of my project. 
** Predictions by PicTar [191], as described in Methods.
Table 3.1. Selection of microRNAs for further analysis.
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MicroRNA Function / special features* Ref
let-7a
Tumour suppressor. Conserved from worms to mammals. 
One of the most studied microRNAs. Believed to be a 
master regulator of cell proliferation pathways.
[210]
miR-21
Oncogene ("oncomiR"). Promotes cell growth and 
proliferation in various cancers. Upregulated in keratinocytes 
following stimulation with TGF-beta.
[142, 211]
miR-34a
Tumour suppressor. Induced by p53 in response to DNA 
damage and oncogenic stress. Causes cell-cycle arrest in 
tumour-derived and primary cells.
[212]
miR-192
Upregulated in glomeruli of mouse model of diabetic 
nephropathy, as well as in mesangial cells stimulated with 
TGF-beta. Responsible for an increase in collagen 1-alpha 2 
synthesis after TGF-beta stimulation in mesangial cells.
[152]
miR-200b
Ectopic expression of miR-200c in breast and lung cancer 
cell lines resulted in an increase in E-cadherin (according to 
the microarray data, in HK-2 cells miR-200b is the most 
abundant among the miR-200 family members).
[213]
* Reported before October 2007.
Table 3.2. Selection of microRNAs potentially regulated by TGF-beta.
CHAPTER FOUR:
A t t e m p t s  t o  r e pr e ss  e x p r e ssio n
OR FUNCTION OF ALL MICRORNAS IN 
PROXIMAL TUBULAR EPITHELIAL CELLS
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4.1 Introduction
There are several common elements in biosynthesis and mode of action of all 
microRNAs. Therefore, one might predict that blocking a single enzyme crucial 
for either of those processes will be sufficient to globally reduce microRNA 
expression or function. The observed changes would then suggest physiological roles 
of microRNAs in the studied model. In fact, many discoveries regarding microRNA 
functions have been made by investigating the effects of general microRNA 
inhibition.
Choosing the right protein for blockade is of fundamental importance in this 
approach. As described earlier (see 1.4.3), following microRNA-specific transcription 
of pri-microRNAs, there are a few major steps in microRNA biosynthesis shared 
by most microRNAs. These are sequentially: i) processing of pri-microRNA 
by the Microprocessor complex (comprising of the endonuclease Drosha 
and the RNA-binding protein DGCR8), giving approximately 70-nucleotide-long 
stem-loop structure called pre-microRNA, ii) nuclear export by Exportin-5, 
and iii) cleavage of the pre-microRNA by Dicer. The mature microRNA is then 
loaded with help of Dicer, TRBP, and PACT into the miRISC complex and may 
perform its functions.
A number of proteins are involved in those steps. Inhibition of some of them, 
e.g. Drosha, DGCR8, Exportin-5, Dicer, TRBP, Argonautes (Ago 1-4), or GW182, has 
been shown to affect microRNA maturation or action [214-216]. However, 
the majority of them would not be ideal to study the role of microRNAs in biological 
processes because of their other important functions in the cell. In particular, Drosha
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is involved in rRNA processing [217], while Exportin-5 transfers to the cytoplasm 
also other short RNA species containing a mini-helix motif, such as tRNA. [218].
Until recently, inhibition of Dicer seemed to be a perfect option. It was known solely 
for its function in processing of precursors of short silencing RNAs: microRNAs 
and siRNAs. For a long time it was commonly accepted that the latter type 
of processing did not occur in mammalian cells in physiological conditions. Instead, 
it was associated either with viral infection or transfection with artificial long double­
stranded RNA. The presence of endogenous siRNAs in mammals was described 
for the first time in 2008 [219, 220]. Until then however, manipulation of Dicer 
expression seemed to give easily interpretable results and became the most commonly 
used method to study microRNA functions. That was also the reason why in this 
chapter I focused mainly on Dicer inhibition.
There is a single Dicer gene in humans. It encodes a rather large protein of predicted 
molecular weight of 217 kDa, consisting of nearly two thousand amino acid residues. 
It belongs to the RNase III family, which is a group of enzymes that specifically 
recognise and cleave double-stranded RNA into short discrete fragments 
of 21-27 nucleotides in length [221]. Crucial for Dicer hydrolytic activity are two 
ribonuclease domains characteristic to the whole RNase III family (often called 
the RNase III domains) and one PAZ domain binding to the end of double-stranded 
RNA. Each RNase III domain catalyses cleavage of one RNA strand, together 
generating products with the characteristic two-nucleotide-long overhangs 
at the 3' ends [221]. After the cleavage, presumably using its HExD/H-box helicase 
domain, Dicer helps the two strands of the short double-stranded RNA to separate. 
Subsequently, by interaction with the components of the miRISC complex and other
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supporting proteins, it facilitates the loading of one of the strands into the miRISC 
complex.
The importance of Dicer and microRNAs in various processes has been highlighted 
by a number of Dicer knockout and knockdown experiments. The most spectacular 
examples include embryonic lethality of Dicer knockout mice [135], death of cardiac- 
specific Dicer knockout mice prenatally or shortly after birth due to defects in heart 
development [137], or fatal defects in brain development after Dicer conditional 
knockout in mouse neocortex [138]. In addition, in 2008, so after completion 
of the experiments presented below, three independent groups reported that 
conditional Dicer knockdown in renal podocytes results in advanced kidney failure 
and mouse death at six to eight weeks, providing evidence that Dicer is essential for 
normal kidney function [148-150].
This chapter was meant to facilitate the subsequent functional studies of individual 
microRNAs selected in Chapter Three. This would be achieved by finding out which 
of the processes related to renal fibrosis were microRNA-dependent, i.e. were affected 
following knockdown of Dicer or, as justified later, TRBP or GW182 in HK-2 cells.
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4.2 Results
4.2.1 Transient knockdown of Dicer or TRBP 
using siRNA
Dicer knockdown
In order to inhibit microRNA biosynthesis, transient knockdown of Dicer was carried 
out in HK-2 cells using specific siRNA, as described in the literature [198].
To start with, a time course experiment was performed to establish the best time 
needed to observe maximal reduction in Dicer and mature microRNA expression. 
Total RNA was extracted from cells 24, 48, 72, or 96 hours after transfection 
with 18 nM Dicer-specific or control siRNA. Expression of Dicer and miR-16 
(as an example of mature microRNA) was examined by qRT-PCR (Figure 4.1). 
Although Dicer expression was substantially lower in samples with Dicer knockdown 
at all four time points, there was no accompanying difference in miR-16 expression. 
That result might suggest that microRNA half-life in HK-2 cells was longer than 
the last time point (96 hours). Therefore, a double (sequential) transfection was 
performed. The cells were transfected with 18 nM siRNA against Dicer or control 
siRNA, or left untransfected. After 72 hours the transfection was repeated. The cells 
were lysed and RNA extracted 72 hours later. Dicer and miR-16 expression were 
analysed by qRT-PCR (Figure 4.2). The double transfection results were similar
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to the previous, in that Dicer expression was markedly reduced, whereas 
the expression of miR-16 was not.
In the next attempt, I tested if higher siRNA concentrations would result in a better 
inhibition of the microRNA biosynthesis pathway. In addition to 18 nM final siRNA 
concentration, 30 nM (the most commonly used in the department) and 100 nM 
(maximum recommended by the manufacturer) concentrations were examined. 
The analysis was performed 72 hours after transfection by qRT-PCR (Figure 4.3). 
Again, Dicer expression was clearly reduced, but there was no difference in miR-16 
expression, regardless the siRNA concentration.
Assuming that the observed lack of reduction in the microRNA expression was due 
to incomplete (approximately 70%) downregulation of Dicer, I tried two additional 
siRNAs specific to Dicer. HK-2 cells were transfected with all three kinds of siRNAs 
separately or in combination. After 72 hours, Dicer and miR-16 expression was 
examined by qRT-PCR (Figure 4.4). Even though Dicer knockdown was slightly 
more efficient when using the new siRNAs, it was still not sufficient to cause 
a difference in miR-16 expression.
As it was conceivable that the change in Dicer expression at the mRNA level was not 
followed by a change in the actual protein concentration, I also looked at Dicer 
at the protein level. The cells were transfected as previously, using the most effective 
of the three siRNAs. Subsequently, Dicer protein was examined by Western blot 
(Figure 4.5). The results confirmed the considerable downregulation of Dicer 
by the siRNA, yet the protein was still detectable.
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Inhibition of TRBP (alone or together with Dicer)
Since inhibition of Dicer on its own did not result in the expected decrease 
in microRNA expression, another gene involved in microRNA biogenesis was 
silenced -  alone or in combination with Dicer. The selected gene was TRBP 
(the human immunodeficiency virus transactivating response RNA-binding protein), 
known to co-operate with Dicer in the process of microRNA loading into the miRISC 
complex [199]. Moreover, TRBP has been shown to stabilise Dicer 
posttranscriptionally, and its knockdown in HeLa cells resulted in reduction 
of expression of various microRNAs, including miR-16 [199].
HK-2 cells were transfected with siRNA specific to TRBP, Dicer, or both at the same 
time. After 72 hours, expression of TRBP, Dicer, and three microRNAs of different 
abundances in HK-2 cells (miR-16, miR-26a, miR-200b) was examined by qRT-PCR 
(Figure 4.6). Despite substantial downregulation of both Dicer (75%) and TRBP 
(60%), the three microRNAs were unaffected.
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4.2.2 Long-term knockdown of Dicer or GW182 
with shRNA
Dicer downregulation
One of possible reasons why the transient Dicer knockdown with siRNA did not have 
any impact on microRNA expression was that the microRNAs could have especially 
long half-lives in HK-2 cells. In such situation, only long-term inhibition of Dicer 
would result in noticeable microRNA reduction. Therefore, HK-2 cells were stably 
transfected with short-hairpin RNA (shRNA) designed to silence Dicer (based 
on the best Dicer-specific siRNA) or control shRNA, as described in Methods. Dicer 
and miR-16 expression was examined 3, 19, and 43 days after transfection in a mixed 
population of stably transfected cells by qRT-PCR (Figure 4.7). In cells expressing 
Dicer-specific shRNA, Dicer expression was decreasing with time, but there was still 
no effect on miR-16.
Subsequently, single lines that stably express Dicer-specific shRNA were selected 
as described in Methods. About two months after transfection, cells were lysed 
and RNA extracted from six single lines. For comparison, also mixed populations 
of cells stably transfected with Dicer-specific or control shRNA were used. As the cell 
lines differed in their growth rate (three quickly, and three slowly growing), cell 
confluence and their number was only approximately equal in all samples at the time 
of the lysis. Therefore, instead of choosing a single endogenous control for qRT-PCR, 
like in the majority of experiments, six genes listed as possible endogenous controls 
by Applied Biosystems were used. These included GAPDH, RPLPO, TBP, B2M,
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HPRT1, and U6. After leaving out B2M, which was unexpectedly upregulated in one 
of the samples, the signal from the other controls was averaged and used 
for normalisation of Dicer, miR-16, miR-26a, and miR-200b expression (Figure 4.8). 
The results showed that even in the line with the greatest downregulation of Dicer 
(78% knockdown), microRNA expression was not affected.
Attempt to reduce GW182 expression
As Dicer and TRBP knockdown did not cause the expected inhibition of microRNA 
biosynthesis, GW182, acting downstream of those genes, was then chosen 
for knockdown. GW182 is a component of the miRISC complex. It directs 
the complex together with a target mRNA to P-bodies, where the mRNA is either 
stored (but not translated) or degraded [222]. It has been shown that GW182 
is required for microRNA function and its knockdown impairs silencing of reporters 
containing microRNA-binding sites in their 3'UTR [200].
Using siRNA sequence from that report [200], plasmid containing GW 182-specific 
shRNA was constructed. HK-2 cells were stably transfected with that or control 
shRNA. After 2 or 25 days the cells were lysed and expression of GW182 was 
analysed by qRT-PCR (Figure 4.9). Since the change in GW182 expression was very 
small, the impact of GW182 knockdown on microRNA activity was not examined.
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4.3 Discussion
Global inhibition of microRNA synthesis or function in HK-2 cells, if successful, 
would be a valuable tool for investigation of microRNA role in renal fibrosis. Firstly, 
it could confirm that microRNAs are not just expressed, but also functional 
in the kidney. Secondly, it would be possible to tell which of the processes 
contributing to the fibrosis are controlled by microRNAs.
Despite a considerable Dicer downregulation by siRNA or shRNA, microRNA 
expression was not changed in any of the attempts described above. The most likely 
explanation is that the remaining -25% of Dicer was enough to perform all its 
functions in HK-2 cells. If that was the case, the improvement of knockdown 
efficiency could solve the problem. In fact, RNA interference, although previously 
employed successfully by other groups [198], is not an ideal method to achieve Dicer 
knockdown. Dicer is used in both siRNA and microRNA pathways, so I attempted 
to silence the machinery necessary for gene silencing.
Among other strategies that have been used so far, blocking Dicer translation 
with a modified oligonucleotide complementary to the translation initiation start 
within Dicer mRNA seems to be very promising. However, this could be used only 
for short term experiments, so it would not be efficient in cells with long-lived 
microRNAs.
Another conceivable method would be a targeted disruption of the human Dicer locus 
in HK-2 cells using AAV vector. Interestingly, in the study describing this approach, 
only 55 of 97 detected microRNAs were found to be significantly downregulated 
in cells lacking functional Dicer [223]. Similarly, conditional Dicer knockout
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in mouse retina demonstrated that biogenesis of some microRNAs is more Dicer- 
dependent than of the others [224]. Perhaps, the lack of effect of Dicer inhibition 
on the expression of select microRNAs reflects the fact that another gene of similar 
function to Dicer exists in mammals.
Experiments demonstrating effects of global microRNA downregulation in a studied 
model were very popular a few years ago. Their main purpose was to show that 
microRNAs play a role in a particular organ or process. Nowadays, it is generally 
accepted that regulation by microRNAs is remarkably widespread. Therefore, instead 
of wondering if microRNAs are involved in process X, researchers would rather ask 
now which of them are involved in X and what their mRNA targets are. These are 
also the questions I will address in the next chapter.
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Figure 4.1. Transient Dicer knockdown -  time course. HK-2 cells were 
transfected with 18 nM control siRNA (grey bars) or siRNA against Dicer (black 
bars). Expression of Dicer (A) and mature miR-16 (B) was examined 24, 48, 72, 
or 96 hours after transfection by qRT-PCR. RPLP0 was used for normalisation.
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Figure 4.2. Sequential transfection with siRNA silencing Dicer. HK-2 cells were 
transfected with 18 nM control siRNA (grey bars) or siRNA against Dicer (black 
bars). The transfection was repeated 72 hours later and the cells incubated for 
another 72 hours. Dicer (A) and mature miR-16 expression (B) were analysed by 
qRT-PCR. In some cases the cells were transfected only once, at the beginning 
of the experiment (+-) or in the middle (-+). RPLP0 was used as an endogenous 
control.
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Figure 4.3. Transient Dicer knockdown -  dose response. HK-2 cells were 
transfected with indicated concentrations of control siRNA (grey bars) or siRNA 
silencing Dicer (black bars). Expression of Dicer (A) and mature miR-16 (B) was 
measured 72 hours later by qRT-PCR. RPLPO was used as an endogenous control.
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Figure 4.4. Transient Dicer knockdown using three siRNAs against Dicer.
HK-2 cells were transfected with 25 nM of siRNA against Dicer (siRNA 1-3), alone 
or in combination. Cells transfected with 25 nM or 75 nM control siRNA (Scrl), 
and untransfected cells (UnTx) were used as controls. Dicer (A) and mature 
miR-16 (B) expression was examined 72 hours after transfection by qRT-PCR. 
RPLPO was used for normalisation. Averaged values from three independent 
transfections +/- SEM are shown.
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Figure 4.5. Transient Dicer knockdown at the protein level. HK-2 cells were 
transfected with indicated concentrations of control siRNA (Scrl), siRNA silencing 
Dicer (siRNA3), or left untransfected. Dicer expression was analysed by Western 
blot 72 hours later (A). Additionally, expression of Dicer (B) and mature miR-16 (C) 
was examined by qRT-PCR. The experiment was carried out in duplicate.
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Figure 4.6. Transient knockdown of Dicer and TRBP. HK-2 cells were 
transfected with 25 nM control siRNA (Scrl), siRNA against Dicer (siRNA3), 
siRNA against TRBP, or combination of Dicer and TRBP siRNAs. Expression 
of Dicer (A), TRBP (B), mature miR-16 (C), miR-26a (D), and miR-200b (E) was 
analysed by qRT-PCR 72 hours after transfection. RPLP0 was used for 
normalisation. The experiment was performed in triplicate; SEM is shown.
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Figure 4.7. Long-term Dicer knockdown. HK-2 cells were transfected with 
the siSTRIKE U6 plasmid for expression of shRNA silencing Dicer (based on 
siRNA3) or a control shRNA (based on Scrambled 1 siRNA). Expression of Dicer 
and mature miR-16 was analysed 3 (A), 19 (B), and 43 days (C) after transfection 
by qRT-PCR in a mixed population of transfected cells. Puromycin was used to 
eliminate untransfected cells, as described in Methods (see 2.1.1.5). GAPDH was 
used as an endogenous control. The experiment was performed in triplicate; SEM 
is shown.
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Figure 4.8. Selection of single lines that stably express shRNA silencing Dicer.
Single lines were obtained from HK-2 cells stably expressing shRNA against Dicer, 
as described in Methods (see 2.1.1.5). Three quickly (2B, 6F, 10F), and three slowly 
growing (7B, 8G, 10A) lines were analysed by qRT-PCR together with mixed 
populations of cells that stably express shRNA against Dicer or control shRNA 
(Scrl). Expression of six potential endogenous controls: B2M, GAPDH, HPRT1, 
RPLP0, TBP, and U6 was examined (A). Dicer (B) and three mature microRNAs 
(C) were subsequently normalised to the combination of them all except B2M.
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Figure 4.9. GW182 knockdown. HK-2 cells were transfected with the siSTRIKE 
plasmids for expression of shRNA silencing GW182 or a control shRNA (Scrl). 
Expression of GW182 was analysed 2 (A), and 25 days (B) after transfection by 
qRT-PCR in a mixed population of transfected cells. For the longer time point, 
puromycin was used to eliminate untransfected cells. GW182 expression was 
normalised to GAPDH. The experiment was performed in triplicate; SEM is shown.
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CHAPTER FIVE:
MlCRORNA FUNCTION IN THE KIDNEY: 
THE ROLE OF MlR-192 IN EMT
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5.1 Introduction
In Chapter Three I examined microRNA expression in proximal tubular epithelial cell 
line following treatment with profibrotic stimuli, as well as in renal biopsy samples 
from patients with diabetic nephropathy. That combined strategy led to identification 
of miR-192 as a potentially important factor in kidney fibrosis.
Human miR-192 gene was initially predicted by computational methods 
and subsequently validated experimentally by cloning from human normal colorectal 
mucosae in 2003 [225]. So far, according to the miRBase release 14 [106], miR-192 
homologs have been identified in eleven vertebrate species, from fishes through frogs 
to mammals.
The precursor of human miR-192 has been localized to an intergenic region 
on chromosome 11. It forms a microRNA cluster with miR-194, i.e. its primary 
transcript comprises also of miR-194 precursor, which is located approximately 
100 bp apart from pre-miR-192 [226]. This may suggest similar expression patterns 
for those two microRNAs. In addition, due to similarity of their seed regions, 
miR-192 and miR-215 are predicted to have similar targets/functions, and therefore 
constitute one gene family. Notably, expression of all those three microRNAs, 
miR-192, miR-194, and miR-215, has been reported to be highly specific 
to the kidney in human [143]. Furthermore, miR-192 and miR-194 have been found 
enriched in rat renal cortex [147].
The first insight into miR-192 function came from a study by Kato et al. showing that 
in renal mesangial cells miR-192 contributes to fibrosis by inhibition of ZEB2, one 
of the E-box repressors, which otherwise binds to the promoter region
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of collagen 1-alpha 2 and negatively regulates its synthesis [151]. Interestingly, 
the E-box repressors are best known for their function in E-cadherin regulation 
in both cancer and fibrosis contexts [227, 228]. It has been suggested that repression 
of E-cadherin in renal epithelial cells results in a comprehensive epithelial-to- 
mesenchymal transition (EMT) [229, 230], which is a key step in fibrogenesis 
in the kidney. Thus, one might predict that in different settings ZEB2 inhibition 
by miR-192 may as well prevent renal fibrosis by upregulation of E-cadherin. Indeed, 
at the American Society of Nephrology Meeting in 2008 another group demonstrated 
that TGF-beta downregulates miR-192 in mesangial and proximal tubular epithelial 
cells, as well as in a mouse model of diabetes [154]. In the proximal tubular epithelial 
cells that was associated with an increase in ZEB2 and downregulation 
of E-cadherin [154]. Consistent with this, my results showed downregulation 
of miR-192 after short- or long-term exposure to profibrotic stimuli in vitro or in vivo, 
respectively. This drew my attention to EMT.
EMT and its opposite: mesenchymal-to-epithelial transition (MET), are highly 
conserved processes crucial for morphogenesis in multicellular organisms [231]. 
During EMT, polarized epithelial cells are converted into motile mesenchymal cells, 
loosely embedded in an extracellular matrix. An early and, according to some authors, 
central to EMT change at the molecular level when a cell loses its epithelial 
phenotype is a decrease in E-cadherin expression, which normally connects epithelial 
cells via the adherens junctions [231]. The loss of E-cadherin is usually followed 
by actin reorganization, increase in expression of mesenchymal markers, e.g. vimentin 
and extracellular matrix genes, and enhanced cell migration and invasion [34].
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EMT is regulated by several growth factors, cytokines, hormones, and other 
extracellular factors in a cell-type-dependent manner. Accordingly, numerous 
intracellular signal transduction pathways have been reported for EMT, including 
theTGF-beta pathway, the Wnt pathway, the Notch pathway, and signals from 
Tyrosine Kinase Receptors [232]. As a result, many genes involved in cellular 
adhesion, extracellular matrix deposition, cell migration and invasion are 
transcriptionally altered. The best-studied example is the transcriptional repression 
of E-cadherin. The promoter region of E-cadherin contains the so-called E-box 
elements, which in cells undergoing EMT are bound by some of a few zinc-finger 
transcriptional repressors, called the E-box repressors, such as ZEB1, ZEB2, Snail, 
Slug, and Twist, depending on the cellular context [231].
In addition to normal development, EMT has been shown to play an important role 
also in various pathologies, including chronic kidney disease. The presence of EMT 
in renal fibrosis was first demonstrated in 1995 by Strutz et al. [233]. The authors 
showed that tubular epithelial cells in a mouse model of anti-tubular basement 
membrane disease could express Fspl, a cytoskeleton-associated protein normally 
expressed by fibroblasts but not epithelia [233]. Subsequent work by Hui Lan’s group 
from the Tokai University, Japan, demonstrated that EMT occurs in rats after 5/6 
nephrectomy, as alpha-smooth muscle actin and actin filaments were detected 
in tubular epithelia of the remnant kidney three weeks after nephrectomy [234]. 
In accordance with animal studies, epithelial cells with some EMT features have been 
also observed in human biopsy tissue from various kidney disorders [235, 236]. 
Importantly, their number was associated with serum creatinine and degree 
of interstitial damage, suggesting that EMT participates in the fibrotic process in 
humans [236]. All these studies, however, failed to prove that the cells potentially
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undergoing EMT were not in fact an infiltration of interstitial myofibroblasts. It was 
an elegant work by Iwano et al. [237] that showed, using sophisticated genetic 
approaches, that interstitial fibroblasts could be derived from tubular epithelial cells 
after obstructive injury. Moreover, the authors estimated that among Fspl -positive 
fibroblasts in the fibrotic kidney as many as 36% are derived from epithelial cells, 
14-15% from the bone marrow, and the rest from local proliferation [237]. 
Considering the fact that EMT leads to an increase in a number of myofibroblasts as 
well as tubular atrophy, it emerges as an important mechanism in renal fibrosis.
Strong evidence suggests that EMT also promotes tumour progression. Properties 
of cells that have undergone EMT allow them to detach from the primary tumour, get 
into the circulation, and eventually re-acquire an epithelial phenotype to form 
a metastasis. In keeping with that, loss of E-cadherin, the main feature of EMT, has 
been linked to an aggressive phenotype and poor clinical prognosis in various 
cancers [238, 239]. Remarkably, in 2008 four independent groups, using different 
models, demonstrated that microRNAs of the miR-200 family prevent EMT 
by directly targeting the E-box repressors ZEB1 and ZEB2 [240-243].
Since my data suggested that expression of the miR-200 family was not altered 
in progression of diabetic nephropathy, and miR-192 has been ultimately shown 
to target both ZEB1 and ZEB2 [151, 244], it was conceivable that in the kidney 
miR-192 might play a major role in regulation of EMT. The aim of the present 
chapter was to investigate this possibility.
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5.2 Results
5.2.1 Characterisation of HK-2 cell response 
to TGF-beta
To facilitate subsequent investigation of miR-192 role in EMT, I set out to further 
characterise TGF-beta-induced changes in HK-2 cells.
In the initial experiment, HK-2 cells were stimulated with 10 ng/ml TGF-beta 
for 96 hours. At that time the morphology of the treated cells, as seen under 
a microscope, was evidently altered; the cells were bigger and their shape resembled 
that of fibroblasts (this has been reported previously by numerous groups; for example 
see Figure 2a in [241]). RNA extracted from those cells was analysed by qRT-PCR 
(Figure 5.1).
Firstly, it was important to select a proper endogenous control for normalisation 
of the genes of interest (Figure 5.1 A). Seven genes commonly used as endogenous 
controls in various systems were tested: ACTB, B2M, GAPDH, HPRT1, RPLPO, 
TBP, and TFRC. Among these, B2M, RPLPO, and GAPDH were identified 
as the most stable genes by geNorm VBA applet for Microsoft Excel [195], 
as described in Methods. In the next experiments involving HK-2 cell stimulation 
with TGF-beta, GAPDH was typically used.
Having chosen the endogenous control, I examined expression of EMT markers: 
E-cadherin, vimentin, and PAI-1 (Figure 5.IB). In cells stimulated with TGF-beta, 
the epithelial marker E-cadherin was profoundly downregulated (31% remaining), 
while the both mesenchymal markers were significantly upregulated (1.6- or 64-fold
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increase in vimentin or PAI-1, respectively). The data confirmed that TGF-beta 
induced changes characteristic to EMT in HK-2 cells.
Then, expression of the two E-cadherin repressors ZEB1 and ZEB2, reported to be 
regulated directly by miR-192 and the miR-200 family, was examined (Figure 5.1C). 
ZEB2 was almost 2-fold upregulated by TGF-beta, while ZEB1 was not increased 
at the mRNA level.
Subsequently, the analysis was repeated on cells treated with TGF-beta for 12, 24, 48, 
or 96 hours (Figure 5.2). The results demonstrated that expression of the majority 
of the tested genes was similar at the consecutive time points. The exceptions were 
E-cadherin, gradually decreasing with time in TGF-beta-treated cells, and ZEB1, 
which was modestly upregulated at 24 hours.
5.2.2 Manipulation of miR-192 (and miR-200b) 
expression in HK-2 cells
To investigate the role of miR-192 in TGF-beta-induced EMT in HK-2 cells, its 
expression was altered in those cells by transfection with a specific inhibitor or, 
in separate experiments, its precursor. Manipulation of miR-192 expression in HK-2 
cells was combined with stimulation with TGF-beta to answer two related questions:
i. Does miR-192 inhibition reproduce the effects of TGF-beta?
ii. Does miR-192 overexpression prevent the effects of TGF-beta? 
Additionally, to determine if the miR-200 family is involved in regulation of EMT 
in the kidney, miR-200b (the most abundant member of the miR-200 family in HK-2 
cells) was studied in parallel.
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Inhibition of miR-192 and miR-200b
For inhibition of miR-192 and miR-200b, chemically modified single stranded nucleic 
acids complementary to the microRNAs (Anti-miR miRNA Inhibitors, Ambion) were 
used. HK-2 cells were transfected with the inhibitors at final concentration 100 nM 
(the maximum dose recommended by the manufacturer). Expression of E-cadherin, 
ZEB1, and ZEB2 was analysed 48 or 96 hours later by qRT-PCR (Figure 5.3). 
No substantial difference in expression of any of the genes tested was found between 
control cells and those with the blocked microRNAs.
The experiment was repeated with five times higher dose of the miR-192 inhibitor 
(as found in literature [240]), but no effect on E-cadherin, ZEB1, and ZEB2 was 
observed (data not shown).
Overexpression of miR-192 and miR-200b
In parallel, the effects of miR-192 or miR-200b overexpression on HK-2 cell response 
to TGF-beta were studied. To increase the amount of those microRNAs, the cells 
were transfected with plasmids containing the stem-loop microRNA precursors 
expressed by the human U6 promoter. Analysis of expression of the mature 
microRNAs by stem-loop qRT-PCR confirmed that 72 hours after transfection they 
were clearly upregulated (Figure 5.4). Despite approximately 10-fold or 8-fold 
increase in miR-192 or miR-200b, respectively, E-cadherin expression was not altered 
in control and TGF-beta stimulated cells.
Since the plasmids used in that experiment also contained a puromycin resistance 
gene, it was possible to investigate long-term effects of enforced expression
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of miR-192 and miR-200b in HK-2 cells. Approximately four weeks after 
transfection, E-cadherin expression was analysed by qRT-PCR in control 
and TGF-beta-treated puromycin-resistant cells (Figure 5.5). This time, although 
increases in the microRNA expression were very subtle and statistically 
non-significant, E-cadherin was significantly 5- or over 2-fold upregulated by 
miR-192 and miR-200b, respectively. Treatment with TGF-beta for 96 hours reduced 
E-cadherin in all experimental groups. Importantly, the cells with enforced expression 
of miR-192 expressed after stimulation 2.5 times more E-cadherin than unstimulated 
control cells.
For more detailed characterisation of the observed effects, the kinetics of changes 
in miR-192 and E-cadherin expression was examined by qRT-PCR in cells 
overexpressing miR-192 (Figure 5.6). Consistent with the transient transfection 
results (Figure 5.4) as well as with the changes observed after four weeks (Figure 
5.5), early after transfection there was a great increase in miR-192, but no difference 
in E-cadherin expression. However, already two weeks after transfection, miR-192 
was present only in a slightly higher amount than in control cells, while E-cadherin 
was markedly upregulated and this increased with time.
To ensure that the observed effect on E-cadherin depends on miR-192 (or miR-200b 
in Figure 5.5) and not on the sequence of the control short-hairpin RNA used, two 
other controls were tested in a separate transfection experiment. Mixed population 
of puromycin-resistant cells transfected with three different controls or miR-192 
precursor were analysed four weeks after transfection by qRT-PCR (Figure 5.7). 
Expression of miR-192 and E-cadherin was similar in all three controls 
and, consistently with the previous stable transfection, was lower than in cells 
overexpressing miR-192.
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It was very likely that in the mixed population of stably-transfected cells there would 
be cells producing large amounts of miR-192, as well as those expressing 
the puromycin resistance gene but no miR-192 precursor. Therefore, single lines that 
stably overexpressed miR-192 were selected as described in Methods. Three lines 
with the highest miR-192 expression were used in the subsequent experiments. 
The same was attempted for miR-200b, but among six preliminarily selected lines, 
two died before analysis, one was dying at the time, and three others did not express 
more miR-200b than control. That was consistent with the observation 
by Hurteau et al. [213], that three weeks after transfection of MDA-MB-231 and 
A549 cells with miR-200c the cells begun to detach from the plates and died. 
Therefore, no more attempts to obtain single lines overexpressing miR-200b were 
made.
Expression of miR-192 and E-cadherin was examined by qRT-PCR in the three single 
lines overexpressing miR-192 (Figure 5.8). The results demonstrated approximately 
5-fold increase in miR-192, and 17-fold increase in E-cadherin in the selected lines in 
comparison with control. Additionally, miR-192 prevented TGF-beta-induced 
downregulation of E-cadherin.
To confirm those findings at the protein level, E-cadherin was assessed in control 
and miR-192 overexpressing single lines, treated or not with TGF-beta for 96 hours, 
by Western blot (Figure 5.9 A) and immunofluorescence (Figure 5.9B). 
Both techniques clearly showed large increase in E-cadherin in miR-192- 
overexpressing cells. Moreover, stimulation of cells with TGF-beta reduced 
E-cadherin, but it was still more abundant than in unstimulated control cells.
To investigate the mechanism responsible for the observed upregulation 
of E-cadherin, expression of two E-cadherin repressors and validated direct targets
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of miR-192 [151, 244], ZEB1 and ZEB2, was examined by qRT-PCR (Figure 5.10A). 
ZEB1 and ZEB2 were substantially downregulated in all three lines overexpressing 
miR-192.
The above data was consistent with the hypothesis that miR-192 directly inhibits 
translation and/or causes degradation of the ZEB1 and ZEB2 transcripts; this in turn 
results in an increase in E-cadherin expression. To confirm that miR-192 interacts 
directly with 3'UTR of ZEB1 and ZEB2, reporter plasmids with those 3'UTRs 
downstream the firefly luciferase coding sequence were constructed as described 
in Methods, and the effect of miR-192 overexpression on the luciferase activity was 
examined (Figure 5.1 OB). Unexpectedly, I found no difference in translation 
of transcripts with 3'UTR of ZEB1 or ZEB2 between control cells and those stably 
expressing miR-192 precursor.
Finally, expression of the other two EMT markers, vimentin and PAI-1, was analysed 
in cells overexpressing miR-192 by qRT-PCR (Figure 5.11). ZEB2 has been shown 
to contribute to vimentin regulation in breast cancer [245]. Consistent with that, 
vimentin expression decreased in unstimulated cells that overexpressed miR-192. 
However, miR-192 largely failed to prevent TGF-beta-mediated vimentin 
upregulation. Also PAI-1 expression was unaffected by miR-192, suggesting that 
the effect of miR-192 on E-cadherin was specific, and did not represent a general 
opposition of TGF-beta-dependent effects.
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5.3 Discussion
In Chapter Three I demonstrated decreased miR-192 expression in vivo in advanced 
diabetic nephropathy, and in vitro in HK-2 cells treated with TGF-beta. The goal 
of this chapter was to find causal links between loss of miR-192 expression 
and development of tubulointerstitial fibrosis. EMT is likely to be a key phenomenon 
in progressive renal fibrosis, downstream of TGF-beta. miR-192 had been shown 
to directly target ZEB1 and ZEB2 [151, 244], similarly as the miR-200 family 
members, strongly implicated in prevention of EMT in cancer [240-243]. This led me 
to study the potential role of miR-192 in maintaining a differentiated epithelial 
phenotype in proximal tubular cells, and whether its loss contributed to TGF-beta- 
dependent EMT in these cells.
I used a standard approach for identification of a microRNA function. I attempted 
to inhibit miR-192 in HK-2 cells by a complementary oligonucleotide and check 
if this could reproduce TGF-beta effect on the main EMT marker E-cadherin. 
In parallel, I tested if miR-192 overexpression in HK-2 cells would prevent TGF-beta- 
induced EMT-like changes in those cells.
The inhibition experiments did not reveal any difference in E-cadherin expression 
after miR-192 blockade. The most obvious explanation for this would be that 
the technique (either the inhibitor delivery or its interaction with miR-192) did not 
work properly. As there was no method available, other than functional assays, 
to confirm that, alternative explanations should also be considered. For instance, 
miR-192 inhibition alone might have not been sufficient for E-cadherin 
downregulation; perhaps other TGF-beta-induced changes, such as modulation
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of the E-box repressors other than ZEB1 and ZEB2, were necessary or could 
accelerate miR-192 action. Maybe in transient transfection there was not enough time 
for the changes to occur. Finally, miR-192 might have not been involved in regulation 
of E-cadherin. In light of the overexpression results, however, this option seems very 
unlikely.
Enforced expression of miR-192 also did not cause any change in E-cadherin 
expression in a short term. To my knowledge, ZEB1 and ZEB2 protein half-lives have 
not been investigated in HK-2 cells. Therefore, it is difficult to predict when 
the effects of miR-192 on ZEB1 and ZEB2 would result in detectable E-cadherin 
upregulation. My results suggest that this happens between one and two weeks after 
transfection. However, the data comes from a mixed population of stably transfected 
cells, some of them not expressing miR-192, so one could expect that in cells 
expressing high amounts of supplementary miR-192, the increase in E-cadherin may 
be visible earlier. This highlights the main advantage of using single lines rather than 
a mixed population of transfected cells. For that reason, the major experiments in this 
chapter were done on single lines stably overexpressing miR-192.
In those lines, E-cadherin expression was found to be profoundly upregulated both 
atmRNA and protein levels. Most importantly, miR-192 prevented E-cadherin 
downregulation by TGF-beta. It would be tempting to speculate that miR-192 
introduction into the kidney of patients with a chronic kidney disease might be useful 
in stopping the progression of the disease. However, miR-192 overexpression did not 
seem to affect the whole process of EMT, as judged by lack of effect on the other 
EMT markers tested. Furthermore, miR-192 has been shown to be upregulated 
in animal models of diabetic nephropathy and have a profibrotic effect in murine 
mesangial cells [151]. Interestingly, the authors of that report have demonstrated that
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miR-192 exerted its profibrotic effect in mesangial cells via downregulation of ZEB2, 
showing that miR-192 function in the kidney is very complex and context-dependent.
The most likely mechanism of the upregulation of E-cadherin in miR-192- 
overexpressing cells includes inhibition of ZEB1 and ZEB2 by miR-192; 
subsequently, lower amounts of those repressors would result in an increased 
E-cadherin transcription. This hypothesis was based mainly on the reports 
demonstrating that miR-192 directly targets ZEB1 and ZEB2 [151, 244], 
and the massive evidence showing that ZEB1 and ZEB2 negatively regulate 
E-cadherin transcription [227, 228]. Consistently, ZEB1 and ZEB2 are both markedly 
downregulated at the mRNA level in miR-192-overexpressing HK-2 cells. 
Additionally, the work of my colleague, Dong Dong Luo, shows that the other 
transcriptional repressors of E-cadherin previously implicated in EMT, namely Snail, 
Slug, and Twist, or their regulator HMGA2 [246] are not influenced by miR-192 
overexpression [204].
Surprisingly, the attempt to confirm that miR-192 directly interacts with 3'UTR 
ofZEBl or ZEB2 using reporter plasmids was not successful. Subsequent 
experiments with those plasmids demonstrated that they also did not respond to 
TGF-beta (data not shown), suggesting a possible technical problem 
with the plasmids. Although their sequences were confirmed by sequencing, it has 
been reported recently that microRNA mechanism of action (whether they affect 
an initiation or elongation stage of translation) depends on the nuclear history of 
mRNA, and may differ for identical transcripts if they are derived from different 
promoters [247]. Perhaps, using a different core plasmid than pGL3 it would be
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possible to observe a decrease in ZEB1 and ZEB2 translation in miR-192 
overexpressing lines.
Interestingly, and in some way in accordance with the observation 
by Kong et al. [247], the results presented in this chapter suggest that regulation 
of exogenous miR-192 expression by TGF-beta depends on whether or not 
the construct for expression of miR-192 precursor is integrated into the genome. 
In single lines that stably overexpressed miR-192, it was downregulated by TGF-beta 
similarly as the endogenous microRNA. Strikingly, in transient transfection with 
the same plasmid, TGF-beta did not cause any effect on exogenous miR-192 
expression.
As stable transfection resembles the natural situation well, it is conceivable that 
the mechanism of regulation by TGF-beta seen in miR-192-overexpressing lines 
is at least in part relevant to the regulation of endogenous miR-192 expression. 
The fact that exogenous miR-192 was markedly downregulated by TGF-beta despite 
replacement of the natural miR-192 promoter with the constitutive U6 promoter, 
suggests posttranscriptional regulation of miR-192 by TGF-beta. Recently, TGF-beta 
has been reported to influence processing of miR-21 precursor via interaction 
of SMAD proteins with Drosha [119]. It is not known at present how widespread 
the posttranscriptional regulation of microRNAs by TGF-beta is, but certainly would 
be worth investigating.
The miR-200 family has been strongly implicated in EMT in cancer [240-243]. 
Moreover, the described mechanism of E-cadherin regulation by the miR-200 family 
members was the same as the mechanism proposed above for miR-192. Therefore, 
it was interesting to see how miR-192 compared with miR-200 in the kidney. For that
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reason miR-200b, the most abundant miR-200 family member in HK-2 cells, was 
functionally analysed together with miR-192. Transient transfections with miR-200b 
inhibitor or precursor did not affect E-cadherin, similarly as short-term manipulation 
of miR-192 expression. Due to inability to generate cell lines that stably express 
miR-200b precursor, also reported in the literature before [213], the effects 
of miR-200b on HK-2 cell phenotype could not be investigated fully. The obtained 
results, however, tend to suggest that miR-192 is at least not less important in EMT 
in the kidney than miR-200b. This notion is supported also by the lack of correlation 
between severity of renal fibrosis and miR-200b expression, as found in Chapter 
Three.
In this chapter I showed that miR-192 is involved in control of the early EMT marker, 
E-cadherin, in proximal tubular epithelial cells, and proposed a likely mechanism 
for that regulation. The data clearly show that high expression of miR-192 prevents 
some of TGF-beta-induced changes, and might therefore have implications for future 
therapies. It is also highly probable that the changes in miR-192 expression observed 
in vivo in the course of diabetic nephropathy are functionally linked to the progression 
of the disease.
194
A
2
S
CM 1
“ o'-a
O  2
U 1
Control TGF-beta Control TGF-beta
*:i n  ■ HPR
T1
O 
N>
m
Control TGF-beta Control TGF-beta
200
o  1 I ■
Control TGF-beta
B
c
O 1 IX
T3
•  n I
***
c  2
I; n ■U “
w ControlI TGF-beta
>  ° 1—  
Control TGF-beta
C
ZE
B1
o 
-*■ -- ★
■
2 -|
CM
CQ ! _____ _SoTTl ■
X  2 
a
CL 1 
<O 0
2o  
DC 1
Control TGF-beta
* L O
Control TGF-beta
75 
H  50
Control TGF-beta
Control TGF-beta Control TGF-beta
Figure 5.1. Characterisation of HK-2 response to TGF-beta by qRT-PCR.
HK-2 cells were cultured without serum for 48 hours, and then incubated with 
10 ng/ml TGF-beta (black bars) or control medium (grey bars) for 96 hours.
(A) Selection of a suitable endogenous control. The tested genes are shown in order 
of their relative stability, as found using geNorm [195]. GAPDH was used for 
normalisation in this and subsequent experiments. (B) Expression of the EMT 
markers: E-cadherin, vimentin, and PAI-1. (C) Expression of E-cadherin repressors 
and known miR-192 direct targets: ZEB1 and ZEB2. The experiment was performed 
in triplicate; SEM is shown. Significance levels are marked with asterisks as follows: 
* p<0.05, ** p<0.005, *** p<0.0005.
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Figure 5.2. Characterisation of HK-2 response to TGF-beta by qRT-PCR -  time 
course. HK-2 cells were cultured without serum for 48 hours, and then incubated 
with 10 ng/ml TGF-beta (black bars) or control medium (grey bars) for indicated 
time points. Expression of the EMT markers (A) and the E-cadherin repressors (B) 
was normalised to GAPDH.
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Figure 5.3. Inhibition of miR-192 or miR-200b in HK-2 cells. HK-2 cells were 
transfected with 100 nM anti-miR-192 or anti-miR-200b inhibitors. Expression 
of E-cadherin, ZEB1, and ZEB2 was examined by qRT-PCR 48 (A) or 96 hours (B) 
after transfection. Error bars (B) represent SEM, n=3. A significant difference 
(p < 0.05) was marked with an asterisk.
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Figure 5.4. Transient overexpression of miR-192 and miR-200b in HK-2 cells.
HK-2 cells were transfected with plasmids for expression of miR-192 or miR-200b 
precursors, or a control shRNA (Scrl), using Lipofectamine LTX+. 24 hours after 
transfection, they were stimulated (black bars) or not (grey bars) with 10 ng/ml 
TGF-beta for 48 hours. Expression of mature miR-192 (A) and miR-200b (B) was 
examined by stem-loop qRT-PCR and normalised to the small nuclear RNA, U6. 
(C) E-cadherin expression was measured by qRT-PCR and normalised to GAPDH. 
The experiment was repeated for miR-192.
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Figure 5.5. Stable overexpression of miR-192 and miR-200b in HK-2 cells.
HK-2 cells were stably transfected with plasmids for expression of miR-192 
or miR-200b precursors, or a control shRNA (Scrl). Approximately four weeks after 
transfection, mixed populations of stably transfected cells were cultured in medium 
without FCS for 48 hours and then stimulated with 10 ng/ml TGF-beta (black bars) 
or cultured in control medium (grey bars) for 96 hours. Expression of mature 
miR-192 (A) and miR-200b (B) was examined by stem-loop qRT-PCR 
and normalised to U6. (C) E-cadherin expression was measured by qRT-PCR and 
normalised to GAPDH. The experiment was carried out in triplicate; SEM is shown. 
Significance levels were estimated among TGF-beta-stimulated and unstimulated 
cells, respectively, and are indicated as follows: ** p < 0.005 (for comparison with 
unstimulated Scrl), ## p < 0.005 (for comparison with TGF-beta-treated Scrl).
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Figure 5.6. Stable overexpression of miR-192 -  kinetics. HK-2 cells were stably 
transfected with plasmids for expression of miR-192 precursor (white bars), 
or control shRNA (grey bars). Expression of mature miR-192 (A) and E-cadherin
(B) was examined one, two, and three weeks after transfection by qRT-PCR. miR- 
192 was normalised to miR-16, while E-cadherin -  to GAPDH.
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Figure 5.7. Comparison of three shRNAs expressed by control cells in stable 
transfection experiments. HK-2 cells were stably transfected with plasmids for 
expression of miR-192 precursors, or three different control shRNAs (Scrl-3). 
Approximately four weeks after transfection, mixed populations of stably 
transfected cells were cultured in medium without FCS for 48 hours and then 
stimulated with 10 ng/ml TGF-beta (black bars) or cultured in control medium 
(grey bars) for 96 hours. (A) Expression of mature miR-192 was examined by stem- 
loop qRT-PCR and normalised to U6. (B) E-cadherin expression was measured 
by qRT-PCR and normalised to GAPDH.
201
A6
5
CM 4 
CD *
3 
2 
1 
0
DC
E
Scrl miR-192 miR-192 miR-192
lineB lineC lineE
B
c
0JZ
~o05O
LU
20
15
10
5
0 J Li
Scrl miR-192 miR-192
lineB lineC
J
miR-192
lineE
Figure 5.8. Expression of E-cadherin in single lines that stably overexpress 
miR-192 -  at the mRNA level. Single lines stably expressing miR-192 precursor 
were obtained from the mixed population of stably transfected cells, as described in 
Methods. Three lines (B, C, E) and mixed Scrl were cultured in medium without 
FCS for 48 hours and then stimulated with 10 ng/ml TGF-beta (black bars) 
or cultured in control medium (grey bars) for 96 hours. Expression of mature 
miR-192 (A) and E-cadherin (B) was examined by qRT-PCR. miR-192 was 
normalised to miR-16, and E-cadherin -  to GAPDH. The experiment was performed 
in triplicate; SEM is shown.
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Figure 5.9. Expression of E-cadherin in single lines that stably overexpress 
miR-192 -  at the protein level. Three stable lines with enforced miR-192 
expression and control cells (Scrambledl) were prepared and stimulated 
with TGF-beta as described in Figure 5.8 legend. Then E-cadherin protein was 
examined by Western blot (A) or immunofluorescence (B). E-cadherin expression in 
all three lines was similar; only line B is shown. The experiments were repeated at 
least three times. Magnification in panel B was 400x.
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Figure 5.10. Regulation of ZEB1 and ZEB2 expression by miR-192. Three stable 
lines with enforced miR-192 expression and control cells (Scrl) were prepared 
as described in Figure 5.8 legend. (A) ZEB1 and ZEB2 expression was examined 
in control (grey bars) or TGF-beta-treated cells (black bars) by qRT-PCR. GAPDH 
was used for normalisation. (B) Control cells (Scrl) and one line stably 
overexpressing miR-192 were transfected with pGL3 reporter plasmids containing 
ZEB1 3'UTR, ZEB2 3'UTR, or pGL3 without any insert downstream the firefly 
luciferase CDS. To control for transfection efficiency, pRL plasmid encoding 
Renilla luciferase was used. Activity of firefly and Renilla luciferases was measured 
24 hours after transfection as described in Methods. The experiments were 
performed in triplicate; SEM is shown.
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Figure 5.11. Expression of other EMT markers in single lines that stably 
overexpress miR-192. Three stable lines (B, C, E) with enforced miR-192 
expression, and control cells (Scrl) were prepared as described in Figure 5.8 legend. 
They were cultured in medium without FCS for 48 hours and then stimulated with 
10 ng/ml TGF-beta (black bars) or cultured in control medium (grey bars) 
for 96 hours. Expression of vimentin (A) and PAI-1 (B) was examined by qRT-PCR 
and normalised to GAPDH. The experiment was performed in triplicate; SEM is 
shown.
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IN POSTTRANSCRIPTIONAL REGULATION
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6.1 Introduction
TGF-beta plays a crucial role in the initiation and progression of renal fibrosis. Thus, 
inhibition of its expression seems to be the most obvious therapeutic strategy. That, 
however, has been proven problematical, mostly because of the complexity 
of TGF-beta effects on the organism. Despite long and extensive studies on TGF-beta 
expression and actions, it is still difficult to predict all the outcomes of TGF-beta 
manipulation in vivo. A profound understanding of TGF-beta biology must precede 
any trials of that kind.
Up to now, numerous studies have shown that regulation of TGF-beta expression 
occurs at various levels, including the posttranscriptional step [248-250]. The precise 
mechanisms of such regulation are in most cases not known, and typically the results 
do not exclude the possibility that microRNAs are involved. In particular, a few years 
before the discovery of microRNAs, in 1990, Ruth Wager and Richard Assoian 
reported an RNase system in U937 cells that causes selective degradation of TGF-beta 
transcript, and is inhibited during phorbol ester-induced differentiation [175]. Looking 
at the results, one could speculate that the system employs some microRNAs 
expressed by non-activated U937 cells and downregulated by phorbol esters.
Search for microRNAs potentially targeting TGF-beta mRNA using the most popular 
microRNA target prediction programs available at the end of 2006 (PicTar, miRanda, 
TargetScan) gave a negative result. Therefore, my main strategy for identification 
of TGF-beta-regulating microRNAs relied on the recent (back then) and extremely 
interesting finding by Gupta et al. that a viral microRNA causes degradation of human 
TGF-beta transcript [251]. The authors have shown that miR-LAT, a microRNA
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encoded in the herpes simplex vims 1 latency associated transcript, prevents 
apoptosis in neural cells via downregulation of TGF-beta and SMAD3 at the mRNA 
level. Importantly, they have suggested that those changes in expression are a direct 
effect of miR-LAT, and identified conserved GC-rich regions in 3'UTRs of both 
transcripts potentially interacting with miR-LAT. The paper was retracted 
at the beginning of 2008 [252], potentially explaining some of the negative data 
relating to miR-LAT presented below.
In this chapter I set out to establish if there are any human microRNAs that regulate 
TGF-beta generation, acting similarly to miR-LAT.
6.2 Results
6.2.1 In silico search for human microRNAs 
similar to miR-LAT
In order to find human microRNAs similar to miR-LAT, the miRBase [106], 
a database of all published microRNA sequences, was searched using SSEARCH 
algorithm (see 2.4.2). A few human microRNAs were identified. Three of them: 
miR-608, miR-663, and miR-769_3p, which showed the greatest similarity 
to miR-LAT, were examined further.
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To confirm that those microRNAs are likely to interact with TGF-beta transcript, 
a microRNA target prediction program was used. Since all three microRNAs were 
newly described, the majority of available programs of that kind, including PicTar, 
did not take them into account. Therefore, RNA22 program [193], allowing for testing 
any microRNA and target sequences, was chosen. The program found two microRNA 
binding sites within TGF-beta transcript for miR-608, two for miR-663, and one 
for miR-769_3p. As expected, those sites were in the same conserved GC-rich region 
as described for miR-LAT [251] (Figure 6.1).
Binding of miR-608, miR-663, and miR-769_3p to TGF-beta mRNA as predicted 
by RNA22 was visualised using RNAfold program from Vienna RNA Secondary 
Structure Package [194] (Figure 6.2B,C,D). For comparison, miR-LAT interaction 
with TGF-beta, as described by Gupta et al. [251], is also shown (Figure 6.2A).
6.2.2 Expression of miR-608 and miR-663 
in HK-2 and U937 cells
Having identified the microRNAs that can potentially modulate TGF-beta synthesis, 
an important point was to find out if they are expressed by our model cells -  HK-2 
cells. That had to be determined experimentally, since those microRNAs were too 
novel to be examined through the microRNA profiling with microarrays, 
and no published data was available regarding their abundance in the kidney.
In addition to HK-2 cells, their expression was also evaluated in U937 cells, in which 
possible evidence for a microRNA-based system for TGF-beta regulation had been 
found, as noted above [175].
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miR-608, miR-663, and miR-769-3p were recently described at the time 
of investigation, and a commercial assay existed only for miR-608. Similar assays 
for the other two microRNAs were unavailable, so the detection system for miR-663 
was designed in house especially for this project (see 2.2.32).
miR-608 expression
As there was no information about basal miR-608 expression in HK-2 cells, 
to validate the commercial TaqMan assay for miR-608 detection, RNA isolated from 
cells transfected with synthetic miR-608 was used. Three amounts of the total RNA 
(10, 2, and 0.4 ng) were used in RT reactions (Figure 6.3). The performance 
of the assay, judged as described in Methods, was entirely satisfactory.
Subsequently, miR-608 expression was measured in untransfected and non-activated 
HK-2 and U937 cells (Figure 6.4A). The results for both cell types show that there 
is either very little miR-608 in those cells, or it is not detectable. Since 
the fluorescence signal was in all cases very weak and not reproducible among 
replicates, there was a suspicion that it comes from non-specific PCR products. 
To determine that, after a quantitative PCR run (40 cycles), a few randomly picked 
PCR products were separated on an agarose gel, together with DNA size markers 
and the proper product of the reaction (with RNA from cells transfected 
with synthetic miR-608) (Figure 6.4B). Analysis of the gel confirmed that there were 
various non-specific PCR products present, and they were probably responsible 
for the weak fluorescence signal observed.
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miR-663 expression
The qRT-PCR SYBR Green-based system for miR-663 detection was designed 
as described in Methods. To optimise and validate the system, RNA from HK-2 cells 
transfected with synthetic miR-663 was used. Similarly to the miR-608 assay 
validation, three amounts of total RNA (1000, 200, and 40 ng) were examined 
(Figure 6.5A). Additionally, after the PCR run melting curve analysis was performed 
to ensure that only one PCR product was present, giving acceptable results 
(Figure 6.5B).
The assay was then used to determine the basal miR-663 expression in HK-2 
and U937 cells (Figure 6.6). Unfortunately, as in case of the miR-608 detection, 
performance of the assay was compromised when the microRNA concentration was 
much lower than in the transfected cells (Figure 6.6A,B). In particular, some 
non-specific, longer than expected PCR products appeared. To overcome this 
problem, the reactions were next carried out using small RNA fraction rather than 
total RNA (Figure 6.6C,D). As expected, after the modification only one, most likely 
the specific product was seen, suggesting the presence of miR-663 in the examined 
cell types. However, the lack of proper correlation between RNA input 
and the fluorescence signal raised some doubts about the quantitative character 
of the assay.
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6.2.3 Effects of enforced expression of miR-608 
and miR-663 in HK-2 cells on TGF-beta
Considering the finding that miR-608 and miR-663 are presumably not highly 
(if at all) expressed by HK-2 cells, the microRNA inhibitors could not be used 
to establish if those microRNAs can regulate TGF-beta synthesis. Instead, the cells 
were transfected with the synthetic microRNAs.
Effects on TGF-beta and SMAD3 at the mRNA level
In the work of Gupta et al., transfection of neuroblastoma cells with a fragment 
of the LAT gene containing miR-LAT was shown to cause downregulation 
of TGF-beta and SMAD3 transcripts [251]. To check if the human microRNAs 
similar to miR-LAT would do the same in HK-2 cells, the cells were transfected with 
synthetic miR-608 and miR-663. Subsequently, TGF-beta and (in some experiments) 
SMAD3 were examined by qRT-PCR.
To begin with, HK-2 cells were transfected with miR-608 at the final concentration 
of 30 nM (within the range recommended by the supplier, and most commonly used 
in siRNA experiments in the department). RNA was extracted from the cells every 
24 hours for four days. Finally, TGF-beta expression was measured (Figure 6.7). 
There was no substantial difference between the cells transfected with miR-608 
and control cells at any time point.
It was important then to establish if the delivery of the microRNAs to the cells is 
efficient. Since the synthetic microRNAs are structurally very similar to siRNAs,
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a very effective siRNA targeting CD44 was used as a positive control (Figure 6.8). 
As expected, that siRNA caused reduction of CD44 mRNA by 96% 24 hours after 
the transfection, while there was no significant change in TGF-beta. These results 
suggest that the transfection was very efficient, and the siRNA effect on CD44 -  
specific. Similar transfection with miR-608 or miR-663 resulted in modest, 
but statistically significant reduction of TGF-beta mRNA (by 13% or 19%, 
respectively), and no significant change in CD44.
Additional experiment was performed to confirm the results, find out if miR-608 
and miR-663 have synergistic effect on TGF-beta, and to check if they can 
substantially affect SMAD3 mRNA (Figure 6.9). Again, the differences in TGF-beta 
and SMAD3 expression between control cells and cells transfected 
with the microRNAs were far less profound than those shown for miR-LAT 
by Gupta et al. [251].
Effects on TGF-beta at the protein level
Since microRNAs were best known for their effect on translation rather than mRNA 
stability, the lack of great change in TGF-beta at the mRNA level following 
transfection with the synthetic miR-608 or miR-663 did not exclude the possibility 
that the microRNAs affect TGF-beta synthesis at the translational step. Therefore, 
TGF-beta secretion to medium by control cells and cells transfected with synthetic 
miR-608 was measured by ELISA. Unstimulated HK-2 cells plated at the low density 
required for transfection did not produce enough TGF-beta for detection (data not 
shown). Therefore, in subsequent experiments, HK-2 cells were stimulated with PMA 
for 24 hours after transfection, to stimulate TGF-beta synthesis. In these experiments,
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TGF-beta concentration in the medium collected 24 hours later was not significantly 
different between the control and miR-608 overexpressing cells (Figure 6.10).
6.2.4 Function of exogenous miR-LAT 
in HK-2 cells
The lack of great effects of miR-608 and miR-663 on TGF-beta synthesis in HK-2 
cells provoked the question if miR-LAT itself could affect TGF-beta in those cells. 
It had been reported that microRNA actions were sometimes cell type specific, 
depending on expression of other potential target genes and other modulators 
of microRNA activity [253-255]. Therefore, there was a possibility that another 
model system would be necessary to study regulation of TGF-beta by the microRNAs 
similar to miR-LAT.
Effects on TGF-beta and SMAD3 mRNA
To start with, the effect of miR-LAT on TGF-beta and SMAD3 transcripts in HK-2 
cells was examined. The cells were transfected with synthetic miR-LAT, miR-608, 
or miR-663. Following 24 hour incubation, TGF-beta and SMAD3 mRNAs were 
quantified by qRT-PCR (Figure 6.11). The differences between the samples were 
in all cases very small, and the only statistically significant change was about 20% 
increase in TGF-beta after transfection with miR-LAT. The data was clearly 
inconsistent with the findings by Gupta et al. [251].
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Effects on SMAD-dependent transcription
To confirm that miR-LAT did not behave in HK-2 cells as described 
for neuroblastoma cells, one more experiment inspired by that original paper was 
performed. A reporter plasmid containing four SMAD-binding elements 
in the promoter region of the firefly luciferase gene was used to determine 
if miR-LAT affected the SMAD-dependent transcription in HK-2 cells (Figure 6.12). 
Whether the plasmid and small RNA were delivered to the cells consecutively 
or simultaneously, miR-LAT did not change HK-2 cell response to TGF-beta. 
As a positive control, siRNA against SMAD3 was co-transfected with the reporter 
plasmid, and in both cases almost completely abolished the SMAD-dependent 
transcription after stimulation with TGF-beta (Figure 6.12).
6.3 Discussion
The aim of this chapter was to determine if TGF-beta synthesis was regulated by 
microRNAs. Typical approach to this problem would include the use of microRNA 
target prediction programs to select a few promising microRNAs, and subsequent 
experimental verification. In case of TGF-beta, however, this approach was not valid, 
as the most popular microRNA target prediction programs did not find any 
microRNAs that could potentially interact with TGF-beta mRNA.
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A few features of its transcript make TGF-beta a poor candidate for a microRNA- 
regulated gene. First of all, the 3'UTR, most commonly targeted by microRNAs, 
is relatively short (137 nucleotides). Many of the known microRNA targets have very 
long 3'UTRs, often exceeding 1000 nucleotides, allowing for a complex regulation 
by a large number of microRNAs. Furthermore, over a half of TGF-beta 3'UTR 
is highly GC-rich (containing only about 10% of A or T residues). Sequences of that 
kind tend to form stable secondary structures, which make them inaccessible to small 
RNAs [256].
In view of that, the finding by Gupta et al. [251] that the viral microRNA miR-LAT 
regulates human TGF-beta synthesis, binding to the GC-rich part of its transcript, 
came as a great surprise. It also suggested there might be some human microRNAs 
that could act similarly to miR-LAT.
To identify such microRNAs I searched the publicly available database of all known 
microRNAs, and found a few human microRNAs of similar sequence to miR-LAT. 
All of them were newly described at that time. There were no predicted mRNA 
targets for them or literature regarding their function. Since many molecular biology 
techniques are not suited for manipulation or analysis of nucleic acids with very high 
contents of G and C residues, the fact that those microRNAs were all GC-rich 
provided a possible explanation why they were not well-studied, while they could be 
actually abundant or of great importance.
The difficulty of investigating those microRNAs was already evident when I intended 
to determine their expression in HK-2 cells. The stem-loop TaqMan assays (Applied 
Biosystems), the best performing system for microRNA detection by qRT-PCR, were 
initially unavailable for the three most promising microRNAs. Luckily, during 
the course of the study, the assay for miR-608 became available. Yet, there is still
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(more than two years later) no TaqMan assay for miR-663. Therefore, after 
a disappointing test of a different commercial microRNA detection system (NCode 
SYBR Green qRT-PCR Kit, Invitrogen, for details see 2.23.2), a stem-loop SYBR 
Green assay for miR-663 detection was designed in the laboratory. The uniquely high 
G and C content of miR-663 (containing only one residue different than G or C) made 
this much more challenging than the design of other qRT-PCR microRNA assays 
for the project. In particular, that required an increase in length of the stem-loop 
RT-primer, altered RT conditions, and 15°C higher annealing and extension 
temperature during PCR reaction (see 2.2.3.2).
Both assays, for miR-608 and miR-663 detection, performed well when the RNA 
from HK-2 cells used in the reaction was enriched with the appropriate synthetic 
microRNAs. However, the basal amount of the microRNAs in HK-2 cells was 
apparently too small to allow for a proper quantification. Consistently, in the later 
microRNA profiling in the kidney biopsies (see Chapter Three) miR-608 was not 
detected (while miR-663 was not examined). Also, U937 cells, likely to have 
a functional microRNA-based system for regulation of TGF-beta generation [175], 
did not seem to express either of those microRNAs in large quantities.
The expression data suggest that miR-608 and miR-663 are not highly expressed 
by HK-2 cells. However, there is still a possibility that the weak signal observed 
is a consequence of the microRNAs high GC contents rather than their low 
abundances. For a strict comparison of expression of different microRNAs, 
an absolute quantification system would be needed.
Even assuming that miR-608 and miR-663 were not abundant in HK-2 cells, it was 
still worth checking if they could regulate TGF-beta synthesis in those cells. Firstly, 
microRNA effects are often cell type specific, so finding a microRNA that when
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overexpressed would affect TGF-beta synthesis in proximal tubular epithelial cells, 
would be of great value for nephrology. Secondly, seeing an effect of miR-608 
or miR-663 on TGF-beta would provide an enormous motivation to search for a tissue 
or cell type highly expressing the microRNA.
For that reason, a number of experiments were performed using synthetic miR-608 
and miR-663. Disappointingly, these microRNAs had a very subtle effect 
on TGF-beta synthesis in HK-2 cells at the mRNA and protein level. Moreover, 
synthetic miR-LAT also did not behave in HK-2 cells the same way as described 
in the paper. The potential explanation for that discrepancy would be that effects 
of a microRNA seen in one cell type might be different from those found 
in another [253-255]. In this case, however, the real reason was most likely revealed 
by the retraction of the original paper at the beginning of 2008 [252].
Recent re-evaluation of the data suggests that, despite the retraction, the results might 
be actually of some use. In the middle of the year 2008, two highly informative papers 
about microRNA function were published in Nature [125, 134]. The authors 
for the first time used a large-scale mass-spectrometry-based approach to look 
at the influence of microRNAs on the protein output. They found that a single 
microRNA could repress approximately one thousand genes, but usually those 
changes were very modest. Testing both overexpression and knockdown 
of a particular microRNA, they observed mainly inverse effects on the protein 
production, suggesting that those small effects were not accidental. As many 
of the affected genes could be arranged into functional groups, those small changes 
might have an important impact on the cell.
Looking again at the results of the transfection of HK-2 cells with miR-608 
and miR-663, one might wonder if the very small differences in TGF-beta are not real
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effects of the microRNAs. Especially that statistical analysis of the data from three 
transfection experiments (each done in triplicate) shows that the downregulation 
of TGF-beta by 15% by miR-663 is statistically significant (Figure 6.13). In keeping 
with that, TargetScan (release 5.1) [257], currently the best validated microRNA 
target prediction program, predicts TGF-beta as a target of miR-663. Although 
my data show that its effect on TGF-beta was rather modest, miR-663 may be highly 
important for TGF-beta-related processes, given that microRNAs often regulate many 
genes of similar function. Furthermore, cooperative regulation by multiple 
microRNAs could possibly lead to a greater decrease in TGF-beta. According 
to the TargetScan predictions, another microRNA, miR-744, is also likely to control 
TGF-beta synthesis. The potential interactions of miR-663 and miR-744 
with TGF-beta mRNA are a subject of intensive investigations in the department 
at the moment.
Additionally, there is more and more evidence now that microRNA-binding sites may 
be also located within the CDS or 5'UTR of a transcript. As those regions are not 
routinely considered by microRNA target prediction programs yet, there is a chance 
that TGF-beta regulation occurs also via non-canonical interaction with microRNAs.
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ccccgccgccgccgcccttcgcgccctgggccatctccctcccacctccctccgcggagcagcc
agacagcgagggccccggccgggggcaggggggacgccccgtccggggcacccccccggctctg
agccgcccgcggggccggcctcggcccggagcggaggaaggagtcgccgaggagcagcctgagg
ccccagagtctgagacgagccgccgccgcccccgccactgcggggaggagggggaggaggagcg
ggaggagggacgagctggtcgggagaagaggaaaaaaacttttgagacttttccgttgccgctg
OC ggagccggaggcgcggggacctcttggcgcgacgctgccccgcgaggaggcaggacttggggac
cccagaccgcctccctttgccgccggggacgcttgctccctccctgccccctacacggcgtccc
In tcaggcgcccccattccggaccagccctcgggagtcgccgacccggcctcccgcaaagactttt
ccccagacctcgggcgcaccccctgcacgccgccttcatccccggcctgtctcctgagcccccg
cgcatcctagaccctttctcctccaggagacggatctctctccgacctgccacagatcccctat
tcaagaccacccaccttctggtaccagatcgcgcccatctaggttatttccgtgggatactgag
acacccccggtccaagcctcccctccaccactgcgcccttctccctgaggacctcagctttccc
tcgaggccctcctaccttttgccgggagacccccagcccctgcaggggcggggcctccccacca
caccagccctgttcgcgctctcggcagtgccggggggcgccgcctcccccATGccgccctccgg
gctgcggctgctgccgctgctgctaccgctgctgtggctactggtgctgacgcctggccggccg
gccgcgggactatccacctgcaagactatcgacatggagctggtgaagcggaagcgcatcgagg
ccatccgcggccagatcctgtccaagctgcggctcgccagccccccgagccagggggaggtgcc
gcccggcccgctgcccgaggccgtgctcgccctgtacaacagcacccgcgaccgggtggccggg
gagagtgcagaaccggagcccgagcctgaggccgactactacgccaaggaggtcacccgcgtgc
taatggtggaaacccacaacgaaatctatgacaagttcaagcagagtacacacagcatatatat
C/D gttcttcaacacatcagagctccgagaagcggtacctgaacccgtgttgctctcccgggcagag Q
q  ctgcgtctgctgaggctcaagttaaaagtggagcagcacgtggagctgtaccagaaatacagca 
acaattcctggcgatacctcagcaaccggctgctggcacccagcgactcgccagagtggttatc 
ttttgatgtcaccggagttgtgcggcagtggttgagccgtggaggggaaattgagggctttcgc 
cttagcgcccactgctcctgtgacagcagggataacacactgcaagtggacatcaacgggttca 
ctaccggccgccgaggtgacctggccaccattcatggcatgaaccggcctttcctgcttctcat 
ggccaccccgctggagagggcccagcatctgcaaagctcccggcaccgccgagccctggacacc 
aactattgcttcagctccacggagaagaactgctgcgtgcggcagctgtacattgacttccgca 
aggacctcggctggaagtggatccacgagcccaagggctaccatgccaacttctgcctcgggcc 
ctgcccctacatttggagcctggacacgcagtacagcaaggtcctggccctgtacaaccagcat 
aacccgggcgcctcggcggcgccgtgctgcgtgccgcaggcgctggagccgctgcccatcgtgt 
actacgtgggccgcaagcccaaggtggagcagctgtccaacatgatcgtgcgctcctgcaagtg 
caqcTGAqqtcccaccccqccccqcccccrcccccrcrcaqgcccqqccccaccccqccccqccccc 
gctgccttgcccatgggggctgtatttaaggacacccgtgccccaagcccacctggggccccat 
co o taaagatggagagaggactgcggaaaaaaaaaaaaaaaaaa
Figure 6.1. Human TGF-beta transcript. Start and stop codons are in uppercase. 
The binding site for miR-LAT, according to Gupta et al. [251], is in italics. Two 
predicted miR-608-binding sites are underlined, two predicted miR-663-binding 
sites are red, and one predicted binding site for miR-769_3p is bold. TGF-beta 
mRNA sequence was obtained from NCBI (NM_000660.4).
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Figure 6.2. Predicted interactions between microRNAs and TGF-beta mRNA.
Binding of miR-LAT (A), miR-608 (B), miR-663 (C), and miR-769_3p (D) 
to TGF-beta transcript as predicted by RNA22 was visualised using RNAfold 
program from Vienna RNA Secondary Structure Package [194]. For each predicted 
interaction, microRNA sequence (top) was linked to a fragment of TGF-beta 
(bottom) via a 9-nucleotide-long unrelated sequence (right from the red line), as 
justified in Methods.
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Figure 6.3. Validation of the commercial TaqMan qRT-PCR assay for miR-608 
detection. The reaction was performed on three amounts of total RNA: 10, 2, 0.4 ng, 
isolated from HK-2 cells transfected with synthetic miR-608, as described 
in Methods. Amplification curves are shown for each sample, and also for three 
negative controls (-RT, RT-NTC, PCR-NTC).
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Figure 6.4. Expression of miR-608 in HK-2 and U937 cells. Expression 
of miR-608 was examined in untransfected HK-2 cells (6 samples in triplicate) and 
U937 cells (6 samples in triplicate) using the TaqMan qRT-PCR assay validated 
above. (A) Amplification curves are shown. (B) Seven randomly chosen qRT-PCR 
products (lanes 2-8) were separated on an agarose gel together with size markers 
(Ml -  163 bp, M2 -  59 bp) and qRT-PCR product of the reaction performed on 
RNA from HK-2 cells transfected with synthetic miR-608 (lane 1).
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Figure 6.5. Validation of the miR-663 stem-loop qRT-PCR system designed for 
this project. The reaction was performed on three amounts of total RNA: 1000, 200, 
40 ng (in duplicate), isolated from HK-2 cells transfected with synthetic miR-663, 
as described in Methods. Amplification curves (A) and melting curves (B) are shown 
for each sample, as well as for three negative controls (-RT, RT-NTC, PCR-NTC).
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Figure 6.6. Expression of miR-663 in HK-2 and U937 cells. (A,B) Expression 
of miR-663 was examined in untransfected HK-2 cells using 1000, 500, 250, 125, 
62.5 ng total RNA, and in U937 cells using 250 ng total RNA (red asterisk) 
with the qRT-PCR assay validated above. (C,D) The quantification of HK-2 cell 
miR-663 was repeated using small instead of total RNA fraction (100, 50, 25, 12.5, 
6.25 ng). Amplification plots (A,C) and melting curves (B,D) are shown.
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Figure 6.7. TGF-beta expression in HK-2 following transfection with synthetic 
miR-608. HK-2 cells were transfected with 30 nM synthetic miR-608 using siPORT 
Amine (Ambion), as described in Methods. At 24 hour-time point transfection 
medium (containing 9% (v/v) FCS) was replaced with FCS-free medium. TGF-beta 
expression was examined 24, 48, 72, or 96 hours after transfection by qRT-PCR. 
RPLPO was used for normalisation. Blue bars represent control, green -  miR-608- 
transfected cells.
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Figure 6.8. Transfection with synthetic miR-608 or miR-663. HK-2 cells were 
transfected with 30 nM miR-608, miR-663, or -  to ensure the transfection was 
efficient -  siRNA silencing CD44. After 24 hours CD44 (A) and TGF-beta (B) 
expression was tested with qRT-PCR. RPLP0 was used for normalisation. 
The experiment was performed in triplicate; SEM is shown. The statistical 
significance is indicated as follows: * p < 0.05, ** p < 0.005.
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Figure 6.9. Effects of miR-608 and/or miR-663 on TGF-beta and SMAD3.
HK-2 cells were transfected with 30 nM miR-608, miR-663, or miR-608 
and miR-663 together (15 nM each). After 24 hours the transfection medium was 
replaced with FCS-free medium and the cells were incubated for another 24 hours. 
TGF-beta (A) and SMAD3 (B) expression was examined by qRT-PCR. RPLP0 was 
used for normalisation.
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Figure 6.10. Effect of miR-608 on TGF-beta at the protein level. HK-2 cells were 
transfected with 30 nM miR-608. After 24 hours the cells were stimulated 
with 160 nM PMA in 0.5 ml FCS-free medium per well (12-well-plates). 
(A) TGF-beta secreted to medium was examined by ELISA. (B) AlamarBlue assay 
was used to normalise TGF-beta secretion for cell number. The transfection was 
performed in triplicate. For each sample ELISA was done in duplicate, 
and AlamarBlue in triplicate. After the normalisation, the difference between 
TGF-beta secretion in control and miR-608 transfected cells was non-significant.
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Figure 6.11. Effect of synthetic miR-LAT on TGF-beta and SMAD3. HK-2 cells 
were transfected with 30 nM miR-LAT, miR-608, or miR-663. TGF-beta (A) 
and SMAD3 (B) expression was examined 24 hours later by qRT-PCR. RPLP0 was 
used for normalisation. The experiment was performed in triplicate; SEM is shown. 
Asterisk indicates p < 0.05.
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Figure 6.12. Effect of synthetic miR-LAT on SMAD-dependent transcription.
(A) HK-2 cells were transfected with 30 nM Scrambled siRNA (negative control), 
miR-LAT, or SMAD3 siRNA (positive control). After 40 hours cells were 
transfected with a mix (9:1) of TGF-beta responsive reporter plasmid (with four 
SMAD-binding elements in the promoter region of the firefly luciferase) and control 
plasmid (for constitutive expression of Renilla luciferase). 24 hours after the second 
transfection, the cells were stimulated with 1 ng/ml TGF-beta (black bars) or not 
(grey bars) for six hours. Then, activities of firefly and Renilla luciferases were 
examined using Dual Luciferase Assay (Promega). (B) HK-2 cells were transfected 
with 30 nM Scrambled siRNA, miR-LAT, or SMAD3 siRNA together with the mix 
of the two plasmids used in (A). The transfection medium was replaced with fresh 
FCS-free medium and the cells were incubated for 48 hours. They were incubated 
with 1 ng/ml TGF-beta (black bars) or control medium (grey bars) for six hours. 
Activities of firefly and Renilla luciferases were measured as described above. Both 
experiments were performed in duplicate and both were repeated with the same 
results.
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Figure 6.13. Effect of miR-608 and miR-663 on TGF-beta mRNA - summary.
The data from three transfection experiments presented above (each in triplicate) 
were averaged, SEM calculated, and statistical significance was tested. Two 
asterisks indicate p < 0.005.
232
CHAPTER SEVEN:
G e n e r a l  d is c u s s io n
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The aim of my thesis was to determine the role of microRNAs in renal fibrosis. 
At the start of the project, in 2006, microRNAs were emerging as potentially 
important factors in various physiological and pathological processes; however, there 
was very little known about their expression and function in the kidney, in particular 
in tubulointerstitial fibrosis. In my thesis, I have characterised global microRNA 
expression in vitro in proximal tubular epithelial cells and in vivo in kidney biopsy 
samples, and identified microRNAs altered by profibrotic stimuli. Furthermore, I have 
linked the changes in miR-192 expression with its role in regulation of E-cadherin 
in proximal tubular epithelial cells, indicating that miR-192 may prevent EMT 
in the kidney. Finally, I have examined the possibility that TGF-beta, a crucial 
cytokine in renal fibrosis, is directly regulated by microRNAs.
One of the major strengths of this work, making it unique among all studies 
on microRNAs in the kidney published so far, was the use of FFPE renal biopsy 
samples as a source of RNA for microRNA profiling. This technical advance can be 
widely applied within nephrology. Storage of FFPE kidney biopsies has been 
a routine practice in numerous countries for many years; a vast collection of such 
samples exists and -  as my data show -  they could be successfully used 
for retrospective studies of various kidney disorders. Thus far, limited RNA 
availability has precluded hybridisation-based microRNA analysis in non-surgically 
obtained kidney specimens. For this reason, microRNA expression in human kidneys 
has been studied mostly in tissue obtained at surgical nephrectomy. A key advantage 
of renal biopsy tissue over nephrectomy specimens is the relatively rapid fixation, 
which eliminates the risk that substantial changes in microRNA expression occurring 
after a prolonged period of tissue hypoxia [205] will affect the results.
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Extensive characterisation of microRNA expression in malignancy shows that 
microRNA profiling has promise as a clinical tool for diagnostic and prognostic 
evaluation, as well as for identification of potential therapeutic targets. My results 
suggest that this holds true also for non-malignant diseases such as diabetic 
nephropathy. I have found a number of microRNAs that were differentially expressed 
between patients with early and late stage of diabetic nephropathy, and between 
patients with slow and fast progression of the disease. The greatest difference was 
found in expression of miR-192, which was downregulated in kidney samples from 
patients with severe diabetic nephropathy, and thus was examined further in this 
thesis.
Analysis of miR-192 expression in individual kidney biopsies revealed that 
it correlates well with renal function (eGFR) and inversely correlates with renal 
fibrosis (fibrosis score). Furthermore, in vitro work showed that miR-192 
is downregulated also by short-term treatment with TGF-beta in proximal tubular 
epithelial cells. Subsequent manipulation of miR-192 expression in those cells 
demonstrated that miR-192 is involved in regulation of E-cadherin expression, most 
likely by targeting directly two E-cadherin transcriptional repressors: ZEB1 
and ZEB2. Since downregulation of E-cadherin is the first and crucial step of EMT, 
and EMT is strongly implicated in pathogenesis of renal fibrosis, my data suggest that 
miR-192 might prevent the fibrosis in the kidney.
As discussed in detail earlier, the role of miR-192 in diabetic nephropathy has been 
also studied by two other research groups [151, 154], revealing that miR-192 action 
may be context-dependent and not necessarily beneficial for the kidney. 
All the groups, however, point to miR-192 importance in diabetic nephropathy 
and a need for further investigation. In the context of proximal tubular epithelial cell
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biology, there are still a few unanswered questions. For instance, the mechanism 
of miR-192 downregulation by TGF-beta is not fully understood. My miR-192 
overexpression data presented in Chapter Five suggest that miR-192 is regulated 
posttranscriptionally. In addition, a preliminary in silico analysis of the miR-192 
promoter region identified multiple binding sites for SMADs, HNF-1 alpha, SP1 
and SP3, as well as E-boxes that could potentially interact with ZEB1, ZEB2, or other 
E-box repressors, indicating that endogenous miR-192 is also very likely regulated 
by TGF-beta at the level of transcription. This, together with the possibility that 
miR-192 has also other targets and functions in proximal tubular epithelial cells, 
is under investigation in the department now.
MicroRNA-192, identified by microRNA expression profiling as downregulated in 
severe diabetic nephropathy, was subsequently found to play a potentially important 
role in renal fibrosis. This implies that other changes in microRNA expression found 
in that experiment, i.e. two microRNAs different more than two-fold between 
non-progressors and progressors, and eleven between late presenters and early stage 
biopsies, are very likely to be meaningful too. Moreover, even if their detailed 
characterisation fails to extend the existing knowledge about mechanisms driving 
kidney fibrosis, they could still be used as biomarkers in diabetic nephropathy 
and possibly other kinds of chronic kidney disease.
Currently, diagnosis of chronic kidney disease is based mainly on serum creatinine 
in combination with urinary findings, such as proteinuria. These, however, change 
substantially only in advanced disease, so do not allow for very early detection, which 
is critical for effective management of the condition. Additionally, there is no 
well-established prognostic biomarker, which could help to distinguish between
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patients with quick and low rate of disease progression, so that the treatment could be 
adjusted appropriately.
In the last years, there has been a great interest in microRNAs as biomarkers for 
various diseases, mostly cancers (for review see [258]). Strikingly, recent reports have 
demonstrated the presence of microRNAs in bodily fluids, including urine [259, 260]. 
Furthermore, analysis of microRNA expression in urine samples has been already 
successfully employed to identify potential bladder cancer biomarkers [261]. It is 
tempting to speculate that expression of microRNAs identified in this study 
as potentially important in diabetic nephropathy, including miR-192, would be 
changed not only in renal biopsy tissue, but also in urine samples. That could 
eventually lead to a quick, reliable and -  most of all -  non-invasive method 
for diagnosis or prognosis in chronic kidney disease.
Renal fibrosis, as a result of chronic kidney disease, is a complex condition, which 
is mediated by a whole network of molecular, cellular, and physiological mechanisms. 
A single microRNA is capable of regulating multiple components of a pathway 
or multiple pathways. Therefore, microRNAs are particularly good candidates 
for global regulators of such disorders and they certainly deserve more attention 
in the context of renal fibrosis. The long-term goal is to define functions of all 
microRNAs expressed in the normal and fibrotic kidney by identifying and validating 
their targets, and to examine their potential as future therapeutic, diagnostic 
or prognostic clinical tools. My work presented in this thesis, together with a few 
reports on the subject published in parallel, constitutes a good starting point to achieve 
that.
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APPENDIX: Buffers and Reagents
Reducing Gel Loading Buffer 3x
0.5 M Tris-HCl, pH 6.8 1 ml
Glycerol 2.4 ml
10% (w/v) SDS 4.8 ml
0.05% (w/v) Bromophenol Blue 2 drops 
Beta-mercaptoethanol 1.2 ml
Running Buffer (lOx)
Tris-HCl 30 g/1
Glycine 144 g/1
SDS 10 g/1
pH 8.3
Transfer Buffer (lOx)
Tris-HCl 30 g/1
Glycine 144 g/1
pH 8.3 (no adjustment necessary)
Transfer Buffer (lx)
Transfer Buffer 1 Ox 100 ml/1
Methanol 200 ml/1
TBS (lOx)
Tris 24.2 g/1
NaCl 80 g/1
pH 7.4
Stripping Buffer
0.5 M Tris pH 6.8 5 ml/40 ml
10% (w/v) SDS 8 ml/40 ml
Beta-mercaptoethanol 320tii/40mi
YTx2
Tryptone 16 g/1
Yeast extract 10 g/1
NaCl 5 g/1
YTx2 agar plates
Tryptone 16 g/1
Yeast extract 10 g/1
NaCl 5 g/1
Agar 20 g/1
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